

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 August 2001 (30.08.2001)

PCT

(10) International Publication Number
WO 01/62965 A2

- (51) International Patent Classification⁷: **C12Q 1/68**
- (21) International Application Number: **PCT/GB01/00758**
- (22) International Filing Date: 22 February 2001 (22.02.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0004197.0 22 February 2000 (22.02.2000) GB
0018679.1 28 July 2000 (28.07.2000) GB
- (71) Applicant (for all designated States except US): **OXFORD BIOMEDICA (UK) LIMITED** [GB/GB]; Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford, OX4 4GA (GB).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **KINGSMAN, Alan, John** [GB/GB]; Oxford BioMedica (UK) Limited, Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/62965 A2

(54) Title: **DIFFERENTIAL EXPRESSION SCREENING METHOD**

(57) Abstract: A differential expression screening method is provided for identifying a genetic element involved in a cellular process, which method comprises comparing: (a) gene expression in a first cell of interest; and (b) gene expression in a second cell of interest, which cell comprises altered levels, relative to physiological levels, of a biological molecule implicated in the cellular process, due to the introduction into the second cell of a heterologous nucleic acid directing expression of a polypeptide; and identifying a genetic element whose expression differs, wherein gene expression in said first and/or second cell of interest is compared under at least two different environmental conditions relevant to the cellular process.

DIFFERENTIAL EXPRESSION SCREENING METHOD

Field of the invention

The present invention relates to methods of screening for genes by differential expression.

Background to the invention

5 One of the central goals in the field of gene discovery is to understand and elucidate the relationship between a particular disease state and the gene expression pattern that defines and/or causes this disease state. In this way it is possible to identify genes which potentially are of great medical importance, either for the diagnosis or for the treatment of disease. The products of such genes may be useful directly as therapeutics, the genes
10 themselves may be applicable to gene therapy, or small molecule effectors may be found to modulate the expression or the effects of these genes to treat disease. Research has concentrated on differences in expression patterns between diseased and healthy tissues to elucidate the physiological mechanisms of disease. Identified differences in expression patterns provide putative points for therapeutic intervention to reverse the disease
15 phenotype. These differences also provide markers that are useful for diagnosis, and identify proteins for further investigation as agents implicated in the disease in question.

Differential screening of gene expression is one technique well known in the art which, often together with subtractive cDNA cloning methods, has been used successfully to identify genes involved in a range of cellular processes. Differential screening is generally
20 performed using either a nucleic acid-based method where levels of mRNA expression are determined, or using a proteomics approach where the total protein content of a cell is resolved using techniques such as 2D gel electrophoresis.

One of the problems of the differential screening methods known to date, even those based on DNA chip technology, is that absolute levels of a gene product of interest, and/or the
25 difference in expression of that gene product between two particular states (for example, in the presence and absence of a growth factor or in two different cell types) may be rather low. Consequently, although some very important genes have been identified to date using standard differential expression screening techniques, many genes that may play important roles in cellular processes are difficult to identify because their expression levels are low or
30 because observable changes in their expression levels may be relatively small.

-2-

A further problem suffered by conventional methods of differential screening is that these methods do not allow dissection of the genetic or biochemical pathway that is being studied. Any changes in gene expression that are identified are global, rather than specific to a particular aspect of the pathway under investigation. There is thus a need in the art for
5 a method that would facilitate the molecular dissection of biological pathways.

Summary of the invention

It is therefore an object of the present invention to provide an improved screening method based on differential expression.

In a first aspect of the invention, a differential expression screening method is provided for
10 identifying a genetic element involved in a cellular process which method comprises comparing gene expression in:

- (a) a first cell of interest; and
- (b) a second cell of interest which cell comprises altered levels, relative to physiological levels, of a biological molecule, due to the introduction into the
15 second cell of a heterologous nucleic acid; and

identifying a genetic element whose expression differs.

The term "genetic element" is meant to include genes, gene products (such as RNA molecules, and polypeptides), cis-acting regulatory elements (such as promoter elements and enhancer elements). The method allows differences in the patterns of expression of any
20 of these molecule types to be evaluated, and put into a biological context in the light of the cellular process that is being studied. The method also allows differences in the constituent genetic elements to be investigated, for example, to identify mutations and polymorphisms that affect the biological response to a particular cellular process.

In one embodiment, the first cell of interest also comprises altered levels, relative to
25 physiological levels, of the biological molecule. However, in an alternative embodiment the first cell of interest has normal physiological levels of the biological molecule. The biological molecule may be functionally characterised, or not fully characterised.

Typically, in the second cell of interest, the levels of the biological molecule are enhanced or reduced. In a preferred embodiment, the biological molecule and the polypeptide

-3-

encoded by the heterologous nucleic acid are the same molecule. The polypeptide may be functionally characterised, or not fully characterised.

Preferably, the nucleic acid directs expression of a polypeptide. Preferably, a polypeptide encoded by the heterologous nucleic acid is involved in the cellular process. By "involved in the cellular process" is meant that the gene has been found to possess a distinct role in a genetic or metabolic pathway in a cell. The polypeptide may be involved in susceptibility to, generation of, or maintenance of a particular disease phenotype or physiological condition. As will be apparent to the skilled reader, any point in any pathway may be the unique point at which a cell departs from the normal physiological response and generates a disease phenotype. Often the effect that is manifested as a disease is the result of a mutation event, in which a mutation occurs in the sequence of a gene encoding a protein that functions in a relevant physiological pathway.

Preferably, the nucleic acid is delivered to the cell using a viral vector. In this case, the heterologous nucleic acid should be co-linear with a viral vector. As the skilled reader will appreciate, different viral vectors are appropriate for various cell types. Preferred viral vectors for use in accordance with the present invention are derived from retroviruses, lentiviruses, such as the Equine Infectious Anaemia Virus (EIAV) or human immunodeficiency virus, type 1 (HIV-1), adenoviruses, adeno-associated viruses, herpes virus and pox viruses such as entomopox.

Preferred features of viral vectors for the purpose of the present invention are the ability efficiently to transduce the target cells, and the ability to minimise any perturbations in gene expression which may result from the use of the viral vector *per se* but which have unrelated specifically to the introduction of the heterologous nucleic acid of interest ("phenotypic silence"). As will be appreciated by those skilled in the art of viral-mediated gene transfer, this the field is advancing rapidly, and preferred vectors for various cell types are changing as the field advances. For example, at the time of writing, the preferred vector for the transduction of macrophages is an adenoviral vector, because it enabled the highest possible level of transduction. This vector does not enable phenotypically silent transduction, but it is possible to exclude vector effects on cellular gene expression using appropriate controls. On the other hand, a vector derived from the lentivirus EIAV, which enables phenotypically silent transduction, gives the best available transduction in hippocampal neurones, and so is the vector of choice for that application. Phenotypic

silence of the vector is always desirable, but must be balanced by transduction efficiency. The vector development described in the Examples included herein has been directed at the optimisation of these two features in the cell types described. As will be clear to those skilled in the art of vector technology, the present invention is independent of vector type,
5 but its practice may be enhanced by the optimum choice of vector for each cell type.

Generally, gene expression in the first and second cell may be determined by using proteomic techniques, or by using nucleic acid-based genomic or cDNA techniques.

In a preferred embodiment of the first aspect of the invention, a differential expression screening method is provided for identifying a genetic element involved in a cellular
10 process which method comprises comparing gene expression in:

- (a) a first cell of interest; and
- (b) a second cell of interest, which is different from the first cell and which cell comprises altered levels, relative to physiological levels, of a biological molecule, due to the introduction into the second cell of a heterologous nucleic acid; and
15 identifying a genetic element whose expression differs.

Preferably, the nucleic acid directs expression of a polypeptide, for example, a polypeptide involved in a cellular process, as discussed above.

In a second aspect, the present invention provides a differential expression screening method for identifying a genetic element whose expression is regulated by a signal, which
20 method comprises comparing at two different levels of the signal:

- (a) gene expression in a first cell of interest, wherein the signal is at a first level; and
- (b) gene expression in a second cell of interest, which cell comprises altered levels, relative to physiological levels, of a biological molecule whose activity is
25 responsive to the signal, due to the introduction into the second cell of a heterologous nucleic acid directing expression of a polypeptide, wherein the signal is at a second level; and

identifying a genetic element whose expression differs.

In a third aspect of the present invention, a polypeptide which is known or suspected to be
30 involved in a cellular process is used to identify other components of the same process by

-5-

altering the levels of that polypeptide in a cell to produce an improved signal to noise ratio for the levels of those other components to be identified, making them easier to identify by differential expression techniques.

Accordingly, the present invention also provides a differential expression screening method for identifying a genetic element whose expression is altered in a cellular process which method comprises comparing:

- (a) gene expression in a first cell of interest; and
 - (b) gene expression in a second cell of interest, which cell has been modified to contain altered levels of a polypeptide implicated in the cellular process; and
- 10 identifying a genetic element whose expression differs.

Preferably, the altered levels of the polypeptide are due to the introduction into the cell of a heterologous nucleic acid which directs the expression of the polypeptide in the cell. More preferably, the heterologous nucleic acid is colinear with a viral vector.

In a preferred embodiment of the third aspect of the invention, the expression of the genetic element is regulated by a biological signal, and the method includes the steps of comparing gene expression in the two cell types at two different levels of the signal.

This aspect of the invention therefore provides a differential expression screening method for identifying a genetic element involved in a cellular process, which method comprises comparing:

- (a) gene expression in a first cell of interest; and
- (b) gene expression in a second cell of interest, which cell comprises altered levels, relative to physiological levels, of a biological molecule implicated in the cellular process, due to the introduction into the second cell of a heterologous nucleic acid directing expression of a polypeptide; and

25 identifying a genetic element whose expression differs, wherein gene expression in said first and/or second cell of interest is compared under at least two different environmental conditions relevant to the cellular process. Preferably, gene expression is compared in both the first and the second cell of interest under at least two different environmental conditions relevant to the cellular process.

-6-

The environmental conditions to which the cells are exposed may, in one example, be different levels of a biological signal. Gene expression in the two cell types may be compared under environmental conditions in which the signal is absent, is present at a first level, and/or is present at a second level (for example, different percentages of atmospheric oxygen content between normoxia [20% oxygen] and hypoxia [<1% oxygen]). The use of at least two levels of a biological signal permits the comparison of the effects of the change in environmental conditions and of the heterologous nucleic acid on those cell types, and the identification of genetic elements whose expression behaves in the same way, or in different ways, between the levels of biological signal and environmental conditions tested.

Of course, more than two levels of a biological signal can be applied in the same manner with different types of environmental change, cell type and heterologous nucleic acid.

One embodiment of this aspect of the invention therefore provides a differential expression screening method for identifying a genetic element involved in a cellular process, which method comprises comparing:

- (a) gene expression in a first cell of interest;
- (b) gene expression in the first cell of interest which has been exposed to a biological signal relevant to the cellular process, wherein the biological signal is at a first level;
- (c) gene expression in the first cell of interest which has been exposed to a biological signal relevant to the cellular process, wherein the biological signal is at a second level; and
- (d) gene expression in a second cell of interest, which cell comprises altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to the biological signal, due to the introduction into the second cell of a heterologous nucleic acid directing expression of a polypeptide, wherein the signal is absent, at a first level or at a second level; and

identifying a genetic element whose expression differs.

In an alternative embodiment of this aspect of the invention, the environmental conditions to which the cells are exposed may be different types of environmental change (for example, changes in the levels of different growth factors to which the cells are exposed). The use of two environmental changes permits the comparison of the effects of each

-7-

environmental change and of the heterologous nucleic acid on each cell type, and the identification of genetic elements whose expression behaves in the same way, or in different ways, between those environmental changes tested. More than two environmental changes can be applied in the same manner with each cell type and each heterologous nucleic acid.

This aspect of the invention thus provides a differential expression screening method for identifying a genetic element involved in a cellular process, which method comprises comparing:

- (a) gene expression in a first cell of interest;
- 10 (b) gene expression in the first cell of interest which has been exposed to an environmental change of a first type;
- (c) gene expression in the first cell of interest which has been exposed to an environmental change of a second type; and
- 15 (d) gene expression in a second cell of interest, which cell contains altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to one or both of the environmental changes recited in parts b) and c), due to the introduction into the second cell of a heterologous nucleic acid directing expression of a polypeptide, under conditions in which the cell either has or has not been exposed to the first and/or the second type of environmental
- 20 change; and

identifying a genetic element whose expression differs.

In the above embodiments of the invention, the first cell may also comprise altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to the difference between the environmental conditions, due to the introduction into the cell of a heterologous nucleic acid directing expression of a polypeptide.

The biological molecule in the first cell may be the same biological molecule as that biological molecule whose levels are altered in the second cell. In this embodiment, the levels of the biological molecule in the first and second cells should be different.

-8-

This aspect of the invention thus provides a differential expression screening method for identifying a genetic element involved in a cellular process, which method comprises comparing:

- (a) gene expression in a first cell of interest;
- 5 (b) gene expression in the first cell of interest, wherein the cell has been exposed to a biological signal relevant to the cellular process;
- (c) gene expression in the first cell of interest, which cell contains altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to the biological signal, due to the introduction into the first cell of a
10 heterologous nucleic acid directing expression of a polypeptide, wherein the altered level of the biological molecule is at a first level, and wherein the biological signal is either present or absent;
- (d) gene expression in a second cell of interest;
- (e) gene expression in the second cell of interest, wherein the cell has been exposed
15 to a biological signal relevant to the cellular process;
- (f) gene expression in the second cell of interest, which cell contains altered levels, relative to physiological levels, of the biological molecule, due to the introduction into the second cell of a heterologous nucleic acid directing expression of the polypeptide, wherein the altered level of the biological molecule is at a second
20 level, and wherein the biological signal is either present or absent; and

identifying a genetic element whose expression differs.

The use of two levels of expression of the heterologous nucleic acid permits the comparison of the effects of each level and of the biological signal on each cell type, and the identification of genetic elements whose expression behaves in the same way, or in
25 different ways, between those levels and biological signals tested. More than two levels of expression of the heterologous nucleic acid can be applied in the same manner with each cell type and each biological signal.

Alternatively, the biological molecule in the first cell may be a different biological molecule to that whose levels are altered in the second cell. In this embodiment, the levels

-9-

of the biological molecule in the first and second cells may be the same or may be different.

This aspect of the invention thus provides a differential expression screening method for identifying a genetic element involved in a cellular process, which method comprises
5 comparing:

(a) gene expression in a first cell of interest;

(b) gene expression in the first cell of interest, wherein the cell has been exposed to a biological signal relevant to the cellular process;

10 (c) gene expression in the first cell of interest, which cell contains altered levels, relative to physiological levels, of a first biological molecule whose activity is responsive to the biological signal, due to the introduction into the first cell of a heterologous nucleic acid directing expression of a first polypeptide, wherein the biological signal is either present or absent;

(d) gene expression in a second cell of interest;

15 (e) gene expression in the second cell of interest, wherein the cell has been exposed to a biological signal relevant to the cellular process;

(f) gene expression in the second cell of interest, which cell contains altered levels, relative to physiological levels, of a second biological molecule, due to the introduction into the second cell of a heterologous nucleic acid directing expression
20 of a second polypeptide, wherein the biological signal is either present or absent;
and

identifying a genetic element whose expression differs.

The use of two types of heterologous nucleic acid permits the comparison of the effects of type and of the biological signal on each cell type, and the identification of genetic
25 elements whose expression behaves in the same way, or in different ways, between those types and biological signals. More than two types of the heterologous nucleic acid can be applied in the same manner with each cell type and each biological signal tested. This aspect of the invention has enabled the discovery of genes that are differentially regulated by different biological molecules under particular environmental changes. This raises the
30 possibility of tissue and cell-specific therapeutic modulation of cellular responses.

-10-

In all the above embodiments, the first and second cells whose gene expression is compared may be different cell types (for example, healthy cells and diseased cells). The use of two or more cell types permits the comparison of the effects of the different biological signals and of the heterologous nucleic acid on those cell types, and the
5 identification of genetic elements whose expression behaves in the same way, or in different ways, between those cell types and biological signals tested. More than two cell types can be assessed in the same manner.

In a preferred embodiment of the invention, the polypeptide is implicated in a disease process. Accordingly, the first cell may be from a normal patient and the second cell from
10 a diseased patient or vice-versa. Alternatively, the first cell is from a diseased patient and the second cell is from the same diseased patient or from a patient with the same disease.

A further aspect of the invention thus provides a differential expression screening method for identifying a gene or gene product involved in a cellular process which method comprises:

- 15 (i) comparing gene expression in:
- (a) a first cell of interest; and
 - (b) a second cell of interest;
- (ii) comparing gene expression in
- (a) the first cell of interest; and
 - 20 (b) a third cell of interest which cell comprises altered levels, relative to physiological levels, of a candidate gene or gene product, due to the introduction into the third cell of a heterologous nucleic acid directing amplification or expression of the candidate gene or gene product; and
- (iii) selecting those candidate genes or gene products which give rise to an alteration in
25 the levels, copy number or expression of a second gene or gene product in the third cell of interest relative to the first cell of interest, which second gene or gene product also has altered levels, copy number or of expression in the second cell of interest relative to the first cell of interest.

Preferably the candidate gene product is a polypeptide or RNA molecule.

-11-

In a preferred embodiment of the above aspect of the invention, a differential expression screening method is provided for identifying a gene product involved in a disease process which method comprises:

- (i) comparing gene expression in:
 - 5 (a) a first cell of interest from a normal patient; and
 - (b) a second cell of interest from a diseased patient;
- (ii) comparing gene expression in
 - (a) the first cell of interest; and
 - (b) a third cell of interest from a normal patient which cell comprises altered
 - 10 levels, relative to physiological levels, of a candidate gene or gene product, due to the introduction into the third cell of a heterologous nucleic acid directing amplification or expression of the candidate gene or gene product; and
- (iii) selecting those candidate genes or gene products which give rise to an alteration in the levels, copy number or expression of a second gene or gene product in the third cell of
- 15 interest relative to the first cell of interest, which second gene or gene product also has altered levels, copy number or expression in the second cell of interest relative to the first cell of interest.

In a particularly preferred embodiment of this aspect of the invention, the expression of the gene product is preferably regulated by a signal (such as a biological or other

20 environmental signal relevant to the disease process), and the method includes the steps of comparing gene expression in the cell types at two different levels of the signal.

In the embodiments of the invention described above, the comparison of gene expression is carried out by identifying using nucleic acid techniques those mRNA transcripts whose levels are altered between the different cell types of interest.

25 In the embodiments of the invention that are described above, the comparison of gene expression may be carried out by identifying, using protein analytical techniques, those polypeptides whose levels are altered between the different cell types of interest.

According to a still further aspect of the invention, there is provided a method of increasing the sensitivity of a differential expression screening method in which gene expression of a

30 first and a second cell of interest in response to two different levels of a signal are

compared, the method comprising introducing a heterologous nucleic acid into the first cell or the second cell to increase the level of a biological molecule which modulates the response of the cell to the signal.

Detailed description of the invention

- 5 Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (1989) and Ausubel *et al.*, Short Protocols in Molecular Biology (1999) 4th Ed, John Wiley & Sons, Inc.

- 10 Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

A. Differential expression screening techniques

- Genes encode gene products, mainly polypeptides but also RNAs, that are involved in a huge variety of cellular processes. The technique of differential expression screening is based on the idea that by comparing expression under two sets of conditions, genes whose expression varies between those two conditions can be identified and their function related back to the differences between those conditions. For example, genes involved in a pathway responsive to mitogens such as platelet-derived growth factor (PDGF) can be identified by comparing gene expression in cells exposed to PDGF versus gene expression in cells not exposed to PDGF.

Thus the term "differential expression screening" as used herein means comparing gene expression between two cells under different conditions or two different cells under the same or different conditions, with the aim of identifying genes or gene products that differ in their levels of expression between the two cells.

- 25 The differences in gene expression may be measured using a variety of techniques. The first main type of technique is based on the measurement of nucleic acids and is termed herein as "genomic or cDNA techniques". A useful review is provided in Kozian and Kirschbaum (1999). The second main type of technique is based on the measurement of cellular protein content and is termed herein as "proteomic techniques".

Genomic or cDNA techniques

One method well known in the art is subtractive cDNA hybridisation. This technique involves hybridising a population of mRNAs from one cell (e.g. a control cell) with a population of cDNAs made from the mRNA of another cell (e.g. a cell exposed to PDGF).

5 This step will remove all sequences from the cDNA preparation that are common to both cells. The cDNAs derived from mRNAs whose expression is upregulated in the cell exposed to PDGF will not have a corresponding mRNA from the control with which to hybridise and can be isolated. Typically, the cDNAs are also hybridised with mRNA from the same cell to confirm that they represent coding sequences. This procedure is described
10 in detail in WO90/11361 where mRNA from cells from the roots of plants treated with a chemical, N-(aminocarbonyl)-2-chlorobenzenesulphonamide, were used to produce a cDNA library that was then hybridised with mRNA from untreated root cells. The procedure identified a number of genes whose expression was upregulated by the chemical.

The polymerase chain reaction (PCR) has led to the development of a number of other
15 methods. RT-PCR differential display was first described by Liang and Pardee (1992). This technique involves the use of oligo-dT primers and random oligonucleotide 10-mers to carry out PCR on reverse-transcribed RNA from different cell populations. PCR is often carried out using a radiolabelled nucleotide so that the products can be visualised after gel electrophoresis and autoradiography. Wilkinson *et al.* (1995) used PCR
20 differential display to identify five mRNAs that are upregulated in strawberry fruit during ripening. A review of differential display RT-PCR (also known as differential display of mRNA) is provided in Zhang *et al.* (1998) and a recent improvement using 'long distance' PCR is described in Zhao *et al.* (1999).

Another technique is termed cDNA library screening. A review of this technique and the
25 other two differential expression screening techniques mentioned above is provided in Maser and Calvet (1995).

Differential display competitive PCR is a fairly recent innovation that has been successfully used to study changes in global gene expression in situations where only a few genes change expression levels, such as exposure of MCF17 cell to oestradiol, and in more
30 complex situations such as neuronal differentiation of human NTERA2 cells (Jorgensen *et al.*, 1999).

Other techniques that are suitable for the analysis of the transcriptome of a specific cell type include serial analysis of gene expression (SAGE; Velculescu *et al.*, Science (1995) 270; 484-487), Selective amplification via biotin- and restriction-mediated enrichment (SABRE) (Lavery *et al.*, (1997), PNAS USA 94: p6831-6836); Differential display (for
5 example, indexing differential display reverse transcriptase polymerase chain reaction (DDRT-PCR; Mahadeva *et al.* (1998) J. Mol.Biol. 284, 1391-1398)); representational difference analysis (RDA) (Hubank (1999) Methods in Enzymology 303: 325-349; see Kozian and Kirschbaum (1999) for review and references therein); differential screening of cDNA libraries (see Sagerstrom *et al.* (1997) Annu. Rev. Biochem. 66: 751-783);
10 "Advanced Molecular Biology", R.M. Twyman (1998) Bios Scientific Publishers, Oxford; "Nucleic Acid Hybridization", M. L. M. Anderson (1999) Bios Scientific Publishers, Oxford); Northern blotting; RNase protection assays; S1-nuclease protection assays; RT-PCR; real time RT-PCR (Taq-man); EST sequencing; massively parallel signature sequencing (MPSS); and sequencing by hybridisation (SBH) (see Drmanac R. *et al* (1999),
15 Methods in Enzymology 303:165-178). Many of these techniques are reviewed in "Comparative gene-expression analysis" Trends Biotechnol. 1999 Feb;17(2):73-8.

The actual identification of gene products whose expression differs between the two cell populations can be carried out in a number of ways. Subtractive methods will inherently identify gene products whose expression differs since gene products whose expression is
20 the same are eliminated from the sample. Other methods include simply comparing the expression products from one cell with the expression products from another and looking for any differences (with PCR-based techniques, the number of products in each sample can be limited to a reasonable size), optionally with the aid of a computer program. For example using a PCR-based technique a visual comparison of bands present in different
25 lanes allows the identification of bands unique to one lane. These bands can be cut out of the gel and subsequently analysed.

The advent of DNA chip technology, allows comparisons to be conveniently conducted by the use of microarrays (see Kozian and Kirschbaum, 1999 for review and references therein). Typically, arrays are generated using cDNAs (including ESTs), PCR products,
30 cloned DNA and synthetic oligonucleotides that are fixed to a substrate such as nylon filters, glass slides or silicon chips. To determine differences in gene expression, labelled cDNAs or PCR products are hybridised to the array and the hybridisation patterns

compared. The use of fluorescently labelled probes allows mRNA from two different cell populations to be analysed simultaneously on one chip and the results measured at different wavelengths. A microarray-based differential expression screening technique is described in US-A-5,800,992.

5 Proteomic techniques

Proteomics is the study of proteins' properties on a large scale to obtain a global, integrated view of disease processes, cellular processes and networks at the protein level. A review of techniques used in proteomics is given in Blackstock and Weir (1999) – see also references provided therein. The methods of the present invention are mainly concerned
10 with expression proteomics, the study of global changes in protein expression in cells using electrophoretic techniques and image analysis to resolve proteins. Whereas nucleic acid analysis emphasises the message, proteomics is more concerned with the product. The two approaches are sometimes complementary since proteomic techniques may be useful in detecting changes in polypeptide levels that are due to changes in protein stability rather
15 than mRNA levels.

A well known and ubiquitous technique used in the field of proteomics involves measuring the polypeptide content of a cell using 2D polyacrylamide gel electrophoresis (PAGE) and comparing this with the polypeptide content of another cell. The results of electrophoresis are typically a gel visualised with a dye such as silver stain or Coomassie-blue, or an
20 autoradiograph produced from the gel, all with spots corresponding to individual proteins. Fluorescent dyes are also available.

The aim is therefore to identify spots that differ between the two gels/autoradiographs, i.e. missing from one, reduced in intensity or increased in intensity. Thus in the case of proteomics, comparing gene expression simply involves comparing the protein profile
25 from one cell with the protein profile from another. Commercial software packages are available for automated spot detection.

Spots of interest may be excised from gels and the proteins identified using techniques such as matrix-assisted-laser-desorption-ionisation-time-of-flight (MALDI-TOF) mass spectrometry and electrospray mass spectrometry (see "Proteomics to study genes and
30 genomes" Akhilesh Pandey and Matthias Mann, (2000), Nature 405: 837-846).

-16-

It may be desirable to perform some measure of prefractionation, such as centrifugation or free-flow electrophoresis to improve the identification of low abundance proteins. Special procedures have also been developed for basic proteins, membrane proteins and other poorly soluble proteins (Rabilloud *et al.*, 1997).

- 5 Additionally, the recent developments in the field of protein and antibody arrays now allow the simultaneous detection of a large number of proteins. For example, low-density protein arrays on filter membranes, such as the universal protein array system (Ge H, (2000) Nucleic Acids Res. 28(2), e3) allow imaging of arrayed antigens using standard ELISA techniques and a scanning charge-coupled device (CCD) detector. Immuno-sensor arrays
10 have also been developed that enable the simultaneous detection of clinical analytes. It is now possible using protein arrays, to profile protein expression in bodily fluids, such as in sera of healthy or diseased subjects, as well as in patients pre- and post-drug treatment.

Antibody arrays also facilitate the extensive parallel analysis of numerous proteins that are hypothetically implicated in a disease or particular physiological state. A number of
15 methods for the preparation of antibody arrays have recently been reported (see Cahill, Trends in Biotechnology, 2000 7:47-51).

- The above discussion provides a description of prior art methods available to the skilled person for performing differential expression screening of two or more cell populations in a general sense. The introduction of heterologous genes for the purpose of examining
20 changes in general gene expression has also been described (Busch and Bishop, J Immunol, 1999 162:2555-2561; Robinson *et al.*, Proc Natl Acad Sci USA, 1997 94:7170-7175). However, the present invention is distinguished from these prior art methods in that a further step is required, namely that the levels of particular endogenous biological molecules in a cell are altered by the experimenter, so that the levels of gene products that
25 are responsive to cellular perturbations such as signalling events and are affected by the biological molecule(s) become more readily detectable. In other words, the object is to amplify and/or increase the signal to noise ratio of the differential response normally obtained so as to increase the likelihood of detecting gene products whose levels in a cell are low and/or whose expression normally changes by only a small amount.
- 30 By way of an example, the transcription factor HIF-1 α is responsive to intracellular oxygen levels. Decreases in oxygen levels increase HIF-1 α activity and lead to increased

-17-

transcription from genes controlled by a hypoxia responsive element (HRE). If the levels of HIF-1 α in the cell are raised artificially, for example by infecting cells with a viral vector that directs expression of HIF-1 α , then an increase in the transcriptional response mediated by HIF-1 α is expected. Consequently, changes in the expression of genes whose expression is sensitive to the hypoxia, and mediated by HIF-1 α induction, should be greater than in normal cells expressing physiological levels of HIF-1 α .

B. Biological molecules

The biological molecule can be any compound that is found in cells as a result of anabolic or catabolic processes within a cell or as a result of uptake from the extracellular environment, by whatever means. The term "biological molecule" means that the molecule has activity in a biological sense. Preferably the biological molecule is synthesised within the cell, i.e. is endogenous to that cell, or in the case of multicellular organisms, also within any of the cells of the organism.

Examples of biological molecules will therefore include proteins, peptides, nucleic acids, carbohydrates, lipids, steroids, co-factors, mimetics, prosthetic groups (such as haem), inorganic molecules, ions (such as Ca²⁺), inositides, hormones, growth factors, cytokines, chemokines, inflammatory agents, toxins, metabolites, pharmaceutical agents, plasma-borne nutrients (including glucose, amino acids, co-factors, mineral salts, proteins and lipids), foreign or pathological extracellular components, intracellular and extracellular pathogens (including bacteria, viruses, fungi and mycoplasma). Where appropriate, precursors, monomeric, oligomeric and polymeric forms, and breakdown products of the above are also included.

Examples of polypeptide biological molecules include enzymes, transcription factors, hormones, structural components of cells and receptors, including membrane bound receptors.

Preferably, the biological molecule is known to be involved in the cellular process of interest.

In one embodiment of the invention, the biological molecule is responsive to a change in condition of the cellular environment, also referred to herein as a signal. Examples of such environmental conditions or signals include changes in the cellular microenvironment,

exposure to hormones, growth factors, cytokines, chemokines, inflammatory agents, toxins, metabolites, pH, pharmaceutical agents, hypoxia, anoxia, ischemia, imbalance of any plasma-borne nutrient [including glucose, amino acids, co-factors, mineral salts, proteins and lipids], osmotic stress, temperature [hypo and hyper- thermia], mechanical stress, irradiation [ionising or non-ionising], cell-extracellular matrix interactions, cell-cell interactions, accumulations of foreign or pathological extracellular components, intracellular and extracellular pathogens [including bacteria, viruses, fungi and mycoplasma] and genetic perturbations [both epigenetic or mediated by mutation or polymorphism]. As is clear from the above list, the signal may be an externally applied signal such as an environmental signal, for example redox stress, the binding of an extracellular ligand to a cell surface receptor leading to a cellular response mediated by a signal transduction signal. Alternatively, the signal may be an internally applied signal such as an increase in kinase activity due to falling levels of a cell metabolite.

The levels of the biological molecule may be altered directly or indirectly. Direct alteration may be achieved by, for example, causing cells to take up the molecule by incubating cells in a medium containing levels of the molecule that are altered from physiological levels, for example, higher physiological levels, of the molecule. Other methods include vesicle-mediated delivery and microinjection. In the case of nucleic acids and polypeptides, the level of the biological molecule in the cell may be raised by the introduction of a heterologous nucleic acid into the cell which directs the expression of the nucleic acid or polypeptide.

The term "heterologous nucleic acid" in the present context means that the nucleic acid is not present in its natural context i.e. the cell has been modified so as to contain the nucleic acid which would otherwise not be present in the form in which it is introduced. For example, the nucleic acid may be extrachromosomal, such as encoded on a bacterial plasmid, bacteriophage, transposon, yeast episome, insertion element, yeast chromosomal element, a virus (including, for example, baculoviruses and SV40 (simian virus), vaccinia viruses, adenoviruses, fowl pox viruses, pseudorabies viruses and retroviruses, or combinations thereof, such as those derived from plasmid and bacteriophage genetic elements, including cosmids and phagemids. The nucleic acid may be incorporated into the chromosome, such as by the use of retroviral vectors, including murine or feline leukaemia virus, or the Lentiviruses human immunodeficiency virus and equine infectious anaemia

- virus. Human, bacterial and yeast artificial chromosomes (HACs, BACs and YACs respectively) may also be employed to deliver larger fragments of DNA than can be contained and expressed in other vectors. The nucleic acid may also be integrated into the genome, for example, by viral transduction or by homologous recombination (see, for example, International patent application WO99/29837), or by the microinjection techniques used to generate transgenic animal embryos or stem cells. Nonetheless, part or all of the heterologous nucleic acid molecule may be identical to a corresponding genomic sequence, since the introduction of additional copies of a gene is a convenient means for increasing the levels of expression of that gene.
- Indirect means for altering the levels of the biological molecule are numerous and include increasing the levels of an inhibitory or stimulatory molecule using the methods described above. Inhibitory molecules include antisense nucleic acids, ribozyme or an EGS (external guide sequence) directed against the mRNA encoding the biological molecule, a transdominant negative mutant directed against the biological molecule, transcription factors, enzyme inhibitors, and intracellular antibodies, such as scFvs. Examples of stimulatory molecules include enzyme activators, and transcriptional activators. Thus, cells may be manipulated in a number of ways such that ultimately the levels of the biological molecule are altered. Reduced expression may be achieved by expressing an anti-sense RNA.
- According to the invention, the levels of the biological molecule should be altered relative to physiological levels. Thus they may be enhanced or reduced. The term "relative to physiological levels" means relative to the concentration or activity of the biological molecule typically present in the cell type under normal physiological conditions prior to manipulation of those levels. Thus the intention is that by deliberate means, the activity of the biological molecule is altered above or below that which is found in the cell under a range of normal physiological conditions. "Physiological conditions" includes the conditions normally found *in vivo* and the conditions normally used *in vitro* to culture the cells.
- By way of an example, the activity or concentration may be increased or decreased 2-fold, 5-fold, 10-fold, 20-fold, 50-fold or 100-fold compared to the normal physiological activity or concentration found in the cell prior to introducing, for example, the heterologous nucleic acid.

-20-

The invention allows the identification of genetic elements that are involved in a cellular process. As discussed above, the term "genetic element" is meant to include genes, gene products (such as RNA molecules, and polypeptides), and cis-acting regulatory elements (such as promoter elements and enhancer elements). Compared to conventional differential screening techniques, the invention considerably facilitates the identification of genes and gene products that are involved in a cellular process, since the level and/or ratio of signal to noise is considerably improved using the described method.

Of particular note is the ability that the invention imparts to identify genes and gene products involved in a cellular process, and thus to investigate the role of these genes and gene products further. For example, if a particular polypeptide is known to have a role in a cellular process, this paves the way for the development of agents that modify or regulate the polypeptide, and thus influence the cellular process itself. Such information clearly has great relevance in the analysis, diagnosis and treatment of disease, in identifying candidate points for intervention, and paving the way for the development of agents that are able to prevent or redress any physiological imbalance in any cellular process that leads to undesirable effects, such as disease.

In addition to identifying genes and gene products, the invention allows the identification of other elements that are associated with genes that are implicated in a particular cellular process. Examples of such elements include promoter elements and enhancer elements that regulate the transcription of genes that are expressed in the cellular process. The identification of such elements would have great value in the study of cellular processes, and, for example, would pave the way for the development of synthetic regulatory elements that are responsive to biological signals generated in a particular cellular process.

Included in this aspect of the invention is the identification of mutations and polymorphisms in genes and their regulatory elements, that affect the response of the gene to the cellular process under study. This type of information would be of great value in evaluating and dissecting the differences in expression patterns that are found between different individuals under different biological conditions.

The differential expression screening method of the invention also allows the molecular dissection of biological pathways, by altering particular aspects of the pathway under study, as desired. In this way, the method of the invention is advantageous over conventional differential expression screening methods that are known in the art. These

prior art methods compare gene expression profiles between cell populations under different biological conditions, and thus generate a global perspective on the gene expression patterns in the two populations, even if heterologous nucleic acids are used without reference to specific biological pathways and responses. In contrast, by influencing
5 the level of a particular biological molecule that is implicated in the pathway under study, through the introduction of a heterologous nucleic acid into one cell population, the method of the invention allows a pathway to be dissected into its precise molecular components.

This aspect of the invention may be illustrated with the particular example of the biological
10 response to hypoxia, although the skilled reader will appreciate that analogous cellular processes will be equally applicable to study by this method. The biological response to hypoxia is complex, having a large number of participating molecular components. Two important components are the proteins HIF1 α and EPAS1. By introducing into one cell population, a heterologous nucleic acid encoding HIF1 α , this allows the evaluation of the
15 differences in gene expression profile that are generated by HIF1 α itself. A similar experiment, performed using a heterologous nucleic acid encoding EPAS1, allows the dissection of this particular aspect of the molecular response to hypoxia. By identifying molecular components that are regulated by one pathway (HIF1 α) and not the other (EPAS1), this cellular process can be selectively regulated, for example, using agents that
20 are specific to a component of the HIF1 α pathway. The application of the present invention to the hypoxic response has enabled the discovery of novel genes which are differentially regulated by HIF1 α and EPAS1, and thus has raised the possibility of tissue and cell-specific therapeutic modulation of the cellular response to hypoxia.

HIF1 α agonists or antagonists potentially have application to up or down-regulate,
25 respectively, responses to hypoxia such as angiogenesis and erythropoiesis. For example, it is known that the production of erythropoietin in the kidney is regulated by HIF1 α (Bunn *et al* (1998) Erythropoietin: a model system for studying oxygen-dependent regulation, *J Exp Biol* 201:1197-1201), and thus HIF1 α antagonists may cause anaemia by down-regulation of erythropoietin. The application of the present invention to the identification
30 of genes which are differentially regulated by HIF1 α and EPAS1, and the clear recognition of the different effects of these two closely-related transcription factors, permits the development of EPAS1 agonists or antagonists, or modulators of the activity of specific

-22-

differentially-regulated genes, to overcome any potentially negative clinical effects of HIF1 α modulation, and thereby enable the identification and development of diagnostic and therapeutic products for diagnosing and treating hypoxia-related diseases.

Whereas in a preferred embodiment of the invention, the levels of the biological molecule
5 are altered by the introduction of a heterologous nucleic acid, typically a nucleic acid that directs expression of a polypeptide, the heterologous nucleic acid should comprise a coding sequence operably linked to a control sequence that is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" means that the components described are in a relationship
10 permitting them to function in their intended manner. A regulatory sequence "operably linked" to a coding sequence may be ligated to the coding sequence in such a way that expression of the coding sequence is achieved under conditions compatible with the control sequences.

The control sequences may be modified, for example, by the addition of further
15 transcriptional regulatory elements to make the level of transcription directed by the control sequences more responsive to transcriptional modulators.

Control sequences suitable to be operably linked to sequences encoding the protein of the invention include promoters/enhancers and other expression regulation signals. These control sequences may be selected to be compatible with the host cell in which the
20 expression vector is designed to be used. The term "promoter" is well known in the art and encompasses nucleic acid regions ranging in size and complexity from minimal promoters to promoters including upstream elements and enhancers.

The promoter is typically selected from promoters that are functional in mammalian cells, although promoters functional in prokaryotic cells or other eukaryotic cells may be used
25 where appropriate. Thus, the promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression is to occur. Eukaryotic promoters may be promoters that function in a ubiquitous manner (such as promoters of α -actin, β -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase).
30 Tissue-specific promoters specific for particular cells may be used. They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors. Viral promoters may also be used, for example the Moloney murine

-23-

leukaemia virus long terminal repeat (MMLV LTR) promoter, the Rous sarcoma virus (RSV) LTR promoter or the human cytomegalovirus (CMV) IE promoter.

It may be advantageous for the promoters to be inducible so that the levels of expression from the heterologous nucleic acid can be regulated during the lifetime of the cell.

5 Inducible means that the levels of expression obtained using the promoter can be regulated.

In addition, any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

Examples of suitable vectors include plasmids, artificial chromosomes and viral vectors.

10 Viral vectors include adenoviral vectors, herpes simplex viral vectors, and retroviral vectors. Vectors/polynucleotides may be introduced into suitable host cells using a variety of techniques known in the art, such as transfection, transformation, electroporation, infection with recombinant viral vectors such as retroviruses, herpes simplex viruses and adenoviruses, direct injection of nucleic acids and biolistic transformation. It is particularly preferred to use recombinant viral vector-mediated techniques.

Viral vectors

The viral vectors used to introduce heterologous nucleic acids into cells according to the present invention may be derived from or may be derivable from any suitable virus. A large number of different viruses have been identified, and subclasses exist, including

20 retroviruses, lentiviruses, which are a subclass of retroviruses, adenoviruses and herpes simplex virus. Examples of retroviruses include: murine leukemia virus (MLV), human immunodeficiency virus, type 1 (HIV-1), human immunodeficiency virus, type 2 (HIV-2), simian immunodeficiency virus, human T-cell leukaemia virus (HTLV), equine infectious anaemia virus (EIAV), feline immunodeficiency virus (FIV), bovine immunodeficiency

25 virus (BIV), Jembrana virus, simian immunodeficiency virus (SIV), caprine arthritis-encephalitis virus (CAEV), gibbon ape leukemia virus (GALV), spleen focus forming virus (SFFV), mouse mammary tumour virus (MMTV), Rous sarcoma virus (RSV), Fujinami sarcoma virus (FuSV), Moloney murine leukemia virus (Mo-MLV), FBR murine osteosarcoma virus (FBR MSV), Moloney murine sarcoma virus (Mo-MSV), Abelson

30 murine leukemia virus (A-MLV), Avian myelocytomatosis virus-29 (MC29), and Avian erythroblastosis virus (AEV). A detailed list of retroviruses may be found in Coffin *et al.*,

1997, "Retroviruses", Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 758-763.

Details on the genomic structure of many retroviruses may be found in the art. By way of example, details on HIV, EIAV and Mo-MLV may be found from the NCBI Genbank
5 (Genome Accession Nos. AF033819, U01866 and AF033811, respectively).

The lentivirus subgroup of retroviruses can be split even further into "primate" and "non-primate" viruses. Examples of primate lentiviruses include the human immunodeficiency virus, type 1 (HIV-1), the causative agent of acquired-immunodeficiency syndrome (AIDS), and simian immunodeficiency virus (SIV). The non-primate lentiviral group
10 includes the prototype "slow virus" visna/maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) and Jembrana virus.

The basic structure of a retrovirus genome is a 5' LTR and a 3' LTR, between or within
15 which are located a packaging signal (*psi*) to enable the genome to be packaged, a primer binding site, integration sites to enable integration into a host cell genome and *gag*, *pol* and *env* genes encoding the packaging components - these are polypeptides required for the assembly of viral particles. More complex retroviruses have additional features, such as *rev* and RRE sequences in HIV, which enable the efficient export of RNA transcripts of the
20 integrated provirus from the nucleus to the cytoplasm of an infected target cell. Additional features present in the HIV-1 genome are *tat*, *vif*, *vpu*, *vpr*, and *nef* which encode accessory proteins which are essential for infectivity of the virus or modulate the infectivity of the virus. An additional feature present in the genomes of lentiviruses is the central polypurine tract/central termination sequence (cPPT/CTS) which facilitates infection of non-dividing
25 cells.

In the provirus, these genes and other elements are flanked at both ends by regions called long terminal repeats (LTRs). The LTRs are responsible for proviral integration, and transcription. As such they contain enhancer-promoter sequences and can control the expression of the viral genes. Encapsidation of the retroviral RNAs occurs by virtue of a
30 *psi* sequence which is located near the 5' end of the viral genome.

The LTRs themselves are identical sequences that can be divided into three elements, which are called U3, R and U5. U3 is derived from the sequence unique to the 3' end of

-25-

the RNA. R is derived from a sequence repeated at both ends of the RNA and U5 is derived from the sequence unique to the 5' end of the RNA. The sizes of the three elements can vary considerably among different retroviruses. The R regions at both ends of the viral RNA are repeated sequences, whereas U5 and U3 represent unique sequences
5 at the 5'- and 3'-ends of the RNA genome, respectively.

In a typical retroviral vector for use in the screening methods of the invention, at least part of one or more of the *gag*, *pol* and *env* protein coding regions essential for replication of the virus may be removed. This makes the retroviral vector replication-defective. Other modifications, such as the removal of promoter/enhancer elements from the U3 region, or
10 deletion of genes for accessory proteins, can also render the vector replication defective. The removed portions may even be replaced by a nucleotide sequence of interest (NOI), such as a nucleotide sequence encoding a biological molecule as described above, to generate a vector capable of integrating its genome into a host genome but wherein the modified viral genome is unable to propagate itself due to a lack of structural proteins.

15 When integrated in the host genome, expression of the NOI occurs either as a result of transcription from the LTR of the vector or as a result of transcription from a promoter sequence placed in an appropriate position, for example, between the LTR's, and with respect to the NOI. It should be noted that it is also possible to replace the viral promoter present in the LTR with a different promoter. The promoter sequence will typically be
20 active in mammalian cells. The promoter sequence driving expression of the one or more first nucleotide sequences may be, for example, a constitutive or a regulated. The promoter may, for example, be a viral promoter such as the natural viral promoter or a CMV promoter or it may be a mammalian promoter. It is particularly preferred to use a promoter that is preferentially active in a particular cell type or tissue type or that can be
25 regulated. Thus, in one embodiment, a tissue-specific regulatory sequence may be used. In mammalian cells an example of a regulatable promoter system is the tetracycline-inducible promoter system (Clontech, Palo Alto, CA).

Thus, the transfer of an NOI into a site of interest is typically achieved by: integrating the NOI into the recombinant viral vector; packaging the modified viral vector into a virion
30 particle; and allowing transduction of a site of interest - such as a targeted cell or a targeted cell population.

-26-

A minimal genome of a retroviral vector for use in the present invention will therefore comprise (5') R - U5 - a packaging signal (*psi*) and one or more first nucleotide sequences - U3-R (3'). However, the plasmid vector used to produce the vector genome within a host cell/packaging cell will also include transcriptional regulatory control sequences operably
5 linked to the vector genome to direct transcription of the genome in a host cell/packaging cell. These regulatory sequences may be the natural sequences associated with the transcribed retroviral sequence, i.e. the 5' U3 region, or they may be a heterologous promoter such as another viral promoter, for example, the CMV promoter.

Production of retroviral vectors

- 10 Replication-defective retroviral vectors can be produced by using either producer cell lines, packaging cell lines or by transient transfection of a suitable cell line.

Producer cell lines are cell lines which express all the components required for assembly of vector particles capable of transduction. That is, they express *gag/pol* and envelope proteins, which are required for formation of vector particles and produce transcripts of the
15 vector genome which are packaged into vector particles. Conventionally, producer cells differ from packaging cells only by the fact that they also stably express the vector RNA. The vector RNA can be introduced into the packaging cell, to make the producer cell, either by transfection of a plasmid which is capable of directing expression of the vector RNA, or by transduction of a vector genome which is capable of directing synthesis of
20 vector RNA following integration into the nuclear DNA of the host cell. Packaging cells can also be converted into producer cells on a temporary basis by transient transfection of a plasmid which directs the transcription of vector RNA. A producer cell can also be made from a cell line which comprises only two of the three components required for formation of transduction competent vector particles. For example, in the field of MLV vectors, the
25 TelCEB cell line stably expresses MLV *gag/pol* and the genome of the MLV vector, MFGnlsLacZ. It can be converted to a producer cell line by introduction of a plasmid which directs expression of an envelope gene. In this respect it should be noted that while the *gag/pol* genes are derived from the same virus, the *env* may be derived from the same virus or be from a different virus. When infectious particles are formed as a result of the
30 use of an envelope function from a different virus, the vector particles are said to have been 'pseudotyped'. For example, in the field of lentiviral vectors, it is common to make

-27-

vectors which are pseudotyped by the G protein of the rhabdovirus, vesicular stomatitis virus.

Vector particles can also be made transiently, by transfection of a suitable cell line with plasmids which express the components required for transduction particle formation. For example, MLV, EIAV or HIV vector particles can be produced by transfection of the human cell line, HEK 293T, with plasmids which direct expression of the gag/pol, vector genome and the envelope (Soneoka *et al.*, 1995). Additional plasmids may also be co-transfected, for example, for the purpose of increasing titre.

The transient transfection method may advantageously be used to measure levels of vector production when vectors are being developed. In this regard, transient transfection avoids the longer time required to generate stable vector-producing cell lines and may also be used if the vector or retroviral packaging components are toxic to cells. Components typically used to generate retroviral vectors include a plasmid encoding the gag/pol proteins, a plasmid encoding the env protein and a plasmid containing an NOI. Vector production involves transient transfection of one or more of these components into cells containing the other required components. If the vector encodes toxic genes or genes that interfere with the replication of the host cell, such as inhibitors of the cell cycle or genes that induce apoptosis, it may be difficult to generate stable vector-producing cell lines, but transient transfection can be used to produce the vector before the cells die. Also, cell lines have been developed using transient transfection that produce vector titre levels that are comparable to the levels obtained from stable vector-producing cell lines.

It has now become standard practice within the field of retroviral vectors to arrange for the genes which encode the components for particle formation to be encoded separately. For example, the FLYA13 MLV packaging cell line, has separate transcriptional units for expression of MLV gag/pol and env. This strategy reduces the potential for production of a replication-competent virus since three recombinant events are required for wild type viral production. As recombination is greatly facilitated by homology, reducing or eliminating homology between the genomes of the vector and the helper can also be used to reduce the problem of replication-competent helper virus production.

Producer cells/packaging cells can be of any suitable cell type. Most commonly, mammalian producer cells are used but other cells, such as insect cells are not excluded. Clearly, the producer cells will need to be capable of efficiently translating the env and

-28-

gag, pol mRNA. Many suitable producer/packaging cell lines are known in the art. The skilled person is also capable of making suitable packaging cell lines by, for example stably introducing a nucleotide construct encoding a packaging component into a cell line.

It is highly desirable to use high-titre virus preparations in both experimental and practical applications. One techniques for increasing viral is to concentrate of viral stocks. This is conveniently achieved by centrifugation, however other methods such as column chromatography can be used.

Vector systems based on lentiviruses are particularly suited for use in this invention. This is because they are capable of infecting dividing or non-dividing cells. Examples of the non-dividing cells in which gene transfer can be achieved include neurons and haematopoietic stem cells. In addition, lentiviral vectors can be configured so that they express only the NOI in the target cell. In effect they are phenotypically silent. Thus, the process of introducing the transgene causes minimal perturbation to the host cell. Vector systems based on HIV-1, ELAV and FIV have been developed and have been developed to a point where they are described as minimal. Minimal vector systems for HIV-1 and ELAV are described in WO 98/17815 and WO 99/32646 and in Kim *et al.* (1998) J. Virol, 72, 811-816, and Mitrophanous *et al.*(1996) Gene Therapy, 6, 1808-1818. In these minimal systems the vector component is engineered to express only the NOI in the target cell and furthermore the expression of viral proteins in the cell used for production is reduced to a minimum. For both the HIV-1 and ELAV systems the only lentiviral genes which must be expressed for infectious particle formation are *gag/pol* and *rev*. Rev, working in conjunction with the Rev-response element (RRE), is necessary to achieve the levels of Gag/Pol required for high levels particle formation. One way to reduce the requirement for lentiviral proteins even further is to codon optimise *gag/pol*. This renders expression independent of Rev/RRE. The process of codon-optimisation of the lentiviral *gag/pols* is described in WO 99/41397, in Kotsopoulou *et al.*, (2000) J.Virol. 74, 4839-4852. The codon optimisation process for ELAV *gag/pol* is described in UK Patent Application 0009760.0.

More information concerning the codon optimisation process is given here by way of explanation. Cells from various species differ it their usage of particular codons. This codon bias is reflected in a bias in the relative abundance of particular tRNAs in the cell type. By altering the codons in the sequence so that they are tailored to match the relative

-29-

abundance of corresponding tRNAs, it is possible to increase expression. By the same token, it is possible to decrease expression by deliberately choosing codons for which the corresponding tRNAs are known to be rare in the particular cell type. Thus, an additional degree of translational control is available.

- 5 Many viruses, including HIV and other lentiviruses, use a large number of rare codons and by changing these to correspond to commonly used mammalian codons, increased expression of the packaging components in mammalian producer cells can be achieved. Codon usage tables are known in the art for mammalian cells, as well as for a variety of other organisms.
- 10 Codon optimisation has a number of other advantages. By virtue of alterations in their sequences, the nucleotide sequences encoding the packaging components of the viral particles required for assembly of viral particles in the producer cells/packaging cells have RNA instability sequences (INS) eliminated from them. At the same time, the sequence coding sequence for the packaging components is retained so that the viral components
- 15 encoded by the sequences remain the same, or at least sufficiently similar to ensure that the function of the packaging components is not compromised. Codon optimisation also overcomes the Rev/RRE requirement for export, rendering optimised sequences Rev independent. Codon optimisation also reduces homologous recombination between different constructs within the vector system (for example between the regions of overlap
- 20 in the gag-pol and env open reading frames). The overall effect of codon optimisation is therefore a notable increase in viral titre and improved safety.

In one approach, only codons relating to INS are codon optimised. However, in highly preferred embodiment, the sequences are codon optimised in their entirety, with the exception of the sequence encompassing the frameshift site. The *gag/pol* gene comprises

25 two overlapping reading frames encoding gag and pol proteins, respectively. The expression of both proteins depends on a frameshift during translation. This frameshift occurs as a result of ribosome "slippage" during translation. This slippage is thought to be caused at least in part by ribosome-stalling RNA secondary structures. Such secondary structures exist downstream of the frameshift site in the *gag/pol* gene. For HIV, the region

30 of overlap extends from nucleotide 1222 downstream of the beginning of *gag* (wherein nucleotide 1 is the A of the *gag* ATG) to the end of *gag* (nt 1503). Consequently, a 281 bp fragment spanning the frameshift site and the overlapping region of the two reading frames

-30-

is preferably not codon optimised. Retaining this fragment will enable more efficient expression of the gag-pol proteins. For EIAV the beginning of the overlap has been taken to be nt 1262 (where nucleotide 1 is the A of the *gag* ATG). The end of the overlap is at nt1461. In order to ensure that the frameshift site and the *gag-pol* overlap are preserved,
5 the wild type sequence has been retained from nt 1156 to 1465.

Derivations from optimal codon usage may be made, for example, in order to accommodate convenient restriction sites, and conservative amino acid changes may be introduced into the gag-pol proteins.

In a highly preferred embodiment, codon optimisation was based on highly expressed
10 mammalian genes. The third and sometimes the second and third base may be changed.

Due to the degenerate nature of the Genetic Code, it will be appreciated that numerous *gag/pol* sequences can be achieved by a skilled worker. Also there are many retroviral variants described which can be used as a starting point for generating a codon optimised *gag/pol* sequence. Lentiviral genomes can be quite variable. For example there are many
15 quasi-species of HIV-1 which are still functional. This is also the case for EIAV. These variants may be used to enhance particular parts of the transduction process. Examples of HIV-1 variants may be found at <http://hiv-web.lanl.gov>. Details of EIAV clones may be found at the NCBI database: <http://www.ncbi.nlm.nih.gov>.

The strategy for codon optimised *gag-pol* sequences can be used in relation to any
20 retrovirus. This would apply to all lentiviruses, including EIAV, FIV, BIV, CAEV, Maedi/Visna, SIV, HIV-1 and HIV-2. In addition this method could be used to increase expression of genes from HTLV-1, HTLV-2, HFV, HSRV and human endogenous retroviruses (HERV), MLV and other retroviruses.

The performance of lentiviral vectors may be enhanced in several ways. Most notably
25 there are modifications to the vector genome which improve the efficiency of transduction and the expression level of the NOI. Both of these types of modification may improve the utility of lentiviral vectors for use in the applications described herein. The efficiency of transduction can be improved by incorporation of an element termed the central polypurine tract and the central termination sequence (cPPT/CTS). This element of approximately
30 200nt is naturally located near the centre of the viral genome and has been shown to improve transduction by HIV-1-based vectors (Follenzi *et al.*, (2000) Nat Genet. 2000 Jun;25(2):217-22; Sirven *et al.*, Blood. 2000 Dec 15;96(13):4103-10. Expression of the

NOI may be improved utilising the woodchuck hepatitis virus post-transcriptional regulatory element (WHPRE). It is a 600bp element that enhances the expression of proteins by increasing the half-life of mRNA through a mechanism involving enhanced polyadenylation. Its beneficial effect has been demonstrated in a number of vectors including HIV-1 based vectors (Zufferey, J Virol. (1999) Apr;73(4):2886-92; Ramezani *et al.*, Mol Ther. 2000 Nov;2(5):458-69). This and other methods of use of the element are described in WO 99/14310.

Vectors derived from poxviruses, which include vectors derived from vaccinia, avian pox virus and entomopox viruses, may also be used achieve expression of NOI in a wide range of target cell type. Their use is reviewed in B Moss. 1996 (Poxviridae: The viruses and their replication In Virology Ed BN Fields *et al.* Chap 83 pp2637-2671 Lippincott-Raven Publishers; PA USA). The use of vectors derived from alphaviruses and poxvirus are reviewed in MW Carroll *et al.*, 2001 (Mammalian expression systems and vaccination ; In Genetically Engineered Viruses, pp 107-158 Ed. C Ring & E Blair BIOS Scientific Publishers Ltd Oxford UK). Adeno-associated viral vectors may also be used as gene transfer vectors and their use is reviewed in the following publication: "Adeno-associated viral vectors for gene transfer and gene therapy" (Bueller, H AUTHOR AFFILIATION: Institut fur Molekularbiologie, Universitat Zurich, Switzerland. SOURCE: Biol Chem 1999 Jun;380(6):613-22).

C. Cells of interest

A cell of interest can be any cell, for example a prokaryotic cell, a fungal cell (for example, yeast), a plant cell or an animal cell, such as an insect cell or a mammalian cell, including a human cell. In the case of cells from multicellular organism, cells may be primary cells or immortalised cell lines, they may comprise a tissue sample, or they may be part of a living organism. Although cells are frequently referred to in the singular, in general cells will be part of a cell population.

In the methods of the invention, a comparison is required between gene expression in at least two distinct cells. Typically the first of the two or more cells is termed a reference cell. In a preferred embodiment of the invention, the cells to be used in the comparison are substantially identical in all respects. For example, they may both be cells of the same cell line or obtained from the same tissue in an organism. One or both of the cells may then be manipulated so that they comprise altered levels, relative to physiological levels, of the

-32-

biological molecule as described in section B. In one embodiment, the first cell is unaltered and the second cell is altered. This is particularly preferred, since it should result in an improved signal to noise ratio. However in another embodiment, both cells are altered.

Nonetheless, it is not necessary that the cells used as the starting point of the investigation be substantially identical. For example, in one aspect of the invention, genes involved in disease processes may be investigated using cells from a diseased organism, such as a mammalian patient. These may be compared with cells from a normal organism or similar cells from the same or a different diseased individual. Where cells from a normal organism and a diseased organism are used, generally the normal cells correspond to the first cell of interest and the diseased cells correspond to the second cell of interest. Consequently, at least the diseased cells are modified as described above in section B so that these cells comprise altered levels of the biological molecule.

In another embodiment of the invention, one cell is a cell comprising a mutant gene, whereas the other cell comprises a wild-type version of the same gene.

Another possibility embraced by the present invention is that the cells are from different tissues or from different stages in development or differentiation.

D. Uses

The present invention provides a number of improved methods for identifying genes by differential expression screening techniques.

In a first aspect, a method is provided for identifying genes involved in a cellular process. Essentially one of the cell types is manipulated so that the levels within that cell of a biological molecule involved in the cellular process are altered. Typically, this may be achieved by the introduction of a heterologous nucleic acid into the cell to direct the expression of a polypeptide. The polypeptide may be the same as the biological molecule or it may modulate the levels of the biological molecule, as described above.

In general, simply modulating the levels of a biological molecule in one of two identical cells and then measuring gene transcription is not the aim of the methods of the present invention since the effect of the biological molecule on gene expression will be measured in the cells, rather than using the change in the levels of the biological molecule to enhance or reduce the response to an event of interest.

However, where the biological molecule is a gene product, such as a polypeptide, that is produced naturally within the cell, altering the levels of the gene product by the introduction of a heterologous nucleic acid may be used simultaneously both to perturb a cellular process and to enhance the response to such a perturbation, so facilitating the identification of gene products that are involved in that cellular process using differential expression techniques. By way of an example, overexpression of HIF-1 α amplifies the downstream elements of the hypoxic response, due its enhanced regulatory effect on HIF-1 α mediated transcription.

Nonetheless, in the broader aspects of the present invention, two main possibilities arise. The first possibility is that the two cell types are different and have inherently different gene expression patterns. In this situation, alterations in the levels of the biological molecule can be used to enhance those differences. The two cells may be, for example, from different tissues, or from different stages in development or differentiation. The two cells may also be different by virtue of one cell being from diseased tissue and the other cell from normal tissue. Other configurations envisaged are given in section C above.

The second possibility is that the two cell types are the same, but one of the cells is stimulated in some manner and the other cell is not (or one is stimulated to a greater extent than the other). For example, one cell may be incubated in the presence of a growth factor and the other not. In this example, the growth factor is therefore not the biological molecule but is instead a stimulus or signal designed to perturb gene expression in the cell, the effects of which may be amplified by the biological molecule, which in turn is altered in level by the polypeptide expressed from the heterologous nucleic acid.

Thus, in this aspect of the invention, there is provided a method whereby genes whose expression is regulated by a signal or by an environmental change, are identified by subjecting two distinct cell populations to different levels of a signal or environmental condition, whereby either or both cell populations have been manipulated so as to alter the levels of a biological molecule whose activity is responsive to the signal or environmental condition, and identifying gene products whose expression differs. The term "whose activity is responsive to the signal or environmental condition" includes any biological molecule whose concentration in the cell varies in response to the signal or environmental condition, as well as biological molecules whose properties (such as enzymatic activity or

affinity for another cellular component) vary in response to the signal or environmental condition.

Thus, returning to the above growth factor example, the cells that are exposed to the growth factor may have been altered to express increased levels of a transcription factor that is involved in the signal transduction cascade that relates to that particular growth factor. Consequently, the effect of the growth factor will be increased downstream of the transcription factor (in either a negative or a positive sense), so facilitating the identification of differentially expressed genes whose expression is regulated by the transcription factor and, ultimately, by the growth factor.

- As discussed above, the signal or environmental condition may be either a physical signal, (such as, for example, a change in redox conditions, CO₂ levels, light, osmotic stress, temperature [hypo and hyper- thermia], mechanical stress, irradiation [ionising or non-ionising], exposure to hypoxia, anoxia, ischemia, or chemical (such as a change in the cellular microenvironment, exposure to ligands that bind to receptors on the cell surface and trigger signal transduction pathways, including hormones, cell surface molecules normally attached to other cells, substrates for enzyme reactions that diffuse into or are transported into the cell, growth factors, cytokines, chemokines, inflammatory agents, toxins, metabolites, pH, pharmaceutical agents, imbalance of a plasma-borne nutrient, cell-extracellular matrix interactions, cell-cell interactions, accumulations of foreign or pathological extracellular components, intracellular and extracellular pathogens [including bacteria, viruses, fungi and mycoplasma] and a genetic perturbation.

The first cell may be subjected to the signal at a first level and the second cell subjected to the signal at a second level. In one example, the first level may simply be the absence of the signal and the second level may be the presence of the signal, or vice-versa. The levels of the signals may be adjusted so as to provide a discernible difference in gene expression. In an alternative embodiment, both the first and second cells may be compared at both the first and second levels of the signal. The presence of the heterologous nucleic acid in the second cell will amplify the differences in gene expression that are caused by the change in signal.

- Preferably, the levels of both the signals are at physiologically relevant levels.

-35-

In one aspect of the present invention, knowledge already acquired relating to genes that are involved in a disease or other biological process may be used to generate further information about other genes whose expression is altered in a disease or other biological process. In order to do this, one cell is modified so that the levels of the gene product
5 known to be involved in the disease or other biological process are altered, either directly, for example, by the introduction of a heterologous nucleic acid encoding the gene product, or indirectly as described in section B. Gene expression is then measured in both cells and the results compared to identify gene products whose expression varies.

In this aspect of the invention, the two cells may be identical, except in respect of the
10 change in the levels of the gene product that is known to be involved in the disease or other biological process of interest. The two cells may thus both be normal cells of the same type as a cell type in which the disease or other process manifests itself, or they may both be diseased cells. Alternatively, one cell may be normal, and the other diseased. Preferably, the diseased cell is the modified cell if only one of the cells is modified.

15 In a further aspect of the invention, differential expression screening methods are used to identify genes involved in a disease or other process in a two stage procedure. Firstly, gene expression is compared between a first cell of interest, for example, a cell from a normal patient, and a second cell of interest, for example, a corresponding cell from a diseased patient. As discussed above, the first cell and the second cell will be different in
20 some aspect, such that they exhibit different expression patterns. This may be because the cells are from different tissues or because they are from different individuals (for example, from a normal patient and from a diseased patient). The cells may be of similar origin but have been treated differently in some respect.

Gene products whose expression differs between the first cell and the second cell are then
25 identified. Secondly, a third cell of interest, essentially identical to the first cell is used in a this screening procedure, where a candidate gene is introduced into the third cell so that levels of the genes are altered (typically raised). Gene expression in this cell is compared with gene expression in the first cell and gene products whose expression differs between the first cell and the third cell that comprises altered levels of the candidate gene are
30 identified. If a gene product whose expression is altered in the second cell also has altered gene expression in the third cell, then the candidate gene is selected for further study.

Preferably there is a correlation over two or more gene products, preferably at least four or five gene products to minimise false positives.

The invention will now be described with reference to the examples which are illustrative only and non-limiting. In the examples below, the method of the invention as described above is referred to as "Smartomics".

BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Northern blots performed to confirm overexpression of HIF-1 α and EPAS1 using adenoviral gene transfer in transduced macrophages. RNA loading was as follows: Lanes 1,2: Macrophages transduced with the adenovirus AdApt ires-GFP. Lanes 3,4: Macrophages transduced with the adenovirus AdApt HIF-1 α -ires-GFP. Lanes 4,5: Macrophages transduced with the adenovirus AdApt EPAS1-ires-GFP. In lanes 1,3,5 the macrophages were maintained in normoxia (20% O₂). In lanes 2,4,6 the macrophages were maintained in hypoxia (0.1% O₂). Positions of bands from an RNA size ladder are indicated to the right of each blot in kilobases (kb). Hybridisation probes were complimentary to the genes HIF-1 α (A), EPAS1 (B) and 28s ribosomal RNA (C).

Figure 2: A scatter plot of two representative RNA samples analysed using Research Genetics GeneFilters. RNA from non-transduced macrophages in normoxia (Y-axis) or hypoxia (X-axis) was hybridised to two Research Genetics GeneFilters GF200 arrays. Analysis was output as normalised intensity for each gene on the array, with two values per gene corresponding to the signals from normoxia and hypoxia. These values were plotted as a scatter graph, with each dot representing a gene on the array. Genes expressed at similar levels between the RNA samples are located at the x=y line. In this representation an indication is apparent of the dynamic range of detection.

Figure 3: Analysis of Lactate Dehydrogenase A expression with Smartomics. In section A, thumbnail images of spots corresponding to the lactate dehydrogenase-A (LDH-A) gene are shown. Contrast levels were set at a level to allow optimal visualisation of this gene, but are at a constant setting throughout this figure. Each strip of 6 images corresponds to a discrete array position or experiment, over the range of RNA samples. Figures beneath individual spot images are ratios of the normalised intensity of that spot compared to the reference condition (gfp; 20%O₂). Array location: Identity of the spot as defined by Research Genetics. Clone: IMAGE identification. The histogram (section B) shows the

average of the figures shown and error bars are standard deviation. gfp: cells transduced with AdApt ires-GFP. Hif-1a: Cells transduced with AdApt Hif-1 α -ires-GFP. Epas1: Cells transduced with AdApt Epas1-ires-GFP.

Figure 4: Analysis of Glyceraldehyde 3-phosphate dehydrogenase expression with Smartomics. In section A, thumbnail images of spots corresponding to the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene are shown. Contrast levels were set at a level to allow optimal visualisation of this gene, but are at a constant setting throughout this figure. Each strip of 6 images corresponds to a discrete array position or experiment, over the range of RNA samples. Figures beneath individual spot images are ratios of the normalised intensity of that spot compared to the reference condition (gfp; 20%O₂). Array location: Identity of the spot as defined by Research Genetics. Clone: IMAGE identification. The histogram (section B) shows the average of the figures shown and error bars are standard deviation. gfp: cells transduced with AdApt ires-GFP. Hif-1a: Cells transduced with AdApt Hif-1 α -ires-GFP. Epas1: Cells transduced with AdApt Epas1-ires-GFP.

Figure 5: Analysis of Platelet derived growth factor beta expression with Smartomics. In section A, thumbnail images of spots corresponding to the Platelet derived growth factor beta (PDGF Beta) gene are shown. Contrast levels were set at a level to allow optimal visualisation of this gene, but are at a constant setting throughout this figure. Each strip of 6 images corresponds to a discrete array position or experiment, over the range of RNA samples. Figures beneath individual spot images are ratios of the normalised intensity of that spot compared to the reference condition (gfp; 20%O₂). Array location: Identity of the spot as defined by Research Genetics. Clone: IMAGE identification. For this gene, different IMAGE clones corresponding to the same gene are present. The histogram (section B) shows the average of the figures shown and error bars are standard deviation. gfp: cells transduced with AdApt ires-GFP. Hif-1a: Cells transduced with AdApt Hif-1 α -ires-GFP. Epas1: Cells transduced with AdApt Epas1-ires-GFP.

Figure 6: Analysis of Monocyte Chemotactic Protein-1 expression with Smartomics. In section A, thumbnail images of spots corresponding to the Monocyte Chemotactic Protein-1 (MCP-1) gene are shown. Contrast levels were set at a level to allow optimal visualisation of this gene, but are at a constant setting throughout this figure. Each strip of 6 images corresponds to a separate experiment, over the range of RNA samples. Figures

beneath individual spot images are ratios of the normalised intensity of that spot compared to the reference condition (gfp; 20%O₂). Array location: Identity of the spot as defined by Research Genetics. Clone: IMAGE identification. The histogram (section B) shows the average of the figures shown and error bars are standard deviation. *gfp*: cells transduced with AdApt ires-GFP. *Hif-1a*: Cells transduced with AdApt Hif-1 α -ires-GFP. *Epas1*: Cells transduced with AdApt Epas1-ires-GFP.

Figure 7: Discovery of a novel gene (Hs.16335) using Smartomics. In section A, thumbnail images of spots corresponding to the EST from UniGene cluster Hs.16335 are shown. Contrast levels were set at a level to allow optimal visualisation of this gene, but are at a constant setting throughout this figure. For this gene, contrast levels are at maximum. Each strip of 6 images corresponds to a separate experiment, over the range of RNA samples. Figures beneath individual spot images are ratios of the normalised intensity of that spot compared to the reference condition (*gfp*; 20%O₂). Array location: Identity of the spot as defined by Research Genetics. Clone: IMAGE identification. The histogram (section B) shows the average of the figures shown and error bars are standard deviation. *gfp*: cells transduced with AdApt ires-GFP. *Hif-1a*: Cells transduced with AdApt Hif-1 α -ires-GFP. *Epas1*: Cells transduced with AdApt Epas1-ires-GFP.

Figure 8: Virtual Northern blot hybridisation to validate discovery of Hs.16335 by Smartomics. A) Hybridisation probe = Hs.16335. B) Hybridisation probe = β actin. Lanes 1-6 are the RNA samples used in Figures 3-7, from cells transduced with adenovirus. Lanes 7-10 are from non-transduced macrophages with (lanes 9,10) or without (lanes 7,8) prior activation. Histograms show relative mRNA expression levels, from phosphorimager analysis, relating to the Northern blots positioned above. Figures are relative expression ratios compared to *gfp* (20% O₂).

Figure 9: Plasmid map for pONY8Z.

Figure 10: Plasmid map for pONY8.1SM.

Figure 11: Plasmid map for pSMART CMV-HIF.

Figure 12: Plasmid map for pSMART CMV-empty.

EXAMPLES**Example 1: The use of Smartomics for gene discovery in macrophages**

Macrophages are associated with a variety of disease conditions, including cancer, atherosclerosis and inflammatory diseases such as arthritis. In many of these conditions, the macrophage secretes factors that exacerbate the disease condition. These factors include angiogenic factors, chemotactic agents and inflammatory cytokines. Some of these factors are known, but it is likely that there are other factors that are currently not known and that may be important targets for therapy. In many disease states, macrophages exist in areas of low oxygen (hypoxia) and it is this physiological state that acts as a signal to turn on a number of genes. Given this background, it is reasonable to suggest that important targets for drug development in the fields of cardiovascular disease, cancer and inflammatory disease may be induced in the hypoxia environment.

A simple approach, that would represent the current state of the art, would be to take a population of monocyte/macrophages, divide them in two and place one set in normal oxygen concentrations and the other set in conditions of low oxygen. RNA or protein molecules from the two sets could then be used in appropriate differential analyses. The goal would be to identify proteins or cDNA molecules that are present under conditions of hypoxia but that are not present in those cells that were maintained in normal oxygen concentrations.

If the present invention were to be applied to the identification of hypoxia-induced genes and proteins in macrophages, it would seek to amplify the difference between hypoxia and normoxia in order to increase the signal to noise ratio. This could be achieved by increasing the response to the hypoxia signal by delivering the Hif1 α gene to the macrophages in a configuration in which it is over-expressed. Hif1 α is part of a regulatory process that responds to low oxygen. Hif1 α and other proteins in the hypoxia-induction pathway interact with an enhancer element called the hypoxia response element (HRE) to switch on transcription of hypoxia-induced genes. The HRE, in various guises, is present at a position upstream from many genes that are known to be switched on in conditions of low oxygen. Overexpression of Hif1 α leads to massive over-expression of many hypoxia induced genes and so, in a differential screen, it would amplify the levels of hypoxia-specific cDNAs or proteins. This in turn would increase the probability of detecting those

-40-

molecular species that may be targets for drug development. In this case, therefore, the approach used according to the present invention would be to compare macrophages that are not overexpressing Hif1 α in conditions of normal oxygen with those overexpressing Hif1 α in conditions of low oxygen.

5 Hif1 α delivery and expression could be achieved in a number of ways.

Here, we describe the construction of an adenoviral vector that constitutively expresses the transcription factor HIF1 α . HIF1 α cDNA was isolated from Jurkat mRNA using the following PCR primers that harbour NheI and HpaI restriction sites in the 5' overhangs respectively:

10 Forward primer: 5'-CGGCTAGC-GACCGATTCACCATGGAG-3'

Reverse primer: 5'-CGGTAAAC-GCTCAGTTAACTTGATCC-3'

The PCR product was digested with NheI and HpaI restriction enzymes and inserted into the NheI-HpaI sites in the Introgene AdAptTM transfer vector which contains the human CMV promoter and SV40 polyA sequences. This vector can be linearised using PmlI prior
15 to co-transfection with the right arm of the adenovirus serotype 5 genome into the E1 expressing cell line PerC6 (911 or 293 cells could also be used)

Generation of the AdCMVHIF1 α adenovirus using the PerC6 RCA-free system is described at www.introgene.com (Introgene, Leiden, the Netherlands). Methods for efficient adenoviral transduction of primary human macrophages are described in Griffiths
20 *et al.*, 2000.

Gene expression in transduced and untransduced macrophage populations is compared in a number of possible ways as described below to generate read-outs of genes that are expressed under the control of Hif1 α . In addition, transduced cells incubated at oxygen concentrations of less than 0.5% are compared with non-transduced cells.

25 Total RNA samples are prepared for the analysis of differential gene expression. These are labelled either radioactively or fluorescently, and hybridized to arrays of cDNAs on solid supports. Genes which are upregulated by hypoxia and/or expression of individual HIF proteins produce quantitatively stronger hybridization signals. Array strategies may involve either nylon or glass supports, which are reviewed in Bowtell, 1999. Details of
30 methodologies involved in the glass support approach are detailed in Eisen and Brown,

1999. Here, fluorescently labelled probes are used and hybridization is detected using a laser confocal scanner. For the Nylon support approach, standard molecular biology methods of dot blotting and hybridization are involved as detailed in Molecular Cloning: A laboratory manual Sambrook, J *et al*, Cold Spring Harbor Laboratory Press. Here, RNA
5 samples to be compared are radioactively labelled and hybridization is detected using a phosphorimager.

Arrays can be purchased from Research Genetics, Huntsville, AL or would be fabricated in-house using cDNA clones generated by subtraction cloning (PCR-Select method, owned by Clontech Palo Alto, CA). Fabrication would involve use of an arraying robot
10 (MicroGrid, BioRobotics Ltd, Cambridge, UK).

Example 2: The use of Smartomics for the identification of hypoxia-regulated genes in macrophages

The invention has been applied to the identification of hypoxia-induced genes and proteins in macrophages.

15 Smartomics was utilised to improve the discovery of genes activated or repressed in response to hypoxia in primary human macrophages. As explained in Example 1, this involves augmenting the natural response to hypoxia, by experimentally introducing a key regulator of the hypoxia response, namely hypoxia inducible factor 1 α (HIF-1 α). Overexpression of HIF-1 α was done either in isolation or was done in combination with
20 exposing the cells to hypoxia. This allowed the detection of resulting gene expression changes that would otherwise have not been detectable in response to hypoxia alone.

Although HIF-1 α is well known to mediate responses to hypoxia, other transcription factors are also known or suspected to be involved. These include a protein called endothelial PAS domain protein 1 (EPAS1) or HIF-2 α , which shares 48% sequence
25 identity with HIF-1 α ("Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells." Tian H, McKnight SL, Russell DW. *Genes Dev.* 1997 Jan 1;11(1):72-82.). Evidence suggests that EPAS1 is especially important in mediating the hypoxia-response in certain cell types, and it is clearly detectable in human macrophages, suggesting a role in this cell type ("The macrophage - a novel system to
30 deliver gene therapy to pathological hypoxia." *Gene Ther.* 2000 Feb;7(3):255-62. Griffiths L, Binley K, Iqbal S, Kan O, Maxwell P, Ratcliffe P, Lewis C, Harris A, Kingsman S,

Naylor S.). In the light of this, the current example also utilises overexpression of EPAS1, as an independent means of improving discovery of hypoxia-responsive genes, to overexpression of HIF-1 α . It also illustrates an embodiment of the invention, whereby differences in the response to HIF-1 α or EPAS1 (or other mediators of the hypoxia response) may be identified, with the goal of identifying therapeutic target molecules more suitable for specific and efficient treatment of disease.

As discussed in Example 1, the introduction of foreign gene sequences (i.e. HIF-1 α or EPAS1) to primary macrophages may be achieved by recombinant adenovirus. As discussed in Example 1, a commercially available system was used to produce adenoviral particles involving the adenoviral transfer vector AdApt, the adenoviral genome plasmid AdEasy and the packaging cell line Per-c6 (Introgene, Leiden, The Netherlands). The standard manufacturer's instructions were followed.

Three derivatives of the AdApt transfer vector have been prepared, named AdApt ires-GFP, AdApt HIF-1 α -ires-GFP and AdApt EPAS1-ires-GFP. In these vectors, for convenience, AdApt was modified such that inserted genes (i.e. HIF-1 α or EPAS1) expressed from the powerful cytomegalovirus (CMV) promoter were linked to the green fluorescent protein (gfp) marker, by virtue of an internal ribosome entry site (ires). Therefore presence of green fluorescence provides a convenient indicator of viral expression of HIF-1 α or EPAS1 in transduced mammalian cells.

Standard molecular biology methods were used to construct the derivatives of AdApt, which included reverse transcriptase PCR (RT-PCR), transfer of DNA fragments between plasmids by restriction digestion, agarose gel DNA fragment separation, "end repairing" double stranded DNA fragments with overhanging ends to produce flush blunt ends, and DNA ligation. Subcloning steps were confirmed by DNA sequencing. These techniques are well known in the art, but reference may be made in particular to Sambrook *et al.*, Molecular Cloning, A Laboratory Manual (1989) and Ausubel *et al.*, Short Protocols in Molecular Biology (1999) 4th Ed, John Wiley & Sons, Inc.

Briefly, AdApt ires-GFP was made by inserting the encephalomyocarditis virus EMCV ires followed by the green fluorescent protein gene (GFP), into the end-repaired HpaI restriction site of AdApt, immediately downstream of and in the same orientation as the CMV promoter. Both EMCV ires and GFP sequences are widely used and can be obtained

from commonly available plasmids. SEQ ID NO:1 recites the exact nucleotide sequence of the joined ires-GFP which was inserted into the AdApt plasmid.

The plasmid AdApt HIF-1 α -ires-GFP was derived from AdApt ires-GFP by inserting the protein coding sequence of human HIF-1 α between the CMV promoter and the ires-GFP elements of AdApt ires-GFP. To do this, human HIF-1 α cDNA was cloned by RT-PCR
5 from human mRNA, and the sequence was verified by comparison to the published HIF-1 α cDNA nucleotide sequence (Genbank accession U22431). The HIF-1 α sequence was ligated as an end-repaired fragment into the end-repaired AgeI restriction site of AdApt ires-GFP [this is also the AgeI restriction site of the parental vector AdApt immediately
10 downstream of the CMV promoter]. The exact DNA sequence encoding HIF-1 α that was inserted into AdApt ires-GFP is shown in SEQ ID NO: 2.

The plasmid AdApt EPAS1-ires-GFP was derived from AdApt ires-GFP by inserting the protein coding sequence of human EPAS1 between the CMV promoter and the ires-GFP elements of AdApt ires-GFP. To do this, human EPAS1 cDNA was cloned by reverse
15 transcriptase PCR (RT-PCR) from human mRNA, and the sequence was verified by comparison to the published EPAS1 cDNA nucleotide sequence (GenBank accession U81984). The EPAS1 sequence was ligated as an end-repaired fragment into the end-repaired AgeI restriction site of AdApt ires-GFP [this is also the AgeI restriction site of the parental vector AdApt immediately downstream of the CMV promoter]. The exact DNA
20 sequence containing EPAS1 which was inserted into AdApt ires-GFP is shown in SEQ ID NO:3.

The adenoviral transfer vectors AdApt HIF-1 α -ires-GFP and AdApt EPAS1-ires-GFP, were verified prior to production of adenoviral particles, for their ability to drive expression of functionally active HIF-1 α or EPAS1 protein from the CMV promoter in
25 mammalian cells. This was achieved by transient transfection luciferase-reporter assays as described (Boast K, Binley K, Iqbal S, Price T, Spearman H, Kingsman S, Kingsman A, Naylor S. *Hum Gene Ther.* 1999 Sep 1;10(13):2197-208. "Characterisation of physiologically regulated vectors for the treatment of ischemic disease.").

Using the aforementioned Introgene adenoviral system, caesium-banded, pure adenoviral
30 particles were produced for each of the vectors AdApt ires-GFP, AdApt HIF-1 α -ires-GFP and AdApt EPAS1-ires-GFP. Following the Introgene manual, adenoviral preparations

-44-

were quantitated by spectrophotometry, yielding values of viral particles (VP) per milliliter.

To isolate human macrophage, monocytes were derived from peripheral blood of healthy human donors. 100ml bags of buffy coat from the Bristol Blood Transfusion Centre (Bristol, UK) were mixed with an equal volume of RPMI1640 medium (Sigma). This was layered on top of 10ml ficol-paque (Pharmacia) in 50ml centrifuge tubes and centrifuged for 25 min at 800 x g. The interphase layer was removed, washed in MACS buffer (phosphate buffered saline pH 7.2, 0.5% bovine serum albumin, 2mM EDTA) and resuspended at 80 microliter per 10^7 cells. To this, 20 microliter CD14 Microbeads (Miltenyi Biotec) were added, and the tube incubated at 4 degrees for 15 min. Following this, one wash was performed in MACS buffer at 400 x g and the cells were resuspended in 3 ml MACS buffer and separated on an LS+ MACS Separation Column (Miltenyi Biotec) positioned on a midi-MACS magnet (Miltenyi Biotec). The column was washed with 3 x 3ml MACS buffer. The column was removed from the magnet and cells were eluted in 5 ml MACS buffer using a syringe. Cells were washed in culture medium (AIM V (Sigma) supplemented with 2% human AB serum (Sigma), and resuspended at 2×10^5 cells per ml in the same medium and placed in large teflon-coated culture bags (Sud-Laborbedarf GmbH, 82131 Gauting, Germany) and transferred to a tissue culture incubator (37 degrees, 5% CO₂) for 7-10 days. During this period, monocytes spontaneously differentiate to macrophages. This is confirmed by examining cell morphology using phase contrast microscopy. Cells are removed from the bags by placing at 4 degrees for 30 min and emptying the contents.

The macrophages were washed and resuspended in DMEM (Gibco, Paisley, UK) supplemented with 4% fetal bovine serum (Sigma). 4×10^6 cells were plated into individual 10cm Primaria (Falcon) tissue culture dishes in a total volume of 8 ml per plate, with 6×10^9 adenoviral particles per ml. Following culture for 16 hr, during which the macrophages adhere to the plate and are infected by the adenoviral particles, the medium is removed and replaced by AIM V medium supplemented with 2% human AB serum. A further 24 hr period of culture is allowed prior to experimentation, to allow gene expression from the transduced adenovirus.

The above dosage of adenoviral particles was determined to be the minimum amount required to achieve transduction of the majority (over 80%) of the macrophage population,

-45-

using green fluorescence as a marker of gene transfer. This was confirmed using a separate adenoviral construct containing the LacZ reporter gene. By selecting the minimum dose of virus, possible non-specific effects of viral transfer are minimised.

- For experimentation with hypoxia, identical culture dishes were divided into two separate incubators: One at 37 degrees, 5% CO₂, 95% air (=Normoxia) and the other at 37 degrees, 5% CO₂, 94.9% Nitrogen, 0.1% Oxygen (=Hypoxia). After 8 hours culture under these conditions, the dishes were removed from the incubator, placed on a chilled platform, washed in cold PBS and total RNA was extracted using RNazol B (Tel-Test, Inc; distributed by Biogenesis Ltd) following the manufacturer's instructions.
- The design of this experiment was to obtain six populations of cells (referred to for simplicity as "cell types"), differing only in their treatment with adenovirus and/ or hypoxia, as shown below:

<u>"Cell Type"</u>	<u>Adenovirus</u>	<u>Expressed gene</u>	<u>Oxygen condition</u>
1	AdApt ires-GFP	none	Normoxia (20% Oxygen)
2	AdApt ires-GFP	none	Hypoxia (0.1% Oxygen)
3	AdApt HIF-1 α -ires-GFP	HIF-1 α	Normoxia (20% Oxygen)
4	AdApt HIF-1 α -ires-GFP	HIF-1 α	Hypoxia (0.1% Oxygen)
5	AdApt EPAS1-ires-GFP	EPAS1	Normoxia (20% Oxygen)
6	AdApt EPAS1-ires-GFP	EPAS1	Hypoxia (0.1% Oxygen)

- Gene discovery can be implemented by comparing gene expression profiles between these "cell types". According to conventional methods available in the literature, one would make comparisons between cell types 2 and 1. By implementing the present invention (Smartomics), several other possibilities are seen. Firstly, a comparison can be made between cell types 3 or 5 and cell type 1. Here, the stimulus of overexpressing key molecules involved in the hypoxia response may exceed the natural response the hypoxia, as seen for cell type 2. Secondly, in a preferred embodiment of the invention, a comparison can be made between cell types 4 or 6 and cell type 1. In this situation, the natural response to hypoxia is being augmented or boosted by overexpressing key molecules involved in the hypoxia response. It should be noted that the experimental design illustrated above uses a control adenovirus in place of untreated cells. By doing this, any non-specific effects of viral transduction should occur equally throughout the analysis, and will disappear.

Although efficient adenoviral gene transfer was indicated by green fluorescence in the transduced macrophages, Northern blotting was used to confirm overexpression of HIF-1 α and EPAS1. RNA samples extracted from cell types 1-6 as described above were analysed by Northern blotting (Figure 1). The RNA samples (8 μ g total RNA per lane) were
5 electrophoresed on a formaldehyde denaturing 1% agarose gel, then transferred to a nylon membrane (Hybond-N, Amersham, UK), and sequentially hybridised with ³³P-labelled DNA probes complementary in nucleotide sequence to HIF-1 α (Figure 1a), EPAS1 (Figure 1b) or 28S ribosomal RNA (Figure 1c). The methodology used for Northern blotting, probe hybridisation under stringent conditions, and removal of probes between
10 hybridisations, is well known in the art.

In Figure 1a, it can be seen that all lanes contain a faint band of approximately 4 kb, corresponding to the endogenous HIF-1 α mRNA. In lanes 3,4, which contain RNA from cells transduced with AdApt HIF-1 α -ires-GFP, a much stronger band of a similar size is observed, indicating successful overexpression of HIF-1 α .

15 In Figure 1b, it can be seen that all lanes contain a very faint band of approximately 5 kb, corresponding to the endogenous EPAS1 mRNA. In lanes 5,6, which contain RNA from cells transduced with AdApt EPAS1-ires-GFP, a much stronger band at approximately 4 kb is observed, indicating successful overexpression of EPAS1. The difference in size of the endogenous and overexpressed EPAS1 is due to the long untranslated region of the
20 endogenous gene, which is of no consequence.

In Figure 1c, it can be seen that 28S ribosomal RNA is detected in all lanes, indicating equal loading of RNA on the gel.

By phosphorimager quantitative analysis of Figures 1a and 1b, it is apparent that overexpression levels of both HIF-1 α and EPAS1 are approximately 80-fold over the
25 endogenous levels. Adenoviral-directed mRNA overexpression of these genes is not further augmented by hypoxia. For example, in Figure 1a, the band intensity for lane 4 does not exceed that for lane 3. However at the protein and functional levels, hypoxia potentiates the action of the proteins encoded by these mRNAs (Semenza GL. *Annu Rev Cell Dev Biol.* 1999;15:551-78. "Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1").
30

Global mRNA expression profiles from the RNA samples isolated from the six "cell types" were obtained using Research Genetics Human GeneFilters Release 1 (GF200) (Research Genetics, Huntsville, AL). This method uses pre-made arrays of DNA complementary to 5,300 genes covering a range of levels of characterisation, including sequences which only
5 match unannotated ESTs or cDNA sequences of unknown function.

The arrays are nylon in composition, and are spotted with DNA derived from specific IMAGE consortium cDNA clones (<http://image.llnl.gov/image/>). The arrays are hybridised to RNA samples which have been radioactively labelled with the isotope ³³P to measure the abundance of individual genes within the RNA samples. Multiple RNA samples are
10 labelled and hybridised in parallel to separate copies of the array, and spot hybridisation signals are compared between the RNA samples.

Key issues in array-based mRNA expression analysis are sensitivity and reliability. Currently two other methods are available; glass microarrays and DNA chips, both of which utilise fluorescently labelled RNA (Bowtell DD. *Nat Genet.* 1999 Jan;21(1 Suppl):25-32. "Options available--from start to finish--for obtaining expression data by
15 microarray."). Although these methods are often believed to offer increased sensitivity over Nylon-based methods, this belief lacks definitive proof. To the contrary, a careful comparison of the three approaches shows that for similar amounts of unamplified RNA, the nylon-based radioactive method is superior (Bertucci F, Bernard K, Liorod B, Chang YC, Granjeaud S, Birnbaum D, Nguyen C, Peck K, Jordan BR. *Hum Mol Genet.* 1999
20 Sep;8(9):1715-22. "Sensitivity issues in DNA array-based expression measurements and performance of nylon microarrays for small samples."). The microarray and DNA chip methods require much larger amounts of RNA which are often not easily obtained from primary cells, or complicated amplification methods, which are liable to introduce error.

To demonstrate the sensitivity of the array-based gene expression method used in the current exemplification of Smartomics, a scatter plot of two representative RNA samples analysed in our laboratory using Research Genetics GeneFilters, demonstrates a range of detection approaching 4-logs (Figure 2). By comparison, arguably the most sophisticated array-based method, the DNA chip, is quoted as having a range of detection of 3-logs
25 (Affymetrix).
30

Therefore, it is reasonable to assume that the improvements afforded by Smartomics regarding sensitivity issues, as illustrated by the current exemplification, could not easily

be obtained by utilising an alternative array-based method. In any case, any potentially superior array methodology could be further improved by utilising the Smartomics invention described here. An important utility of the present invention is that a high-throughput method such as array hybridisation can be used to identify expression changes which usually are only detectable by a very sensitive low throughput method such as RT-PCR or Northern blot.

RNA extracted from the 6 "cell types" as described above, was radioactively labelled and hybridised to separate copies of the Research Genetics Human GeneFilter GF200 (experiment #1). Methods provided by the manufacturer were followed (http://www.resgen.com/products/GF200_protocol.php3). Images of hybridised arrays were obtained using a Molecular Dynamics Storm phosphorimager. RNA was then stripped from the arrays, following the aforementioned protocol.

To ensure reproducibility, this procedure was repeated with the same RNA samples (experiment #2). The entire data set was then imported and analysed using Research Genetics Pathways 3.0 software, as explained in the Pathways 3.0 manual. Key aspects of the current analysis are summarised below:

Project Tree set-up

"Condition Pairs" mode was used to simultaneously analyse multiple experiments. "Condition" means several arrays hybridised to similar RNA samples, derived from the same "cell type".

Condition	"Cell Type"	Adenovirus	Oxygen	Experiment #
1	1	AdApt ires-GFP	Normoxia	1
1	1	AdApt ires-GFP	Normoxia	2
25 2	2	AdApt ires-GFP	Hypoxia	1
2	2	AdApt ires-GFP	Hypoxia	2
3	3	AdApt HIF-1 α -ires-GFP	Normoxia	1
3	3	AdApt HIF-1 α -ires-GFP	Normoxia	2
4	4	AdApt HIF-1 α -ires-GFP	Hypoxia	1
30 4	4	AdApt HIF-1 α -ires-GFP	Hypoxia	2
5	5	AdApt EPAS1-ires-GFP	Normoxia	1
5	5	AdApt EPAS1-ires-GFP	Normoxia	2
6	6	AdApt EPAS1-ires-GFP	Hypoxia	1
35 6	6	AdApt EPAS1-ires-GFP	Hypoxia	2

Normalisation set-up

The “all data points” option and Y. Chen algorithm with default settings were selected, as explained in the Pathways 3.0 manual. The two experiments were treated as separate normalisation groups, such that global differences between hybridisation signals from different arrays from the same experiment were corrected.

Comparison analysis

Pair-wise comparisons were made between condition 2 and condition 1
condition 3 and condition 1
condition 4 and condition 1
condition 5 and condition 1
condition 6 and condition 1

In other words, pair-wise comparisons were made using condition 1 (i.e. cell type 1) as the reference condition. This corresponds to cells transduced with the control adenovirus AdApt ires-GFP and placed under normal oxygen concentration (normoxia). Comparisons are made in this way for all genes present on the Research Genetics GF200 array. By comparing conditions, the analysis considers data from both experiments #1 and #2.

Filter settings

Filtering was then done to select genes with expression ratios of above 2.0 for at least one of the five pair-wise comparisons detailed above. Genes with low signal intensities for all of the six conditions were automatically eliminated, using an Intensity II filter of min 0.2, max 1000. Genes that did not respond in a reproducible way in experiment #1 and #2, were automatically eliminated using the Students t-test filter (90% confidence level).

Results were output as expression profiles of individual genes, showing normalised signal intensity and expression ratio. A key advantage of analysis in Pathways 3.0 is that high magnification thumbnail images of individual spots are displayed. This allows visual verification that the area being measured truly covers the region containing the hybridised array spot, and that the spot is real and not a background artefact.

Minor differences between quantitative data and corresponding thumbnail images are sometimes seen even though the sampled area is clearly the *bona fide* array spot. For example, by eye there might seem to be a small difference between two spots, though the

quantitative analysis might suggest a larger difference. It should be noted that thumbnail images are not normalised to compensate for global differences, and are limited in image quality. Greyscale images are inherently limited in their capacity to depict quantitative differences in intensity. Digital images generated by the Storm phosphorimager cover a linear dynamic range of 100,000 for a single pixel, whereas printed images can only be depicted as 256 shades of grey.

Results for three representative known hypoxia-regulated genes

As demonstration that overexpression of HIF-1 α or EPAS1 together with hypoxia exposure is superior to using non-transduced hypoxic cells, in terms of discovering *bona fide* hypoxia-regulated genes, results are shown for genes which are already known in the art to be regulated in hypoxia.

Three genes have been selected which are represented as double spots on the Research Genetics GF200 array. Therefore, because the whole experiment was repeated, a total of four repeat comparisons are possible for these genes.

The lactate dehydrogenase A (LDH-A) gene is known in the art to be activated by hypoxia (Webster KA. *Mol Cell Biochem.* 1987 Sep;77(1):19-28. "Regulation of glycolytic enzyme RNA transcriptional rates by oxygen availability in skeletal muscle cells."). In Figure 3, it can be seen that in response to hypoxia alone (gfp 0.1% O₂) there is on average a 2.24-fold increase in mRNA expression compared to normoxia (gfp 20% O₂).

By overexpressing HIF-1 α there is on average a 3.39-fold increase in LDH-A expression, providing a significant improvement over the natural response (Figure 3; HIF-1 α 20% O₂). By utilising a preferred embodiment of the Smartomics method, and simultaneously overexpressing HIF-1 α in the presence of hypoxia, the average response of LDH-A is elevated further to 4.50-fold (Figure 3; HIF-1 α 0.1% O₂).

In the prior art it has been established that HIF-1 α is responsible for mediating the hypoxia-induced activation of LDH-A (Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL. *Genes Dev.* 1998 Jan 15;12(2):149-62 "Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 alpha."). However it has never been envisaged or demonstrated that overexpression of HIF-1 α in a stable manner using viral gene transfer techniques, both with or without simultaneous hypoxia, causes secondary changes in gene expression which

-51-

are markedly greater than the natural hypoxia response. The response to hypoxia of LDH-A is also improved by overexpressing EPAS1 (Figure 3; EPAS1), though this is less dramatic than overexpressing HIF-1 α .

5 Like LDH-A, the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene is known in the art to be activated by hypoxia (Webster KA. *Mol Cell Biochem.* 1987 Sep;77(1):19-28. "Regulation of glycolytic enzyme RNA transcriptional rates by oxygen availability in skeletal muscle cells."). In Figure 4, it can be seen that in response to hypoxia alone (gfp 0.1% O₂) there is on average a 1.52-fold increase in mRNA expression compared to normoxia.

10 By overexpressing HIF-1 α there is on average a 3.33-fold increase in GAPDH expression, providing a significant improvement over the natural response (Figure 4; HIF-1 α 20% O₂). By utilising the full embodiment of the Smartomics method, and simultaneously overexpressing HIF-1 α in the presence of hypoxia, the average response of GAPDH is elevated further to 4.57-fold (Figure 4; HIF-1 α 0.1% O₂).

15 In the published literature, it has been established that HIF-1 α is responsible for mediating the hypoxia-induced activation of GAPDH (Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, Gassmann M, Gearhart JD, Lawler AM, Yu AY, Semenza GL. *Genes Dev.* 1998 Jan 15;12(2):149-62 "Cellular and developmental control of O₂ homeostasis by hypoxia-inducible factor 1 alpha."). However in the art, it has never been
20 envisaged or demonstrated that overexpression of HIF-1 α in a stable manner using viral gene transfer techniques, both with or without simultaneous hypoxia, causes secondary changes in gene expression which are markedly greater than the natural hypoxia response.

For GAPDH, it can be seen that overexpression of EPAS1 (Figure 4; EPAS1 20% O₂ and 0.1% O₂), has a significantly smaller effect than overexpressing HIF-1 α . This
25 demonstrates a separate embodiment of the Smartomics method, whereby genes are identified which respond selectively or preferentially to overexpression of EPAS1 or HIF-1 α .

Platelet derived growth factor beta (PDGF β) is also known in the art to be activated by hypoxia (Kourembanas S, Hannan RL, Faller DV. *J Clin Invest.* 1990 Aug;86(2):670-4
30 "Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells."). In Figure 5, it can be seen that in response to hypoxia

-52-

alone (gfp 0.1% O₂) there is on average a 2.14-fold increase in mRNA expression compared to normoxia.

By overexpressing EPAS1, there is on average a 9.28-fold increase in PDGF β expression (Figure 5; EPAS1 20% O₂), providing a large improvement over the natural response. In this case, the combination of hypoxia and EPAS1 overexpression does not exceed the response of EPAS1 overexpression alone, indicating saturation of the dose-response (Figure 5; EPAS1 0.1% O₂).

From Figure 5, it is clear that there is a striking specificity in the response of PDGF β to EPAS1 and HIF-1 α , in the opposite manner observed for GAPDH. Overexpression of HIF-1 α alone has no significant effect on PDGF β , whereas overexpression of EPAS1 produces large effects. This demonstrates a separate embodiment of the Smartomics method, whereby genes are identified which respond selectively or preferentially to overexpression of different factors which act in the same pathway.

The gene encoding monocyte chemotactic protein 1 (MCP-1) is known in the art to respond to hypoxia in a negative fashion, by decreasing mRNA expression (Negus RP, Turner L, Burke F, Balkwill FR. *J Leukoc Biol.* 1998 Jun;63(6):758-65. "Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors"). In Figure 6 it can be seen that in response to hypoxia alone (gfp 0.1% O₂) there is on average a 0.407-fold change (i.e. a 2.46 fold decrease) in mRNA expression compared to normoxia.

By overexpressing HIF-1 α , there is on average a 0.243-fold change (i.e. a 4.11-fold decrease) in MCP-1 expression, providing a significant improvement over the natural response (Figure 6; HIF-1 α 20% O₂). By utilising a preferred embodiment of the Smartomics method, and simultaneously overexpressing HIF-1 α in the presence of hypoxia, the average response of MCP-1 is further improved to a 0.112-fold change (i.e. an 8.93-fold decrease) (Figure 6; HIF-1 α 0.1% O₂). Even more pronounced improvements in the hypoxia-induced inhibition of MCP-1 expression are obtained by overexpressing EPAS1 (Figure 6; EPAS1 20% O₂ and 0.1% O₂). This demonstrates a use of Smartomics to improve the discovery of genes that are inhibited or repressed by disease signals.

The finding that overexpressing HIF-1 α or EPAS1 potentiates hypoxia-induced gene repression, as exemplified by MCP-1, is totally without precedent in this field. The structure of both HIF-1 α and EPAS1 proteins is that they contain transactivation domains

but not known transcriptional repressor domains (Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, Ratcliffe PJ. *J Biol Chem.* 1997 Apr 25;272(17):11205-14. "Activation of hypoxia-inducible factor-1; definition of regulatory domains within the alpha subunit.").

5 The results explained above relate to an array gene expression analysis, in which over 50 genes were identified as being regulated in hypoxia, from a total set of approximately 5300 genes on the array. By focusing on genes known in the art to be regulated in hypoxia, and showing how the Smartomics method can significantly enhance the response, an argument is provided that Smartomics would provide an improved method for the identification of novel *bona fide* hypoxia-regulated genes. In the current study, this can also be shown
10 directly, for novel genes which were discovered using the Smartomics method, as presented below. Because expression changes arising from a conventional analysis are also covered in this analysis (i.e. hypoxia / normoxia comparisons without viral overexpression), the advantage of the Smartomics invention is clearly demonstrated.

Table 1 lists unannotated genes or ESTs which were identified in this analysis as being
15 activated in response to viral-directed overexpression, but which would not have been identified from a hypoxia / normoxia comparison as done in the prior art. The final five columns of Table 1 show expression ratios compared to cells transduced with AdApt-ires-GFP in normoxia. The first of these five columns is the response without Smartomics, and in all cases shown here, the levels are below significance. The other four columns represent
20 results obtained using the present invention, and significant responses are seen here. In particular, in the final rows of this table, novel genes are identified which show large responses to EPAS1 overexpression.

Table 1: Novel Genes Identified By Smartomics

Title	NUCLEOTIDE		PROTEIN		RATIO (compared to gfp N)				
	Seq ID	Accession	Seq ID	Accession	gfp H	hif N	hif H	epas N	epas H
ESTs, Moderately similar to AFI19917_63 PRO2831		N68173		none	0.85	2.44	1.85	1.67	1.66
ESTs		H82330		none	1.06	1.11	0.90	1.88	2.79
ESTs		T97204		none	1.25	1.20	0.84	2.03	2.76
ESTs		R25464		none	0.96	1.51	1.41	2.15	3.01
ESTs		R25464		none	1.12	1.70	1.35	2.23	2.92
ESTs		R95132		none	0.91	1.38	1.06	2.32	2.79
ESTs, Weakly similar to A49134 Ig kappa chain V-J region		N80371		none	1.70	1.26	2.02	2.07	1.87
ESTs		R09498		none	1.06	1.73	1.53	1.94	2.18
PRO0518 hypothetical protein		R11658		AAF69617	0.89	1.11	0.97	3.81	3.89
ESTs		N74648		none	0.94	0.78	1.01	3.39	3.13
ESTs		T86016		none	1.42	1.73	1.59	3.78	3.65
ESTs		N99839		none	0.98	2.02	1.46	2.88	3.91
hypothetical protein LOC51317		R02569		AAF64262	1.13	1.31	1.32	2.92	2.63
ESTs		R06745		none	1.00	2.17	1.77	3.00	2.59
ESTs, Highly similar to A53770		R00332		BAB15101	1.71	1.41	1.58	6.79	6.45
ESTs		N64734		none	1.44	0.97	1.36	9.50	10.29
ESTs		T85201		none	0.87	1.18	1.06	14.99	14.71

Column 1 is the gene title as used in the UniGene database on 16 Feb 2001. Nucleotide and protein accessions are from the Genbank database. The final five columns show expression levels expressed as a ratio compared to cells transduced with AdApt ires-GFP in normoxia. gfp H: Expression in cells transduced with AdApt ires-GFP in hypoxia. Hif N: Expression in cells transduced with AdApt Hif-1 α -ires-GFP in normoxia. Hif H: Expression in cells transduced with AdApt Hif-1 α -ires-GFP in hypoxia. EPAS N: Expression in cells transduced with AdApt Epas1-ires-GFP in normoxia. EPAS H: Expression in cells transduced with AdApt Epas1-ires-GFP in hypoxia.

Figure 7 shows the expression profile of one of these genes, corresponding to an EST (GenBank accession N64734; IMAGE clone 293336). In the UniGene EST database (<http://www.ncbi.nlm.nih.gov/UniGene/>) this EST is currently clustered with only two other ESTs with accessions AI051607 (IMAGE 1674154) and T87161 (IMAGE 293336). The UniGene cluster number is Hs.16335, and it is totally unannotated in the database. Sequence analysis shows that this rare sequence is incomplete and lacks information on the protein coding sequence. In the Ensembl database of human genome project gene annotation (<http://www.ensembl.org/>) blast searches of predicted or confirmed cDNA

sequences do not identify this EST. It is therefore apparent that from public domain information, the gene corresponding to EST IMAGE 293336, is a truly novel and unannotated gene.

In Figure 7, thumbnail array spot images are shown at maximal contrast, such that the background signal is apparent. It can be seen that in response to hypoxia alone (gfp 0.1% O₂) there is on average a 1.4-fold increase in mRNA expression compared to normoxia. However, this is not significant, because it is derived from widely different ratios from individual experiments (2.41 and 0.46). From the thumbnail images for gfp 20% O₂ and gfp 0.1% O₂ it is evident that expression of the genes under these conditions is below the detection threshold of the array-based method. However, when the Smartomics invention is used, and EPAS1 is overexpressed using viral gene transfer methods, a clearly detectable response is seen, with induction ratios of over 8-fold (Figure 7; EPAS1 20% O₂ or 0.1% O₂). The expression profile in Figure 7 also demonstrates a separate embodiment of Smartomics, for the identification of genes which respond selectively to HIF-1 α or EPAS1.

To confirm the results presented in Figure 7, a more sensitive method was used to study expression of the gene corresponding to IMAGE clone 293336, namely virtual Northern blotting. It should be noted that this method would not have been suitable for the original discovery that IMAGE clone 293336 is induced by hypoxia, because virtual Northern blotting and similar methods do not allow simultaneous screening of large numbers of genes. The technique is similar to conventional Northern blotting, with the exception that double stranded cDNA corresponding to the mRNA population of expressed genes is resolved by electrophoresis and blotted onto a nylon membrane. It relies on a method of cDNA synthesis which produces full length cDNA molecules, which is commercially available (SMART PCR cDNA Synthesis Kit; Clontech Laboratories Inc, Palo Alto, CA, USA).

The method for virtual Northern blotting was followed as described in the instruction manual for the SMART PCR cDNA Synthesis Kit. Briefly, 600ng cDNA was synthesised from the six RNA samples used for array hybridisation. An additional four RNA samples were also processed, derived from non-transduced macrophages cultured in normoxia and hypoxia (6 hours at 0.1% O₂) both with and without pre-treatment for 16 hours with 100 ng/ml Lipopolysaccharide (*E.coli* 026:B6 Sigma, UK) and 1000 u/ml human gamma

-56-

interferon (Sigma, UK). This combination of factors causes macrophage activation, a process key to the physiological and pathophysiological actions of the macrophage. All 10 cDNA samples were resolved on an agarose gel, and alkali transfer onto Hybond N+ membrane (AmershamPharmacia, UK) was carried out according to the Hybond N+ instructions. Stringent hybridisations with ³³P-labelled cloned cDNA probes were performed as for standard Northern blot hybridisation, which is well known in the art. cDNA probes were radiolabelled using a commercially available kit (Prime-a-Gene, Promega, UK). The virtual Northern blot was hybridised first with the cDNA insert of IMAGE clone 1674154 from UniGene cluster Hs.16335 (Figure 8a). The blot was then stripped, by a high temperature / low salt wash, and was re-probed with the protein coding region of the human β -actin gene (Figure 8b).

From Figure 8a, it can be seen that the mRNA corresponding to Hs.16335 is detected as a doublet band of approximately 4.5 kb. This gene is strongly induced by adenoviral-directed overexpression of EPAS1 (lanes 5,6), consistent with the array data from Figure 7. The higher induction ratios in this non-array analysis are due to increased sensitivity afforded by the virtual Northern technique. Unlike the array data, expression of Hs.16335 is within the range of detection for all RNA samples. Importantly, hypoxia alone is seen to cause an induction ratio of approximately 60-fold (Figure 8a; lanes 2, 8). Therefore Hs.16335 is identified as a *bone fide* hypoxia-regulated gene, despite being beneath the detection level of an array screen in the absence of the present invention (Smartomics).

The results in Figure 8a also demonstrate a separate embodiment of the Smartomics method, whereby genes are identified which respond selectively or preferentially to overexpression of EPAS1 or HIF-1 α . Overexpression of HIF-1 α causes an induction ratio of 18.9-fold (lane 3), whereas overexpression of EPAS1 causes a much larger induction ratio of 141-fold (lane 5).

In Figure 8a lane 9, it is shown that activation of macrophages by LPS and TNF α causes a 10.8-fold increase in expression of the gene corresponding to Hs.16335. Therefore this novel gene is possibly relevant to the inflammatory functions of macrophages.

In Figure 8b expression of the human β -actin gene is found to be roughly constant throughout this experiment, consistent with the differences in Figure 8a being due to specific changes in gene expression.

-57-

Rapid amplification of cDNA ends (RACE) may be performed to clone the full length version of the gene corresponding to Hs.16335, based on the size of the cDNA size on the virtual Northern blot. Sequencing and functional analysis of this gene will possibly lead to the identification of a new therapeutic target molecule. Crucial to this process was the initial use of the Smartomics invention.

Example 3: EIAV vector construction

This example describes the generation of an EIAV vector (pONY8.1SM) with four unique cloning sites downstream of a CMV promoter. pONY8.1SM is the most minimal EIAV vector to date in terms of EIAV sequence that it contains (~1.1kb) and EIAV proteins it expresses (none). The vector is an example of a gene transfer system that could be used in a differential expression screening method according to our invention. However, other gene transfer systems based on any other lentivirus, retrovirus, herpesvirus, adenovirus, alphavirus, adeno-associated virus, herpes virus or DNA in any appropriate formulation, could be used

15 Construction of EIAV-based vector pONY8.1SM

The starting point was pONY4.0Z (GB9727135.7 and Mitophanous *et al.*, 1999). The first two ATG triplets in the EIAV gag region were replaced with ATTG to eliminate the expression of gag from the EIAV genome while maintaining gag sequences in the vector. The gag sequence was found to be important for maintaining high titre vector production.

20 The ATG to ATTG change was carried out by PCR. Primers ATTG1 and PS2 were used to PCR amplify the EIAV leader/gag sequence. The template for this was the plasmid pONY3.1 (GB9727135.7 and Mitophanous *et al.*, 1999). This PCR fragment contains a Nar I and Xba I site at the 5' and 3' ends respectively. This fragment was inserted into pONY4Z cut with a Nar I and Xba I to produce pONY8.0Z.

25 ATTG1 Primer: AGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTA
CCTGTTGAACCTGGCTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTAC
AGAAGTCTTCTGGAGGTGTTCTTGGCCAGAACACAGGAGGACAGGTAAGATTG
GGAGACCCTTTGACATTGGAGCAAGGCGCTCAAGAA

Underlined = Nar I site

30 PS2 primer: TAGTTCTAGAGATATTCTTCAGAG

Underlined = Xba I site

pONY8.1SM is an EIAV vector genome containing an internal CMV promoter from which any gene of interest is expressed. It was made by deleting a part of the env sequence from pONY8Z. pONY8Z was cut with Sbf I (position 5885). This was then partially cut with Sap I (there are two Sap I sites in pONY8Z, see Figure 9). The molecule cut at site 8056 was then purified, blunt ended and re-ligated to give pONY8.1Z. To generate pONY8.1SM pONY8.1Z was cut with Sac II and Sph I, blunt ended and re-ligated. This removes the lacZ gene and creates 4 unique sites, Bsm BI, Sbf I, Eco RI and Hind III (Figure 10) for the insertion of any gene or library of genes. Sbf I has an 8 base recognition sequence which makes it useful for inserting unknown genes.

Example 4: Generation of EIAV vector that expresses HIF1- α

This example describes the generation of an EIAV vector (pONY8.1SMHIF1) that is able to express HIF-1 α from an internal CMV promoter. The accession number for human HIF-1 α is U22431. To make pONY8.1SMHIF1 HIF-1 α was PCR amplified from cDNA generated from mRNA isolated from Jurkat cells. The primers for this were HIFPM1 and HIFPM2 described below. They contain Sbf I sites for cloning and the Kozak sequence has been used to enhance translation. The PCR product generated this way contains Sbf I cloning sites flanking the HIF-1 α open reading frame. This was cut with Sbf I and inserted into pONY8.1SM cut with Sbf I. The plasmid generated this way was called pONY8.1SMHIF1.

HIFPM1 Primer: ATCGCCTGCAGGCCACCATGGAGGGCGCCGGCGGCGCG

Sbf I site = underlined, Kozak sequence = bold and italics, ATG start codon = underlined and italics

HIFPM2 Primer: ACTGCCTGCAGGTCAGTTAACTTGATCCAAAGCTCTGAG

Sbf I site = underlined

This plasmid is used in conjunction with gag-pol and env expressing plasmids to produce EIAV-based vector particles as described in Mitrophanous *et al.*, 1999. These particles are then used to transduce a variety of cell types that may be of interest in the context of genes controlled directly or indirectly by the Hif1 pathway.

-59-

One example is primary human skeletal muscle cells. Transduced and untransduced cell populations are compared. In addition transduced cells in low oxygen concentrations are compared with untransduced cells in normal oxygen concentrations.

- RNA samples are prepared for the analysis of differential gene expression. These are
5 labelled either radioactively or fluorescently, and hybridized to arrays of cDNAs on solid supports. Genes which are upregulated by hypoxia and/or expression of individual HIF proteins produce quantitatively stronger hybridization signals. Array strategies may involve either nylon or glass supports, which are reviewed in Bowtell, 1999. Details of methodologies involved in the glass support approach are detailed Eisen and Brown, 1999.
10 Here, fluorescently labelled probes are used and hybridization is detected using a laser confocal scanner. For the Nylon support approach, standard molecular biology methods of dot blotting and hybridization are involved as detailed in Molecular Cloning: A laboratory manual Sambrook, J *et al*, Cold Spring Harbor Laboratory Press. Here, RNA samples to be compared are radioactively labelled and hybridization is detected using a phosphorimager.
15 Arrays can be purchased from Research Genetics, Huntsville, AL or would be fabricated in-house using cDNA clones generated by subtraction cloning (PCR-Select method, owned by Clontech Palo Alto, CA). Fabrication would involve use of an arraying robot (MicroGrid, BioRobotics Ltd, Cambridge, UK).

Example 5: Generation of codon-optimised ELAV vector expressing HIF1- α

- 20 This example describes the generation of an ELAV-derived vector, pSMART CMV-HIF in which expression of HIF-1 α is driven from a CMV promoter located internally within the vector (Figure 11). A similar vector backbone could be used to achieve expression of other genes for the purposes of differential screening as described in this patent.

- The starting point for construction of pSMART CMV-HIF was pONY4.0Z (WO
25 99/32646) and Mitophanous *et al.*, Gene Ther. 1999 Nov;6(11):1808-18. In the first step, plasmid pONY4.0Z was converted into pONY8.0Z (see Example 3 above) by introducing mutations which 1) prevented expression of TAT by creating an 83nt deletion in exon 2 of tat, 2) prevented S2 ORF expression by a 51nt deletion, 3) prevented REV expression by deletion of a single base within exon 1 of rev, and 4) prevented expression of the N-
30 terminal portion of gag by insertion of T residues within the first and second, ATG codons of the gag region, thereby changing the sequence to ATTG from ATG. With respect to the

-60-

wild type EIAV sequence (Accession No. U01866) these correspond to deletion of 1) nt 5234-5316 inclusive, 2) nt 5346-5396 inclusive, and 3) nt 5538. The insertion of T residues (4)) was after nt 526 and nt 543. These alterations were carried out using techniques readily practicable to one skilled in the art. The resulting vector, pONY8.0Z
5 expresses none of the EIAV accessory proteins or any of the EIAV gag protein.

In the next step, the β -galactosidase reporter gene present in pONY8.0Z was replaced by the enhanced green fluorescence protein (eGFP) reporter gene to create pONY8G. This was done by transferring the SacII –KpnI fragment corresponding to the GFP gene and flanking sequences from pONY2.13GFP (WO 99/32646) into pONY8.0Z cut with the
10 same enzymes.

The presence of sequences termed the central polypurine tract and central termination sequence (cPPT/CTS) has been suggested to improve the efficiency of gene delivery by HIV-1 based vectors to non-dividing cells (Zennou *et al.*, Cell. 2000 Apr 14;101(2):173-85, Follenzi *et al.*, Nat Genet. 2000 Jun;25(2):217-22). The analogous *cis*-acting element
15 of EIAV is located in the polymerase coding region and can be obtained as a functional element by using PCR amplification from any plasmid which contains the EIAV polymerase coding region (for example pONY3.1, WO 99/32646) as follows. The PCR product includes the central polypurine tract and the central termination sequence (CTS). The oligonucleotide primers used in the PCR reaction were:

20

EIAV cPPT POS: CAGGTTATTCTAGAGTCGACGCTCTCATTACTTGTAAC

EIAV cPPT NEG: CGAATGCGTTCTAGAGTCGACCATGTTTCACCAGGGATTTTG

The recognition sequence for *Xba*I is shown in bold face and allows insertion into the
25 pONY8G backbone. Before insertion of the cPPT/CTS PCR product prepared as described above, pONY8G was modified to remove the central termination sequence (CTS) which was already present in the pONY8G vector. This was achieved by subcloning the *Sal*II to *Sca*I fragment encompassing the CTS and RRE region from pONY8.0Z into pSP72, prepared for ligation by digestion with *Sal*II and *Eco*RV. The CTS
30 region was then excised by digestion with *Kpn*I and *Ppu*MI, the overhanging ends 'blunted' by T4 DNA polymerase treatment and then the ends religated. The modified EIAV vector fragment was then excised using *Sal*II and *Nhe*I and ligated into pONY8G

-61-

prepared for ligation by digestion with the same enzymes. This new EIAV vector was termed pONY8G del CTS. pONY8G del CTS has two *Xba*I sites which flank the CMV-GFP cassette and the PCR product representing the cPPT/CTS, after digestion with *Xba*I can be ligated into either site after partial digestion. Ligation into these sites results in plasmids with the cPPT/CTS element in either the positive or negative senses. Clones in which the cPPT/CTS was in the positive sense (functionally active) at either the 5' or 3'-position were termed pONY8G 5'POS del CTS and pONY8G 3'POS del CTS, respectively. Another vector, termed pONY8Z 5'POS del CTS was also made following a similar strategy to that used to make pONY8G 5'POS del CTS. Accordingly, the CTS sequence present in pONY8.0Z was removed in the same way to make pONY8Z del CTS and the cPPT/CTS sequence was introduced into the unique *Xba*I site just upstream of the CMV promoter in pONY8Z del CTS.

The pSMART CMV-HIF vector plasmid was derived from pONY8G 5'POS del CTS by replacement of the coding region for eGFP with that of HIF-1 α . This was achieved by digestion of the latter with *Sac*II and *Not*I, which flank the eGFP gene, and ligation to a *Sac*II-*Not*I fragment obtained from plasmid AdApt HIF-1 α -ires-GFP. Construction of plasmid AdApt HIF-1 α -ires-GFP is as described in Example 2 above.

An additional derivative of pONY8G 5'POS del CTS was also made in order to produce vector preparations which serve as 'negative controls' in transduction experiments. This vector termed, pSMART CMV-empty (Figure 12) was made by digestion of pONY8G 5'POS del CTS with *Bsm*BI and *Not*I, which flank the eGFP gene, followed by religation. On the basis of sequence analysis of the transcript driven by the internal promoter, only a 3 amino acid peptide is expected to be produced in cells transduced with this vector.

The EIAV vectors described above were produced by transient co-transfection of 293T human embryonic kidney cells with either vector plasmid, pONY3.1 (which expresses the EIAV gag/pol protein) and an envelope expression plasmid, pRV67 (which encodes the vesicular stomatitis virus protein G, VSV-G) using the calcium phosphate precipitation method.

Twenty four hours before transfection the 293T cells were seeded at 3.6×10^6 cells per 10cm dish in 10ml of DMEM supplemented with glutamine, non-essential amino acids and 10% foetal calf serum. Transfections were carried out in the late afternoon and the cells were incubated overnight prior to replacement of the medium with 6ml of fresh media

-62-

supplemented with sodium butyrate (5mM). After 7 hours the medium was collected and 6ml of fresh unsupplemented media added to the cells. The collected medium was cleared by low speed centrifugation and then filtered through 0.4micron filters.

Vector particles were then concentrated by low speed centrifugation (6,000g, JLA10.500 rotor) overnight at 4°C and the supernatant poured off, leaving the pellet in the bottom of the tube. The following morning the remaining tissue culture fluid was harvested, cleared and filtered. It was then placed on top of the pellet previously collected and overnight centrifugation repeated. After this the supernatant was decanted and excess fluid was drained. Then the pellet was resuspended in formulation buffer to 1/1000 of the volume of starting supernatant. Aliquots were then stored at -80°C.

Formulation buffer (100ml)

Tissue culture grade water	28.65ml
19.75mM Tris/HCl buffer pH 7.0	19.75ml of a 0.1M solution
40mg/ml lactose	26.6ml of a 150mg/ml solution
37.5mM sodium chloride	24.4ml of a 154mM solution
1mg/ml human serum albumin ^a	500µl of a 20% solution
5µl/ml protamine sulphate ^b	100µl of a 5mg/ml solution

^aHuman serum albumin (20%) (Albutein, Alpha therapeutics UK Ltd, Thetford, Norfolk).

^bProtamine sulphate 5mg/ml (Prosulf, CP Pharmaceuticals, Wrexham, UK).

The sequence of pSMART CMV-HIF is presented in SEQ ID NO:4.

The sequence of pSMART CMV-empty is presented in SEQ ID NO:5.

Example 6: Use of Smartomics for gene identification in hippocampal neurones

As discussed above in Examples 1 and 2, hypoxia is an important component of stroke (cerebral ischaemia). The present invention (Smartomics) has now been utilised to improve the discovery of genes activated or repressed in response to hypoxia in primary rat hippocampal neurones. This involves augmenting the natural response to hypoxia, by experimentally introducing a key regulator of the hypoxia response, namely hypoxia inducible factor 1 α (HIF-1 α). The overexpression of HIF-1 α in combination with exposure of the cells to hypoxia has allowed the detection of gene expression changes which would not been detectable in response to overexpression of HIF-1 α alone, or hypoxia alone.

Primary rat hippocampal neuron cultures were established according to standard procedures from embryonic rats (Dunnett SB, Bjorkland A (Eds.) 1992. Neural Transplantation, A Practical Approach. IRL Press). Briefly, timed-pregnant Wistar rats at eighteen days of gestation were anaesthetised with 0.7 ml isoflurane and killed by cervical dislocation. Pups were removed from the uterus and decapitated. Hippocampi were dissected and stored on ice in Hanks Buffered Saline Solution (HBSS) containing DNase (0.05%) and glucose (2 mM) before incubation in trypsin (0.1%) plus DNase (0.05%) for 5 minutes. After incubation, trypsin was inactivated by the addition of soybean trypsin inhibitor (SBTI, 0.1%) and the solution gently triturated. Cells were pelleted by centrifugation (3000 rpm, 5 minutes) and the trypsin removed. Cells were then washed twice in HBSS containing SBTI and DNase (0.05%), and re-pelleted before final suspension in Dulbecco's Modified Eagle's Medium (DMEM) containing foetal calf serum (10%), glutamine (2 mM), and gentamicin (0.1 mg.ml⁻¹). Cells (3 × 10⁶ cells per dish) were plated out onto 60 mm dishes coated with poly-D-Lysine (50 µg.ml⁻¹) and fibronectin adhesion promoting peptide (10 µg.ml⁻¹). Cultures were placed into a humidified 37°C incubator containing 5% CO₂ and twelve hours after plating, 50% of the plating medium was replaced with Neurobasal Media (Brewer GJ, (1995) "Serum-free B27/neurobasal medium supports differentiated growth of neurons from the striatum, substantia nigra, septum, cerebral cortex, cerebellum, and dentate gyrus", Journal of Neuroscience Research 42:674-83) supplemented with B27 and glutamine (2 mM). Cultures were fed every two days with supplemented neurobasal medium and were transduced on day 3 *in vitro*.

Transduction was carried out in supplemented neurobasal media containing polybrene (2 µg.ml⁻¹), in 0.5 volumes of the typical culture media volume. Five hours after the onset of transduction, the media volume was increased by a factor of 2, and was replaced 12 hours later. The viruses pSMART CMV-HIF (carrying the HIF-1α gene; see Example 5), pSMART CMV-empty (an empty genome used as a control; see Example 5) and pONY8Z 5'POS del CTS (containing the β-galactosidase gene) were produced in parallel according to methods detailed above. The pONY8Z 5'POS del CTS was used to calculate viral titer in D17 cells and in hippocampal neurons. Comparison of the RNA packaging signal by quantitative RT-PCR (Taqman) of the three viral preps, allowed the biological titers of pSMART CMV-HIF and pSMART CMV-empty viruses to be estimated relative to that pONY8Z 5'POS del CTS. All transductions were done using approximately equal

-64-

multiplicity of infections (MOIs) for both viruses, and the MOI used in each experiment was at least ten.

Thirty-six hours after transduction, identical culture dishes were divided into two separate incubators, one at 37°C, 5% CO₂, 95% air (=Normoxia) and the other at 37°C, 5% CO₂, 5 94.9% Nitrogen, 0.1% Oxygen (=Hypoxia). After 6 hours culture under these conditions, the dishes were removed from the incubator, placed on a chilled platform, washed in cold PBS and total RNA was extracted using RNazol B (Tel-Test, Inc; distributed by Biogenesis Ltd) following the manufacturer's instructions.

The experiment yielded four samples, differing only in their treatment with lentivirus and/or hypoxia, as shown below:

<u>Sample</u>	<u>Lentivirus</u>	<u>Expressed gene</u>	<u>Oxygen condition</u>
1	pSMART CMV-empty	none	Normoxia
2	pSMART CMV-empty	none	Hypoxia
15 3	pSMART CMV-HIF	HIF-1 α	Normoxia
4	pSMART CMV-HIF	HIF-1 α	Hypoxia

Gene discovery can be implemented by comparing gene expression profiles between these samples. According to conventional methods published in the art, one would make 20 comparisons between cell types 1 and 2. By implementing the present invention (Smartomics), several other possibilities are seen. Firstly, a comparison can be made between cell types 1 and 3. Here, the stimulus of overexpressing key molecules involved in the hypoxia response may exceed the natural response to hypoxia, as seen for cell type 2. Secondly, a comparison can be made between cell types 1 and 4. In this situation the 25 natural response to hypoxia is being augmented or boosted by overexpressing key molecules involved in the hypoxia response.

Global mRNA expression profiles from the RNA isolated from the four samples were obtained using the Research Genetics Rat GeneFilter GF300 (Research Genetics, Huntsville, AL). This method uses pre-made nylon arrays of DNA derived from 30 I.M.A.G.E./LLNL cDNA clones containing the 3' ends of genes (<http://image.llnl.gov/image/>). The arrays include more than 5,000 genes covering a range

-65-

of levels of characterisation, including sequences which are representative of unannotated ESTs or cDNA sequences of unknown function.

RNA extracted from the 4 samples described above, was radioactively labelled and hybridised to separate copies of the Research Genetics Rat GeneFilter GF300. Methods provided by the manufacturer were followed (http://www.resgen.com/products/GF200_protocol.php3) with the following modifications; RNAsin was added to the labelling reaction, and following labelling the mRNA/cDNA hybrid was denatured by incubation with 45mM EDTA/18mM NaOH at 65°C for 30 minutes.

- 10 Images of hybridised arrays were obtained using a Molecular Dynamics Storm phosphorimager. RNA was then stripped from the arrays, following the aforementioned protocol. To ensure reproducibility, this procedure was repeated with the same RNA samples. Both data sets were then imported and analysed using Research Genetics Pathways 3.0 software, as explained in the Pathways 3.0 manual. Key aspects of the
15 current analysis are summarised below:

Project Tree set-up

“Condition Pairs” mode was used to simultaneously analyse multiple experiments. In this context a condition is equivalent to a sample (e.g. Sample 3, overexpression of HIF-1 α in normoxia).

20 Normalisation set-up

- Data point normalisation was selected, as explained in the Pathways 3.0 manual. This technique generates normalised intensities by dividing all sampled intensities by the mean sampled intensity of all clones (except the control points) on the array. The two experiments were treated as separate normalisation groups, such that global differences in
25 hybridisation signals between different arrays within the same experiment were corrected for.

Comparison analysis

- Condition 1 (i.e. Sample 1) corresponds to cells transduced with the control lentivirus and placed under normal oxygen concentrations (normoxia). This was used as the reference
30 condition in pairwise comparisons with conditions 2, 3 and 4 (i.e. samples 2, 3 and 4).

-66-

Comparisons were made in this way for all genes present on the Research Genetics GF300 array. By comparing conditions the analysis considers data from both experiments.

Results for four representative known HIF-1 α /hypoxia-regulated genes

As demonstration that overexpression of HIF-1 α in hypoxic cells is superior to using non-transduced hypoxic cells or overexpression of HIF-1 α in normoxic cells, in terms of
5 discovering *bona fide* hypoxia-regulated genes, results are shown below for genes which are already known in the art to be regulated by hypoxia and HIF-1 α . Ratios are expressed as average ratios of normalised intensities.

Table 2. Response of known HIF-1 α /hypoxia-regulated genes

10

TITLE	PROTEIN		NUCLEOTIDE		RATIO SAMPLE 1 (normoxia) vs		
	SEQ ID	ACCESSION	SEQ ID	ACCESSION	SAMPLE 2 (hypoxia)	SAMPLE 3 (Hif+normoxia)	SAMPLE 4 (Hif+hypoxia)
Enolase 1, alpha		NP_036686		NM_012554	1.04	0.86	1.40
Glucose-transporter protein		AAA41248		M13979	1.41	0.78	2.14
Glyceraldehyde-3-phosphate dehydrogenase		AAA40814		M29341	1.13	1.42	1.67
Lactate dehydrogenase A		CAA26000		X01964	1.36	1.50	1.77

All four genes listed in Table 2 are known in the art to be regulated by hypoxia, and have been shown by Northern blot analysis to be down-regulated in a HIF1- α knockout (Iyer *et al* (1998) Cellular and developmental control of O₂ homeostasis by hypoxia-inducible
15 factor 1 α . Genes Dev 12:149-162). In the case of Enolase 1, alpha, the response to hypoxia or overexpression of Hif-1 α under normoxia is undetectable by array hybridisation. It is only when Hif-1 α is overexpressed under hypoxia that an increase in expression level relative to normoxia is detected. In the case of glucose-transporter protein the detectable response to hypoxia is increased by the overexpression of Hif-1 α in hypoxia. In the case of
20 both glyceraldehyde-3-phosphate dehydrogenase and Lactate dehydrogenase A the response to hypoxia is detectable, but it is increased by the overexpression of Hif-1 α under normoxia, and even more so by the overexpression of Hif-1 α under hypoxia.

Filter settings

Data filtering was then performed to reduce the data set and select genes with expression
25 ratios of above 2.0 for at least one of the three pair-wise comparisons detailed above.

-67-

Genes with low signal intensities in all four conditions were automatically eliminated, using an Intensity II filter minimum of 0.2. Genes which did not respond in a reproducible way in both experiments were automatically eliminated using the Students t-test filter (90% confidence level).

- 5 Results were output as expression profiles of individual genes, showing normalised signal intensity and expression ratio. A key advantage of analysis in Pathways 3.0 is that high magnification thumbnail images of individual spots from the original images are displayed. This allows visual verification that the area being measured truly covers the region containing the hybridised array spot.

10 Annotation of known and novel genes

- As demonstration that overexpression of HIF-1 α in hypoxic cells is superior to using non-transduced hypoxic cells or overexpression of HIF-1 α in normoxic cells, in terms of discovering novel hypoxia-regulated genes, results are shown below for a gene which is already known in the art to be regulated by hypoxia, but not by HIF-1 α , and for an
15 unannotated gene. Ratios are expressed as average ratios of normalised intensities.

Table 3. Response of novel HIF-1 α regulated genes

TITLE	PROTEIN		NUCLEOTIDE		RATIO SAMPLE 1 (normoxia) vs		
	SEQ ID	ACCESSION	SEQ ID	ACCESSION	SAMPLE 2 (hypoxia)	SAMPLE 3 (Hif+normoxia) a)	SAMPLE 4 (Hif+hypoxia)
Metallothionein-I*		AAA41590		J00750	1.61	1.24	3.49
EST		none		AA901269	1.43	1.08	3.47

*representative metallothionein ESTs are spotted twice on the array, so the data is the average of two points

- 20 Metallothionein-I is known in the literature to be regulated by hypoxia (Murphy *et al* (1999) Activation of metallothionein gene expression by hypoxia involves metal response elements and metal transcription factor-1. Cancer Res 59(6):1315-22), but it is not known to be regulated by HIF-1 α . The data in Table 3 show that the response to overexpression of HIF-1 α in hypoxia greatly exceeds that of hypoxia alone or the overexpression of HIF-1 α in normoxia. The EST (expressed sequence tag) is a completely unannotated DNA
25 sequence. Similarly, the data in Table 3 show that the response to overexpression of HIF-1 α in hypoxia greatly exceeds that of hypoxia alone or the overexpression of HIF-1 α in normoxia.

This data demonstrates that the methods described above enable the further functional annotation of known genes and the functional annotation of completely unannotated novel genes with no known function.

5 **Example 7: The use of Smartomics for the identification of genes regulated by cytokines**

Eosinophils are associated with allergic diseases such as asthma, which is characterised by high numbers of eosinophils in affected tissue. IL-5 is a key cytokine involved in eosinophil differentiation and survival. IL-5 stimulates eosinophilopoiesis and egress from the bone marrow and also prolongs survival of peripheral blood eosinophils. As such IL-5
10 may play a causative role in the pathogenesis of asthma.

Genes which are activated in response to IL-5 stimulation are of interest as potential targets for asthma therapies.

A simple approach representing the state-of-the-art involves taking a population of eosinophils, dividing them in two and placing one set in the presence of IL5 and the other
15 in the absence of IL5. RNA or protein from the two sets is then used in appropriate differential analyses. The goal would be to identify proteins or cDNAs that are present under conditions in which IL5 is present (IL5+) but not present in those cells that are maintained in medium free of IL5 (IL5-).

The present invention as applied to the identification of IL5-induced genes and proteins in
20 eosinophils seeks to amplify the difference between IL5+ and IL5- in order to increase the signal to noise ratio. This is achieved by increasing the response to the IL5 signal by delivering the gene for an IL5 receptor to the eosinophils in a configuration where it is over-expressed.

The IL5 α receptor is present in two isoforms, a membrane bound form which acts as an
25 IL5 agonist and a soluble form which acts as an IL5 antagonist. As cells normally express both isoforms it is likely that they modulate their response in this way by maintaining a balance between the two. Expression of one or the other should 'force' the eosinophil response in a way that simply altering the concentration of exogenous IL5 might not achieve.

30 It is expected that overexpression of the membrane bound form of the IL5 α receptor would render cells hyperresponsive to the cytokine. In a differential screen, overexpression of this

-69-

form of the receptor will lead to amplification of levels of IL5 specific cDNAs or proteins. The probability of detecting targets for drug development will therefore increase. The present invention as applied to this case involves comparison of eosinophils that are not overexpressing the membrane bound form of the IL5 α receptor in the absence of IL5 ligand, with eosinophils exposed to IL5 and overexpressing the membrane bound form of the IL5 α receptor.

Similarly, overexpression of the soluble form of the receptor, which acts as an IL-5 antagonist, would be expected to diminish the response of eosinophils to stimulation by IL-5. The expression profile of eosinophils overexpressing the soluble form of the IL5 α receptor in the absence of IL5 ligand is compared to that of eosinophils exposed to IL5 (but not overexpressing soluble IL5 α receptor). Either of these approaches may be used to distinguish genes which are expressed in response to IL5 and whose products are potential targets for therapy of allergic diseases such as asthma.

Any cell line which expresses IL5 receptor may be used, for example, AML14.3D10, TF-1.8 or HL-60. Delivery and expression of membrane bound and soluble forms of IL5 α receptor may be achieved by a variety of ways. For example, eosinophils may be transfected or transduced with expression constructs as described in the Examples above, and Example 8 below.

Gene expression in transduced and untransduced eosinophil populations is compared in a number of ways as described below to generate read-outs of genes that are expressed in response to IL5. Cells transfected with construct expressing soluble IL5 α receptor in the absence of IL5 are compared with untransfected cells in presence of IL5. Cells transfected with construct expressing membrane bound IL5 α receptor in the presence of IL5 are compared with untransfected cells in absence of IL5.

Total RNA samples are prepared for the analysis of differential gene expression. These are labelled either radioactively or fluorescently, and hybridized to arrays of cDNAs on solid supports. Genes which are upregulated by IL5 produce quantitatively stronger hybridization signals. Array strategies may involve either nylon or glass supports, which are reviewed in Bowtell, 1999. Details of methodologies involved in the glass support approach are detailed in Eisen and Brown, 1999. Here fluorescently labelled probes are used and hybridization is detected using a laser confocal scanner. For the Nylon support

-70-

approach, standard molecular biology methods of dot blotting and hybridization are involved as detailed in Molecular Cloning: A laboratory manual Sambrook, J *et al*, Cold Spring Harbor Laboratory Press. Here, RNA samples to be compared are radioactively labelled and hybridization is detected using a phosphorimager.

- 5 Arrays can be purchased from Research Genetics, Huntsville, AL or would be fabricated in-house using cDNA clones generated by subtraction cloning (PCR-Select method, owned by Clontech Palo Alto, CA). Fabrication would involve use of an arraying robot (MicroGrid, BioRobotics Ltd, Cambridge, UK).

10 The RNA isolated from cells may be reverse-transcribed to cDNA and the cDNA screened accordingly. Alternatively, and as described above, a proteomics approach may be used to identify differentially expressed products, for example, by 2-D gel electrophoresis. Reference is made to Blackstock and Weir (1999) and the references cited therein, in which a variety of proteomics techniques is discussed.

15 The differential expression pattern of other cells which are responsive to IL5, for example, basophils and bone marrow precursors, may also be determined using the above method. Other cells which do not normally respond to IL5 may also be used, provided the β chain of the IL5 is co-expressed with the α chain. In this regard, it is to be noted that a common β chain is shared between the IL-5, IL-3 and GM-CSF receptors.

Example 8: Overexpression of Human IL5 α R Isoforms

- 20 This example describes the generation of two EIAV vectors (pONY8.1SMIL5Rm and pONY8.1SMIL5Rs) that are able to express the interleukin 5 alpha membrane receptor (pONY8.1SMIL5Rm) or the interleukin 5 alpha soluble receptor (pONY8.1SMIL5Rs) from an internal CMV promoter. The accession number for human IL5 α R is A26251.

25 [Human IL5 alpha receptor gene: A26251, AUTHORS: Devos,R., Fiers,W., Plaetinck,G., Tavernier,J. and van der Heyden, TITLE: Human Interleukin-5 receptor, PATENT: EP 0492214-A 11 01-JUL-1992; F. HOFFMANN-LA ROCHE AG]

To make pONY8.1SMIL5Rm, the IL5 α R was PCR amplified from cDNA generated from mRNA isolated from human peripheral blood eosinophils. The primers for this were IL5R1 and IL5R2 described below. They contain Sbf I sites for cloning and the Kozak sequence
30 has been used to enhance translation. The PCR product generated this way contains Sbf I cloning sites flanking the IL5 α R open reading frame. This was cut with Sbf I and inserted

-71-

into pONY8.1SM cut with Sbf I. It is important to check that the IL5 α R has inserted in the correct orientation. The plasmid generated this way was called pONY8.1SMIL5Rm.

This construct will express the wild type IL5 α R. The IL5 α R open reading frame was modified to make pONY8.1SMIL5Rs which expresses the soluble form of IL5 α R.

- 5 This was done by PCR amplification to remove the C terminus of the receptor (Epitope-labelled soluble human interleukin-5 (IL-5) receptors. Affinity cross-link labeling, IL-5 binding, and biological activity. Brown PM, Tagari P, Rowan KR, Yu VL, O'Neill GP, Middaugh CR, Sanyal G, Ford-Hutchinson AW, Nicholson DW). The first 332 amino acids are retained while the last 88 amino acids comprising the transmembrane and
- 10 intracellular region are removed. The primers for this were IL5R1 and IL5R3 described below. They contain Sbf I sites for cloning and the Kozak sequence has been used to enhance translation. The PCR product generated this way contains Sbf I cloning sites flanking the IL5 α R open reading frame. This was cut with Sbf I and inserted into pONY8.1SM cut with Sbf I. It is important to check that the IL5 α R has inserted in the
- 15 correct orientation. The plasmid generated this way was called pONY8.1SMIL5Rs.

IL5R1 Primer

ATCGCCTGCAGGCCACCATGATGATCATCGTGGCGCATGTATTAC

Sbf I site = underlined

- 20 Kozak sequence = bold and italics

ATG start codon = underlined and italics

IL5R2 Primer

ACTGCCTGCAGGTCAAAACACAGAATCCTCCAGGGTC

Sbf I site = underlined

- 25 IL5R3 Primer

ACTGCCTGCAGGTCATCCACATAAATAGGTTGGCTC

Sbf I site = underlined

Other Examples

- Overexpressing anti-apoptotic genes (ie. Bcl-2, Bcl-x) in a dopaminegic cell line leads to neuroprotection from neurotoxins such as MPTP. As the more representative dopaminegic neurons (primary cells) are postmitotic in culture, lentiviral vectors can be used to introduce and overexpress such genes into these neurons and then screen for cellular targets that become differentially expressed.
- Anti-apoptotic targets can also be identified by overexpressing (apoptotic) death receptors in neurons such as Fas and supplying ligand (FasL) in limited amounts. These cells will try to survive by inducing their neuroprotective genes.
- Similarly growth factors (NGF, GDNF etc), and their receptors can be overexpressed in cell lines making the cells supersensitive to the survival effects of the growth factor.
- Heat shock proteins (HSPs) such as HSP70 are expressed after stressful insults in the nervous system and their over-production leads to protection in several different models of nervous system injury. HSPs are implicated in cerebral ischemia, neurodegenerative diseases, epilepsy and trauma. HSPs are chaperones normally bound to heat shock factors (HSFs) which after injury become dissociated in the cytosol, phosphorylated and trimerised and enter the nucleus where they bind to heat shock elements (HSEs) within the promoter of heat shock genes leading to their transcriptional activation. Therefore overexpression of HSPs in neurons, glia or endothelial cells can be used for differential screening in a similar manner to that of Hif1.
- APP (amyloid precursor protein): a trans-membrane protein which is the precursor of the A β peptide which is found in neuritic plaques in Alzheimer's disease. Mutations have been identified which are causative of the some of the familial (early onset) forms of the disease.
- Presenilins 1 and 2: trans-membrane proteins central to the processing of APP and some other membrane proteins. Several mutations have been isolated in some of the familial forms of the disease.
- α -synuclein: A cytoplasmic protein associated with neuronal synapses. Mutations have been found in few Parkinson's pedigrees. Part of Lewy body (intracellular lesions

-73-

characteristic of Parkinson's disease and also found in Alzheimers disease and Lewy body dementia).

- Tau: a microtubule binding protein. Mutations have been found in frontal temporal dementia with Parkinsonism linked to chromosome 17 and Pick's disease.
 - 5 • Parkin: protein of unknown function with some homology to ubiquitin at the N-terminus and a RING-finger motif at the C-terminus. Deletions identified in juvenile form of Parkinson's disease.
 - Ubiquitin (UCH-L1): a thiol protease that forms part of the Lewy body. Mutations have been identified in a German Parkinson's disease pedigree.
- 10 All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be
- 15 unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

References

- 20 Blackstock and Weir (1999) *Trends in Biotech.* 17: 121-126.
 Bowtell (1999) *Nature Genetics* 21: 25-32.
 Eisen and Brown (1999). *Methods Enzymol.* 303: 179-205.
 Griffiths L. *et al.* (2000), *Gene Therapy* 7: 255-262.
 Jorgensen *et al.* (1999), *Electrophoresis* 2: 230-40.
- 25 Kirschbaum and Kozian (1999), *Trends in Biotech* 17: 73-78.
 Mitophanous *et al.* (1999), *Gene Therapy* 6: 1808-1818.
 Pardee and Liang (1992), *Science* 257: 967-971.
 Rabilloud *et al.* (1997), *Electrophoresis* 18: 307-316.
 Soneoka *et al.* (1995), *Nucleic Acids Res.* 23: 628-33.
- 30 Wilkinson *et al.* (1995), *Plant Mol Biol* 6: 1097-108.
 Zhang *et al.* (1998), *Mol Biotechnol* 10(2): 155-65.
 Zhao *et al.* (1999), *J Biotechnol.* 73(1): 35-41.

CLAIMS

1. A differential expression screening method for identifying a genetic element involved in a cellular process, which method comprises comparing:
 - (a) gene expression in a first cell of interest; and
 - 5 (b) gene expression in a second cell of interest, which cell comprises altered levels, relative to physiological levels, of a biological molecule implicated in the cellular process, due to the introduction into the second cell of a heterologous nucleic acid directing expression of a polypeptide; andidentifying a genetic element whose expression differs, wherein gene expression in said
10 first and/or second cell of interest is compared under at least two different environmental conditions relevant to the cellular process.
2. A method according to claim 1, wherein gene expression is compared in both the first and the second cell of interest under at least two different environmental conditions relevant to the cellular process.
- 15 3. A method according to claim 1 or claim 2, which method comprises comparing:
 - (a) gene expression in a first cell of interest;
 - (b) gene expression in the first cell of interest which has been exposed to an environmental change of a first type;
 - (c) gene expression in the first cell of interest which has been exposed to an
20 environmental change of a second type; and
 - (d) gene expression in a second cell of interest, which cell contains altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to one or both of the environmental changes recited in parts b) and c), due to the introduction into the second cell of a heterologous nucleic acid
25 directing expression of a polypeptide, under conditions in which the cell either has or has not been exposed to the first and/or the second type of environmental change; andidentifying a genetic element whose expression differs.

4. A method according to claim 1 or claim 2, wherein the different environmental conditions are different levels of a biological signal.
5. A method according to claim 4, which method comprises comparing:
- (a) gene expression in a first cell of interest;
 - 5 (b) gene expression in the first cell of interest which has been exposed to a biological signal relevant to the cellular process, wherein the biological signal is at a first level;
 - (c) gene expression in the first cell of interest which has been exposed to a biological signal relevant to the cellular process, wherein the biological signal is
10 at a second level; and
 - (d) gene expression in a second cell of interest, which cell comprises altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to the biological signal, due to the introduction into the second cell of a heterologous nucleic acid directing expression of a polypeptide, wherein
15 the signal is absent, at a first level or at a second level; and
- identifying a genetic element whose expression differs.
6. A method according to claim 4, which method comprises comparing:
- (a) gene expression in a first cell of interest;
 - (b) gene expression in the first cell of interest, wherein the cell has been exposed to
20 a biological signal relevant to the cellular process;
 - (c) gene expression in the first cell of interest, which cell contains altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to the biological signal, due to the introduction into the first cell of a heterologous nucleic acid directing expression of a polypeptide, wherein the altered
25 level of the biological molecule is at a first level, and wherein the biological signal is either present or absent;
 - (d) gene expression in a second cell of interest;
 - (e) gene expression in the second cell of interest, wherein the cell has been exposed to a biological signal relevant to the cellular process;

- (f) gene expression in the second cell of interest, which cell contains altered levels, relative to physiological levels, of the biological molecule, due to the introduction into the second cell of a heterologous nucleic acid directing expression of the polypeptide, wherein the altered level of the biological molecule is at a second level, and wherein the biological signal is either present or absent; and

identifying a genetic element whose expression differs.

7. A method according to claim 4, which method comprises comparing:

- (a) gene expression in a first cell of interest;
- (b) gene expression in the first cell of interest, wherein the cell has been exposed to a biological signal relevant to the cellular process;
- (c) gene expression in the first cell of interest, which cell contains altered levels, relative to physiological levels, of a first biological molecule whose activity is responsive to the biological signal, due to the introduction into the first cell of a heterologous nucleic acid directing expression of a first polypeptide, wherein the biological signal is either present or absent;
- (d) gene expression in a second cell of interest;
- (e) gene expression in the second cell of interest, wherein the cell has been exposed to a biological signal relevant to the cellular process;
- (f) gene expression in the second cell of interest, which cell contains altered levels, relative to physiological levels, of a second biological molecule, due to the introduction into the second cell of a heterologous nucleic acid directing expression of a second polypeptide, wherein the biological signal is either present or absent; and

identifying a genetic element whose expression differs.

8. A differential expression screening method for identifying a gene or gene product whose expression is regulated by a signal which method comprises comparing at two different levels of the signal:

- (a) gene expression in a first cell of interest wherein the signal is at a first level; and

-77-

- (b) gene expression in a second cell of interest which cell comprises altered levels, relative to physiological levels, of a biological molecule whose activity is responsive to the signal, due to the introduction into the second cell of a heterologous nucleic acid, wherein the signal is at a second level; and identifying a gene or gene product whose expression differs.
9. A method according to any one of the preceding claims, wherein the first and second cells are different cell types.
10. A method according to any one of the preceding claims, wherein the levels of the biological molecule are enhanced relative to physiological levels.
- 5 11. A method according to any one of claims 1 to 9, wherein the levels of the biological molecule are reduced relative to physiological levels.
12. A method according to any one of the preceding claims wherein the biological molecule and the polypeptide are the same.
13. A method according to any one of the preceding claims wherein the heterologous
10 nucleic acid is introduced into the cell by means of a viral vector.
14. A method according to claim 13, wherein the viral vector is a retrovirus, lentivirus (such as the Equine Infectious Anaemia Virus (EIAV) or human immunodeficiency virus type 1 (HIV-1)), an adenovirus, an adeno-associated virus, a herpes virus or a pox virus (such as entomopox).
- 15 15. A method according to any one of the preceding claims, wherein gene expression is determined by a proteomic technique.
16. A method according to any one of claims 1 to 14, wherein gene expression is determined using a genomic or cDNA technique.
17. A method according to any one of the preceding claims wherein the first cell of interest
20 has normal physiological levels of the biological molecule.
18. A method according to any one of the preceding claims wherein the polypeptide is involved in the cellular process.
19. A method according to any one of the preceding claims, wherein the first cell is from a normal patient and the second cell is from a diseased patient.

20. A method according to any one of claims 1 to 18, wherein the first cell is from a diseased patient and the second cell is from the same diseased patient.
21. A method according to any one of claims 1-7, and 9-20, wherein said genetic element is a gene, a gene product or a regulatory element.
22. A differential expression screening method for identifying a gene product involved in a disease process which method comprises:
- (i) comparing gene expression in:
 - (a) a first cell of interest; and
 - (b) a second cell of interest;
 - (ii) comparing gene expression in
 - (a) the first cell of interest; and
 - (b) a third cell of interest which cell comprises altered levels, relative to physiological levels, of a candidate gene product, due to the introduction into the first cell of a heterologous nucleic acid directing expression of the candidate gene product; and
 - (iii) selecting those candidate gene products which give rise to an alteration in the levels of expression of a second gene product in the third cell of interest relative to the first cell of interest, which second gene product also has altered levels of expression in the second cell of interest relative to the first cell of interest.
23. A method according to claim 22, wherein the candidate gene product is a polypeptide.
24. A method according to claim 22 or 23, wherein the comparison of gene expression is carried out by identifying, using nucleic acid techniques, those mRNA transcripts whose levels are altered between the first cell of interest and the second cell of interest, and between the first cell of interest and the third cell of interest.
25. A method according to claim 22 or 23, wherein the comparison of gene expression is carried out by identifying, using protein analytical procedures, those polypeptides whose levels are altered between the first cell of interest and the second cell of interest, and between the first cell of interest and the third cell of interest.

26. A method according to any one of claims 22-25, wherein said gene product is regulated by a signal, and gene expression is compared in said cells at two different levels of the signal.
27. A method of increasing the sensitivity of a differential expression screening method in which gene expression of a first and a second cell of interest in response to two different levels of a signal are compared, the method comprising introducing a heterologous nucleic acid into the first cell or the second cell to increase the level of a biological molecule which modulates the response of the cell to the signal.
28. A method according to any preceding claim, in which the heterologous nucleic acid encodes a biological molecule selected from the group consisting of: HIF1 α , EPAS1, a membrane bound form of the IL5 α receptor, a soluble form of an IL5 α receptor, Bcl-2, Bcl-x, FasL, NGF, GDNF, heat shock proteins (HSPs), APP, Presenilin 1, Presenilin 2, α -synuclein, Tau, Parkin and ubiquitin.
29. A method according to claim 7, wherein said first polypeptide is HIF1- α , and said second polypeptide is EPAS1.





FIG. 1

2/15

FIG. 2




3/15


FIG. 3A

Experiment #1


Array Location: 1.c.13.1
Clone: 43550
Gene: LDH-A




Array Location: 1.c.13.2
Clone: 43550
Gene: LDH-A

**Experiment #2**



Array Location: 1.c.13.1
Clone: 43550
Gene: LDH-A



Array Location: 1.c.13.2
Clone: 43550
Gene: LDH-A



4/15



5/15


FIG. 4A

Experiment #1

Array Location: 2,f,22,1

Clone: 50117


Gene: GAPDH



Array Location: 1,f,22,1

Clone: 50117


Gene: GAPDH

**Experiment #2**

Array Location: 2,f,22,1

Clone: 50117


Gene: GAPDH



Array Location: 1,f,22,1

Clone: 50117

Gene: GAPDH



6/15


FIG. 5A

Experiment #1

Array Location: 2,e,21,12

Clone: 343320


Gene: PDGF Beta



Array Location: 1,g,7,8

Clone: 67654


Gene: PDGF Beta

**Experiment #2**

Array Location: 2e,21,12

Clone: 343320


Gene: PDGF Beta



Array Location: 1,g,7,8

Clone: 67654

Gene: PDGF Beta



7/15

FIG. 5B





FIG. 6A

Experiment #1

Array Location: 1,a,22,2
Clone: 768561
Gene: MCP-1



Experiment #2

Array Location: 1,a,22,2
Clone: 768561
Gene: MCP-1




FIG. 6B

Average Relative mRNA level





FIG. 7A

Experiment #1

Array Location: 2,a,30,5
Clone: 293336
Gene: (only ESTs)



Experiment #2

Array Location: 2,a,30,5
Clone: 293336
Gene: (only ESTs)






FIG. 7B


Average Relative mRNA level



10/15




11/15




12/15

FIG. 9




13/15

FIG. 10




14/15

FIG. 11



15/15

FIG. 12



SEQ ID NO:1

Nucleotide sequence of ires-GFP DNA fragment

CTAGAGTGTGATTTTAAGGGCGAATTCTGCAGATATCCATCACACTGGCGGGCCGCACTAGAGGAATTGCCCCC
TCTCCCTCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGGAAATAAGGCCGCTGTGTGTTTGTCTATATGT
5 GATTTTCCACCATATTGCCGCTCTTTTGGCAATGTGAGGGCCCGGAAACCTGGCCCTGTCTTCTTGACGAGCAT
TCCTAGGGGTCTTTCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTG
GAAGCTTCTTTGAAGACAAACACGTCTGTAGCGACCCCTTTGCAGGCAGCGGAACCCCCACCTGGCGACAGGT
GCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGGCACAACCCACGTGCCACGTTGTGAG
10 TTGGATAGTTGTGGAAGAGTCAAATGGCTCTCCTCAAGCGTAGTCAACAAGGGGCTGAAGGATGCCCAGAAG
GTACCCCATTTGTATGGGAATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAA
AAGCTCTAGGCCCCCGAACCACGGGGACGTGGTTTTCTTTGAAAAACACGATGATACCATGGTGAGCAAGG
GCGAGGAGCTGTTTACCGGGGTGGTGCCCATCCTGGTGCAGCTGGACGGCGACGTAACGGCCACAAGTTTCAG
CGTGTCGGCGGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCCACGGCAAG
CTGCCCCGTGCCCTGGCCACCTCTGTGACCACCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACC
15 ACATGAAGCAGCAGCACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAA
GGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTTCGAGGGCGACACCTGGTGAACCGCATCGAGCTG
AAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAGCTGGAGTACAACACAACAGCCACAACG
TCTATATCATGGCCGACAAGCAGAAGAAGCGCATCAAGGTGAAGTTCAAGATCCGCCACAACATCGAGGACGG
CAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCATCGGCGACGGCCCCGTGCTGCTGCTGCCGACAAC
20 CACTACCTGAGCACCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCTGCTGGAGT
TCGTGACCGCCGCGGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAAGCGCCGCGACT

SEQ ID NO:2

Nucleotide sequence of DNA fragment containing human HIF-1 α protein coding sequence

CTAGCCGTAGAATCCGACCGATTACCATGGAGGGCGCGCGCGCGAACCACAAGAAAAAGATAAGTTCTG
AACGTGCAAAAAGAAAAGTCTCGAGATGCAGCCAGATCTCGGCGAAGTAAAGAACTCTGAAGTTTTTTATGAGCT
TGCTCATCAGTTGCCACTTCCACATAATGTGAGTTTCGATCTTGATAAGGCCTCTGTGATGAGGCTTACCATC
AGCTATTTGCGTGTGAGGAACTTCTGGATGCTGGTGATTTGGATATTGAAGATGACATGAAAGCACAGATGA
25 ATTGCTTTTATTGAAAGCCTTGGATGGTTTGTGTTATGGTTCTCACAGATGATGGTGACATGATTTTACATTTT
TGATAATGTGAACAAATACATGGGATTAACCTCAGTTTGAACCTAAGTGGACACAGTGTGTTTGTATTTACTCAT
CCATGTGACCATGAGGAAATGAGAGAAATGCTTACACACAGAAATGGCCTTGTGAAAAAGGGTAAAGAACAAA
ACACACAGCGAAGCTTTTTTCTCAGAAATGAAGTGTACCCTAAGTAGCCGAGGAAGAACTATGAACATAAAGTC
TGCAACATGGAAGGTATTGCACTGCACAGGCCACATTCACGTATATGATACCAACAGTAACCAACCTCAGTGT
GGGTATAAGAAACCACTATGACCTGCTTGGTGTGATTTGTGAACCCATTCTCACCACATCAAAATATTGAAA
35 TTCTTTTAGATAGACAGCTTTTCTCAGTCGACACAGCCTGGATATGAAATTTTCTTATTGTGATGAAAGAAAT
TACCGAATTGATGGGATATGAGCCAGAAGAACTTTTAGGCCGCTCAATTTATGAATATATCATGCTTTGGAC
TCTGATCATCTGACCAAACTCATCATGATATGTTTACTAAAGGACAAGTACCACAGGACAGTACAGGATGC
TTGCCAAAAGAGGTGGATATGTCTGGGTGAAACTCAAGCAACTGTCTATATAACACCAAGAATTCTCAACC
ACAGTGCATTTGATGTGTGAATTACGTTGTGAGTGGTATTATTCAGCACGACTTGATTTTCTCCCTTCAACAA
40 ACAGATATGTGTTCTTAAACCGTTGAATCTTCAGATATGAAAAAGTCACTCAGCTATTACCAAAGTTGAATCAG
AAGATACAAGTAGCTCTTTGACAACTTAAGAAGGAACCTGATGCTTTAACTTTGCTGGCCCCAGCCGCTGG
AGACACAATCATATCTTTAGATTTTGGCAGCAACGACACAGAACTGATGACCAGCAACTTGAGGAAGTACCA
TTATATAATGATGTAATGCTCCCTCACCAACGAAAAATTACAGAATATAAATTTGGCAATGTCTCCATTAC
CCACCGCTGAAACGCCAAAGCCACTTCGAAGTAGTCTGACCTGCATCAATCAAGAAGTTGCATTAAAAATT
45 AGAACCAATCCAGAGTCACTGGAACCTTTCTTTTACCATGCCCCAGATTCAGGATCAGACACCTAGTCCTTCC
GATGGAAGCATAGACAAAAGTTTACCTGAGCCTAATAGTCCAGTGAATATTGTTTTTATGTGGATAGTGATA
TGGTCAATGAATTCAAGTTGGAATTGGTAGAAAACTTTTGTCTGAAGACACAGAAGCAAGAACCCATTTTCT
TACTCAGGACACAGATTTAGACTTGGAGATGTTAGTCCCTATATCCCAATGGATGATGACTTCCAGTTACGT
TCTTTCGATCAGTTGTACCATTAGAAAGCAGTTCCGCAAGCCCTGAAAGCGCAAGTCTCAAAGCACAGTTA
50 CAGTATTCCAGCAGACTCAAATACAAGAACCTACTGCTAATGCCACCCTACCACAGCCACCCTGATGAATT
AAAAACAGTGACAAAAGACCGTATGGAAGACATTAATAATATTGATTGCATCTCCATCTCCTACCCACATACAT
AAAGAACTACTAGTGCCACATCATCACCATAGAGATACCTCAAAGTCGACAGCCCTCACCAAACAGACAG
GAAAAGGAGTCATAGAACAGACAGAAAAATCTCATCCAAGAAGCCCTAACGTGTTATCTGTGCGCTTTGAGTCA
AAGAATAACAGTTCTTGAGGAAGAACTAAATCCAAGATACCTAGCTTTGCAGAATGCTCAGAGAAAAGCGAAAA
55 ATGGAACATGATGGTTCACTTTTCAAGCAGTAGGAATTGGAACATTATTACAGCAGCCAGACGATCATGCAG
CTACTACATCACTTTCTTGGAAACGTGTAAGGATGCAAACTTAGTGAACAGAATGGAATGGAGCAAAAGAC

AATTATTTTAATACCCCTCTGATTTAGCATGTAGACTGCTGGGGCAATCAATGGATGAAAGTGGATTACCACAG
CTGACCAGTTATGATTGTGAAGTTAATGCTCCTATACAAGGCAGCAGAAACCTACTGCAGGGTGAAGAATTAC
TCAGAGCTTTGGATCAAGTTAACTGAGCGGATCCGACGGGGATCCT

5 SEQ ID NO:3

Nucleotide sequence of DNA fragment containing human EPAS1 protein coding sequence

AGCTTGCATGCCTGCAGGTCGACTCTAGAGGATCCAGCGACAATGACAGCTGACAAGGAGAAGAAAAGGAGTA
GCTCGGAGAGGAGGAAGGAGAAGTCCCGGGATGCTGCGCGGTGCCGGCGGAGCAAGGAGACGGAGGTGTTCTA
10 TGAGCTGGCCCATGAGCTGCCTCTGCCCCACAGTGTGAGCTCCCATCTGGACAAGGCCTCCATCATGCGACTG
GAAATCAGCTTCTGCGAACACACAAGCTCCTCTCCTCAGTTTGCTCTGAAAACGAGTCCGAAGCCGAAGCTG
ACCAGCAGATGGACAACCTGTACCTGAAAGCCTTGGAGGGTTTCATTGCCGTGGTGACCCAAGATGGCGACAT
GATCTTTCTGTGAGAAAACATCAGCAAGTTCAATGGGACTTACACAGGTGGAGCTAACAGGACATAGTATCTTT
GACTTCACTCATCCCTGCGACCATGAGGAGATTCTGTGAGAACCTGAGTCTCAAAAATGGCTCTGGTTTGGGA
15 AAAAAAGCAAAGACATGTCCACAGAGCGGGACTTCTTCATGAGGATGAAGTGCACGGTCACCAACAGAGGCCG
TACTGTCAACCTCAAGTCAGCCACCTGGAAGGTCTTGCATGACAGGGCCAGGTGAAAGTCTACAACAACCTGC
CCTCCTCACAATAGTCTGTGTGGCTACAAGGAGCCCTGCTGTCTGCCCTCATCATATGTGTGAACCAATCC
AGCACCCTATCCCATGGACATCCCCCTGGATAGCAAGACCTTCTCTGAGCCGCCACAGCATGGACATGAAGTT
CACCTACTGTGATGACAGAATCACAGAATGATTGGTTACCACCCTGAGGAGCTGCTTGGCCGCTCAGCCTAT
20 GAATTTTACCATGCGCTAGACTCCGAGAATGACCAAGAGTCAACAGAATCTGTGCACCAAGGGTCAGGTAG
TAAGTGCCAGTACCGGATGCTCGCAAAGCATGGGGGCTACGTGTGGCTGGAGACCCAGGGGACGGTCATCTA
CAACCTCGCAACCTGCAGCCCCAGTGCATCATGTGTGTCAACTACGTCTGAGTGAAGATTGAGAAGAATGAC
GTGGTGTCTCCATGGACCAAGTGAATCCCTGTTCAAGCCCCACCTGATGGCCATGAACAGCATCTTTGATA
GCAGTGGCAAGGGGGCTGTGTCTGAGAAGAGTAACCTTCTTACCAAGCTAAAGGAGGAGCCCGAGGAGCT
25 GGCCCCAGCTGGCTCCCAACCCAGGAGACGCCATCATCTCTCTGGATTTCGGGAATCAGAATCTCGAGGAGTCC
TCAGCCTATGGCAAGGCCATCTGCCCCGAGCCAGCCATGGGCCACGGAGTTGAGGAGCCACAGCACCAGCA
GCGAGGCTGGGAGCCTGCCTGCCTTCACCGTGCCCCAGGCAGCTGCCCCGGGCAGCACCACCCCACTGCCAC
CAGCAGCAGCAGCAGCTGCTCCACGCCCAATAGCCCTGAAGACTATTACACATCTTTGGATAACGACCTGAAG
ATTGAAGTGATTGAGAAGCTCTTCGCCATGGACACAGAGGCCAAGGACCAATGCAGTACCCAGACGGATTTC
30 ATGAGCTGGACTTGGAGACACTGGCACCCCTATATCCCCATGGACGGGGAAGACTTCCAGCTAAGCCCCATCTG
CCCCGAGGAGCGGCTCTTGGCGGAGAACCCACAGTCCACCCCCAGCACTGCTTCAGTGCCATGACAAACATC
TTCCAGCCACTGGCCCCGTAGCCCCGCACAGTCCCTTCTCTCTGGACAAGTTTCAGCAGCAGCTGGAGAGCA
AGAAGCAGAGCCCCAGCACCAGCCCATGTCTCCATCTTCTTTGATGCCGGAAGCAAAGCATCCCTGCCACC
GTGCTGTGGCCAGGCCAGCACCCTCTCTCTTCATGGGGGGCAGATCCAATACCCAGTGGCCCCCAGATCCA
35 GCATTACATTTTGGGCCCCACAAAGTGGGCGCTCGGGGATCAGCGCACAGAGTTCTTGGGAGCAGCGCCGTTGG
GGCCCCCTGTCTCTCCACCCCATGTCTCCACCTTCAAGACAAGGTCTGCAAAGGGTTTGGGGCTCGAGGCC
AGACGTGCTGAGTCCGGCCATGGTAGCCCTCTCCAACAAGCTGAAGCTGAAGCGACAGCTGGAGTATGAAGAG
CAAGCCTTCCAGGACCTGAGCGGGGGGACCCACCTGGTGGCAGCACCTCACATTTGATGTGGAACGGATGA
AGAACCTCAGGGGTGGGAGCTGCCTTTGATGCCGGACAGCCACTGAGCGCAAATGTACCCAATGATAAGTT
40 CACCCAAAACCCCATGAGGGGCCCTGGGCCATCCCCCTGAGACATCTGCCGCTGCCACAGCCTCCATCTGCCATC
AGTCCCGGGGAGAACAGCAAGAGCAGTTCCCCCAGAGTGTACGCCACCCAGTACCAGGACTACAGCCTGT
CGTCAGCCCAAGGTGTGAGGCATGGCAAGCCGGCTGCTCGGGCCCTCATTTGAGTCTTACCTGCTGCCCGA
ACTGACCAGATATGACTGTGAGGTGAACGTGCCCGTGTGGGAAGCTCCACGCTCCTGCAAGGAGGGGACCTC
CTCAGAGCCCTGGACCAGGCCACCTGAGCCAGGCCTTCTACCTGGGCAGCACCTTGCCACGCGGAGCCCTA
45 TGCAGTCTCGGCCCAAGCTATCAGATCTGCCGGTCTCCCTATAGTGAGTCGTATTAATTTGATAAGCCAGG
TT

SEQ ID NO:4

The nucleotide sequence of pSMART CMV-HIF

50
1 AGATCTTGAA TAATAAATG TGTGTTTGTC CGAAATACGC GTTTTGAGAT
51 TTCTGTTCGCC GACTAAATTC ATGTGCGCGC ATAGTGGTGT TTATCGCCGA
101 TAGAGATGGC GATATTGGAA AAATTGATAT TTGAAAATAT GGCATATTGA
151 AAATGTCGCC GATGTGAGTT TCTGTGTAAC TGATATCGCC ATTTTTCCTAA
55 201 AAGTGATTTT TGGGCATACG CGATATCTGG CGATAGCGCT TATATCGTTT
251 ACGGGGGATG GCGATAGACG ACTTTGGTGA CTTGGGCGAT TCTGTGTGTC
301 GCAAATATCG CAGTTTCGAT ATAGGTGACA GACGATATGA GGCTATATCG

	351	CCGATAGAGG	CGACATCAAG	CTGGCACATG	GCCAATGCAT	ATCGATCTAT
	401	ACATTGAATC	AATATGGGCC	ATTAGCCATA	TTATTCAATTG	GTTATATAGC
	451	ATAAATCAAT	ATTGGCTATT	GGCCATTGCA	TACGTTGTAT	CCATATCGTA
5	501	ATATGTACAT	TTATATTGGC	TCATGTCCAA	CATTACCGCC	ATGTTGACAT
	551	TGATTATTGA	CTAGTTATTA	ATAGTAATCA	ATTACGGGGT	CATTAGTTCA
	601	TAGCCCATAT	ATGGAGTTCC	GCGTTACATA	ACTTACGGTA	AATGGCCCCG
	651	CTGGCTGACC	GCCCAACGAC	CCCCGCCCAT	TGACGTCAAT	AATGACGTAT
	701	GTTCCCATAG	TAACGCCAAT	AGGGACTTTC	CATTGACGTC	AATGGGTGGA
10	751	GTATTTACGG	TAAACTGCCC	ACTTGGCAGT	ACATCAAGTG	TATCATATGC
	801	CAAGTCCGCC	CCCTATTGAC	GTCAATGACG	GTAAATGGCC	CGCTGGCAT
	851	TATGCCCAGT	ACATGACCTT	ACGGGACTTT	CCTACTTGGC	AGTACATCTA
	901	CGTATTAGTC	ATCGCTATTA	CCATGGTGAT	GCGGTTTITGG	CAGTACACCA
	951	ATGGGCGTGG	ATAGCGGTTT	GACTCACGGG	GATTTCCAAG	TCTCCACCCC
	1001	ATTGACGTCA	ATGGGAGTTT	GTTTTGGCAC	CAAAATCAAC	GGGACTTTCC
15	1051	AAAATGTCGT	AACAACCTGCG	ATCGCCCCGCC	CCGTTGACGC	AAATGGGCGG
	1101	TAGGCGTGTA	CGGTGGGAGG	TCTATATAAG	CAGAGCTCGT	TTAGTGAACC
	1151	GGGCACTCAG	ATTCTGCGGT	CTGAGTCCCT	TCTCTGCTGG	GCTGAAAAGG
	1201	CCTTTGTAAT	AAATATAATT	CTCTACTCAG	TCCCTGTCTC	TAGTTTGTC
20	1251	GTTTCGAGATC	CTACAGTTGG	CGCCCGAACA	GGGACCTGAG	AGGGGCGCAG
	1301	ACCCTACCTG	TTGAACCTGG	CTGATCGTAG	GATCCCCGGG	ACAGCAGAGG
	1351	AGAACTTACA	GAAGTCTTCT	GGAGGTGTTT	CTGGCCAGAA	CACAGGAGGA
	1401	CAGTAAGAT	TGGGAGACCC	TTTGACATTG	GAGCAAGGGC	CTCAAGAAGT
	1451	TAGAGAAGGT	GACGGTACAA	GGGTCTCAGA	AATTAACCTAC	TGGTAACCTGT
25	1501	AATTGGGCGC	TAAGTCTAGT	AGACTTATTT	CATGATACCA	ACTTTGTAAA
	1551	AGAAAAGGAC	TGGCAGCTGA	GGGATGTCTAT	TCCATTGCTG	GAAGATGTAA
	1601	CTCAGACGCT	GTCAAGACAA	GAAAGAGAGG	CCTTTGAAAG	AACATGGTGG
	1651	GCAATTTCTG	CTGTAAAGAT	GGGCCTCCAG	ATTAATAATG	TAGTAGATGG
	1701	AAAGGCATCA	TTCCAGCTCC	TAAGAGCGAA	ATATGAAAAG	AAGACTGCTA
30	1751	ATAAAAAGCA	GTCTGAGCCC	TCTGAAGAAT	ATCTCTAGAG	TCGACGCTCT
	1801	CATTACTTGT	AACAAAGGGA	GGGAAAGTAT	GGGAGGACAG	ACACCATGGG
	1851	AAGTATTTAT	CACATAATCAA	GCACAAGTAA	TACATGAGAA	ACTTTTACTA
	1901	CAGCAAGCAC	AATCCTCCAA	AAAATTTTGT	TTTTACAAAA	TCCCTGGTGA
	1951	ACATGGTCGA	CTCTAGAACT	AGTGGATCCC	CCGGGCTGCA	GGAGTGGGGA
35	2001	GGCACGATGG	CCGCTTTGGT	CGAGGCGGAT	CCGGCCATTA	GCCATATTAT
	2051	TCATTGGTTA	TATAGCATAA	ATCAATATTG	GCTATTGGCC	ATTGCATACG
	2101	TTGTATCCAT	ATCATAATAT	GTACATTTAT	ATTGGCTCAT	GTCCAACATT
	2151	ACCGCCATGT	TGACATTGAT	TATTGACTAG	TTATTAATAG	TAATCAATTA
	2201	CGGGGTCAAT	AGTTCATAGC	CCATATATGG	AGTTCGCGT	TACATAACTT
40	2251	ACGGTAAATG	GCCCGCCTGG	CTGACCGCCC	AACGACCCCG	GCCCATTTGAC
	2301	GTCAATAATG	ACGTATGTTT	CCATAGTAAC	GCCAATAGGG	ACTTTCCATT
	2351	GACGTCAATG	GGTGGAGTAT	TTACGGTAAA	CTGCCCCACTT	GGCAGTACAT
	2401	CAAGTGTATC	ATATGCCAAG	TACGCCCCCT	ATTGACGTCA	ATGACGGTAA
	2451	ATGGCCCCGCC	TGGCATTATG	CCCAGTACAT	GACCTTATGG	GACTTTCCCTA
45	2501	CTTGGCAGTA	CATCTACGTA	TTAGTCATCG	CTATTACCAT	GGTGATGCGG
	2551	TTTTGGCAGT	ACATCAATGG	GCGTGGATAG	CGGTTTGACT	CACGGGGATT
	2601	TCCAAGTCTC	CACCCCATTT	ACGTCAATGG	GAGTTTGTTT	TGGCACCAAA
	2651	ATCAACGGGA	CTTTCCAAAA	TGTCGTAACA	ACTCCGCCCC	ATTGACGCAA
	2701	ATGGGCGGTA	GGCATGTACG	GTGGGAGGTC	TATATAAGCA	GAGCTCGTTT
50	2751	AGTGAACCGT	CAGATCGCCT	GGAGACGCCA	TCCACGCTGT	TTTGACCTCC
	2801	ATAGAAGACA	CCGGGACCGA	TCCAGCCTCC	GCGGCCGGGA	ACGGTGCATT
	2851	GGAAGCTTGG	TACCGGCTAG	CCGTAGAATC	CGACCGATTG	ACCATGGAGG
	2901	GCGCCGGCGG	CGCGAACGAC	AAGAAAAAGA	TAAGTTCTGA	ACGTCGAAAA
	2951	GAAAAAGTCTC	GAGATGCAGC	CAGATCTCGG	CGAAGTAAAG	AATCTGAAGT
55	3001	TTTTTATGAG	CTTGCTCATC	AGTTGCCACT	TCCACATAAT	GTGAGTTTCGC
	3051	ATCTTGATAA	GGCCTCTGTG	ATGAGGCTTA	CCATCAGCTA	TTTGCCTGTG
	3101	AGGAACTTTC	TGGATGCTGG	TGATTTGGAT	ATTGAAGATG	ACATGAAAGC
	3151	ACAGATGAAT	TGCTTTTATT	TGAAAGCCTT	GGATGGTTTT	GTTATGGTTC
	3201	TCACAGATGA	TGGTGACATG	ATTTACATTT	CTGATAATGT	GAACAAATAC
60	3251	ATGGGATTAA	CTCAGTTTGA	ACTAACTGGA	CACAGTGTGT	TTGATTTTAC
	3301	TCATCCATGT	GACCATGAGG	AAATGAGAGA	AATGCTTACA	CACAGAAATG
	3351	GCCTTGTAAG	AAAGGGTAAA	GAACAAAACA	CACAGCGAAG	CTTTTTTCTC
	3401	AGAATGAAGT	GTACCCTAAC	TAGCCGAGGA	AGAACTATGA	ACATAAAGTC
	3451	TGCAACATGG	AAGGTATTGC	ACTGCACAGG	CCACATTAC	GTATATGATA
	3501	CCAACAGTAA	CCAACCTCAG	TGTGGGTATA	AGAAACCACC	TATGACCTGC
65	3551	TTGGTGCTGA	TTTGTGAACC	CATTCCCTCAC	CCATCAATA	TTGAAATTC

	3601	TTTAGATAGC	AAGACTTTCC	TCAGTCGACA	CAGCCTGGAT	ATGAAATTTT
	3651	CTTATTGTGA	TGAAAGAATT	ACCGAATTGA	TGGGATATGA	GCCAGAAGAA
	3701	CTTTTAGGCC	GCTCAATTTA	TGAATATTAT	CATGCTTTGG	ACTCTGATCA
5	3751	TCTGACCAA	ACTCATCATG	ATATGTTTAC	TAAAGGACAA	GTCACCACAG
	3801	GACAGTACAG	GATGCTTGCC	AAAAGAGGTG	GATATGTCTG	GGTTGAAACT
	3851	CAAGCAACTG	TCATATATAA	CACCAAGAAT	TCTCAACCAC	AGTGCATTGT
	3901	ATGTGTGAAT	TACGTGTGTA	GTGGTATTAT	TCAGCACGAC	TTGATTTTCT
	3951	CCCTTCAACA	AACAGAATGT	GTCTTAAAC	CGGTTGAATC	TTCAGATATG
10	4001	AAATGACTC	AGCTATTAC	CAAAGTTGAA	TCAGAAGATA	CAAGTAGCCT
	4051	CTTTGACAAA	CTTAAGAAGG	AACCTGATGC	TTTAACTTTG	CTGGCCCCAG
	4101	CCGCTGGAGA	CACAATCATA	TCTTTAGATT	TTGGCAGCAA	CGACACAGAA
	4151	ACTGATGACC	AGCAACTTGA	GGAAGTACCA	TTATATAATG	ATGTAATGCT
	4201	CCCTTCACCC	AACGAAAAAT	TACAGAATAT	AAATTGGGCA	ATGCTCCTCC
	4251	TACCCACCGC	TGAAACGCCA	AAGCCACTTC	GAAGTAGTGC	TGACCCCTGCA
15	4301	CTCAATCAAG	AAGTTGCATT	AAAATTAGAA	CCAAATCCAG	AGTCACTGGA
	4351	ACTTTCTTTT	ACCATGCCCC	AGATTTCAGGA	TCAGACACCT	AGTCCCTCCG
	4401	ATGGAAGCAC	TAGACAAAGT	TCACCTGAGC	CTAATAGTCC	CAGTGAATAT
	4451	TGTTTTATG	TGGATAGTGA	TATGGTCAAT	GAATTCAAGT	TGGAATTGGT
	4501	AGAAAACTT	TTTGCTGAAG	ACACAGAAGC	AAAGAACCCA	TTTTCTACTC
20	4551	AGGACACAGA	TTTAGACTTG	GAGATGTTAG	CTCCCTATAT	CCCAATGGAT
	4601	GATGACTTCC	AGTTACGTTT	CTTCGATCAG	TTGTCACCAT	TAGAAAGCAG
	4651	TTCCGCACAG	CCTGAAAGCG	CAAGTCCTCA	AAGCACAGTT	ACAGTATTCC
	4701	AGCAGACTCA	AATACAAGAA	CCTACTGCTA	ATGCCACCAC	TACCACTGCC
	4751	ACCACTGATG	AATTAAAAAC	AGTGACAAAA	GACCGTATGG	AAGACATTAA
25	4801	AATATTGATT	GCATCTCCAT	CTCCTACCCA	CATACATAAA	GAAACTACTA
	4851	GTGCCACATC	ATCACCATAT	AGAGATACTC	AAAGTCGGAC	AGCCTCACCA
	4901	AACAGAGCAG	GAAAAGGAGT	CATAGAACAG	ACAGAAAAAT	CTCATCCAAG
	4951	AAGCCCTAAC	GTGTTATCTG	TCGCTTTGAG	TCAAAGAACT	ACAGTTCCTG
	5001	AGGAAGAACT	AAATCCAAAG	ATACTAGCTT	TGCAGAATGC	TCAGAGAAAG
30	5051	CGAAAAATGG	AACATGATGG	TTCACTTTT	CAAGCAGTAG	GAATTGGAAC
	5101	ATTATTACAG	CAGCCAGACG	ATCATGCAGC	TACTACATCA	CTTCTTGGGA
	5151	AACGTGTAAA	AGGATGCAAA	TCTAGTGAAC	AGAATGGAAT	GGAGCAAAAG
	5201	ACAATTATTT	TAATACCCTC	TGATTTAGCA	TGTAGACTGC	TGGGGCAATC
	5251	AATGGATGAA	AGTGGATTAC	CACAGCTGAC	CAGTTATGAT	TGTGAAGTTA
35	5301	ATGCTCCTAT	ACAAGGCAGC	AGAAACCTAC	TGCAGGGTGA	AGAATTACTC
	5351	AGAGCTTTGG	ATCAAGTTAA	CTGAGCGGAT	CCGACGGGGA	TCCTCTAGCG
	5401	TTATCCATCA	CACCTGGCGG	CGCGACTCTA	GAGTCGACCT	CGAGGGGGGG
	5451	CCCGGACCTA	CTAGGGTGCT	GTGGAAGGGT	GATGGTGCAG	TAGTAGTTAA
	5501	TGATGAAGGA	AAGGGAATAA	TTGCTGTACC	ATTAAACGAG	ACTAAGTTAC
40	5551	TAATAAAACC	AAATTGAGTA	TTGTTGCAGG	AAGCAAGACC	CAACTACCAT
	5601	TGTCAGCTGT	GTTCCTTGAC	CTCAATATTT	GTTATAAGGT	TTGATATGAA
	5651	TCCCAGGGGG	AATCTCAACC	CCTATTACCC	AACAGTCAGA	AAAATCTAAG
	5701	TGTGAGGAGA	ACACAATGTT	TCAACCTTAT	TGTTATAATA	ATGACAGTAA
	5751	GAACAGCATG	GCAGAATCGA	AGGAAGCAAG	AGACCAAGAA	TGAACCTGAA
45	5801	AGAAGAACTT	AAAGAAGAAA	AAAGAAGAAA	TGACTGGTGG	AAAATAGGTA
	5851	TGTTTCTGTT	ATGCTTAGCA	GGAACTACTG	GAGGAATACT	TTGGTGGTAT
	5901	GAAGGACTCC	CACAGCAACA	TTATATAGGG	TTGGTGGCGA	TAGGGGGGAG
	5951	ATTAAACGGA	TCTGGCCAAT	CAAATGCTAT	AGAATGCTGG	GGTTCCTTCC
	6001	CGGGGTGTAG	ACCATTTCAA	AATTACTTCA	GTTATGAGAC	CAATAGAAGC
50	6051	ATGCATATGG	ATAATAATAC	TGCTACATTA	TTAGAAGCTT	TAACCAATAT
	6101	AACCTGCTCTA	TAAATAACAA	AACAGAATTA	GAAACATGGA	AGTTAGTAAA
	6151	GACTTCTGGC	ATAACTCCTT	TACCTATTTC	TTCTGAAGCT	AACACTGGAC
	6201	TAATTAGACA	TAAGAGAGAT	TTTGGTATAA	GTGCAATAGT	GGCAGCTATT
	6251	GTAGCCGCTA	CTGCTATTGC	TGCTAGCGCT	ACTATGTCTT	ATGTTGCTCT
55	6301	AACTGAGGTT	AACAAAAATA	TGGAAGTACA	AAATCATACT	TTTGAGGTAG
	6351	AAAATAGTAC	TCTAAATGGT	ATGGATTTAA	TAGAACGACA	AATAAAGATA
	6401	TTATATGCTA	TGATTCTTCA	AACACATGCA	GATGTTCAAC	TGTTAAAGGA
	6451	AAGACAACAG	GTAGAGGAGA	CATTTAATTT	AATTGGATGT	ATAGAAAGAA
	6501	CACATGTATT	TTGTCATACT	GGTCATCCCT	GGAATATGTC	ATGGGGACAT
60	6551	TTAAATGAGT	CAACACAATG	GGATGACTGG	GTAAGCAAAA	TGGAAGATTT
	6601	AAATCAAGAG	ATACTAACTA	CACCTCATGG	AGCCAGGAAC	AATTTGGCAC
	6651	AATCCATGAT	AACATTCAAT	ACACCAGATA	GTATAGCTCA	ATTTGGAAAA
	6701	GACCTTTGGA	GTCAATATTG	AAATTGGATT	CCTGGATTGG	GAGCTTCCAT
	6751	TATAAAATAT	ATAGTGATGT	TTTTGCTTAT	TTATTTGTGA	CTAACCTCTT
65	6801	CGCCTAAGAT	CCTCAGGGCC	CTCTGGAAGG	TGACCAGTGG	TGCAGGGTCC

	6851	TCCGGCAGTC	GTTACCTGAA	GAAAAAATTC	CATCACAAAC	ATGCATCGCG
	6901	AGAAGACACC	TGGGACCAGG	CCCAACACAA	CATACACCTA	GCAGGCGTGA
	6951	CCGGTGGATC	AGGGGACAAA	TACTACAAGC	AGAAGTACTC	CAGGAACGAC
5	7001	TGGAATGGAG	AATCAGAGGA	GTACAACAGG	CGGCCAAAGA	GCTGGGTGAA
	7051	GTCAATCGAG	GCATTTGGAG	AGAGCTATAT	TTCCGAGAAG	ACCAAAGGGG
	7101	AGATTTCTCA	GCCTGGGGCG	GCTATCAACG	AGCACAAGAA	CGGCTCTGGG
	7151	GGGAACAATC	CTCACCAAGG	GTCCCTTAGAC	CTGGAGATTC	GAAGCGAAGG
	7201	AGGAACATTT	TATGACTGTT	GCATTTAAAGC	CCAAGAAGGA	ACTCTCGCTA
	7251	TCCTTTGCTG	TGGATTTCCC	TTATGGCTAT	TTTGGGGACT	AGTAAATTATA
10	7301	GTAGGACGCA	TAGCAGGCTA	TGGATTACGT	GGACTCGCTG	TTATAATAAG
	7351	GATTTGTATT	AGAGGCTTAA	ATTTGTATAT	TGAAATAATC	AGAAAAATGC
	7401	TTGATTATAT	TGGAAGAGCT	TTAAATCCTG	GCACATCTCA	TGTATCAATG
	7451	CTCAGTATG	TTTAGAAAAA	CAAGGGGGGA	ACTGTGGGGT	TTTTATGAGG
	7501	GGTTTATATA	ATGATTATAA	GAGTAAAAAG	AAAGTTGCTG	ATGCTCTCAT
15	7551	AACCTTGTAT	AACCCAAAGG	ACTAGCTCAT	GTTGCTAGGC	AACTAAACCG
	7601	CAATAACCGC	ATTTGTGACG	CGAGTTCCCC	ATTGGTGACG	CGTTAACTTC
	7651	CTGTTTTTAC	AGTATATAAG	TGCTTTGTATT	CTGACAATTG	GGCACTCAGA
	7701	TTCTGCGGTC	TGAGTCCCTT	CTCTGCTGGG	CTGAAAAGGC	CTTTGTATAA
	7751	AATATAATTC	TCTACTCAGT	CCCTGTCTCT	AGTTTGTCTG	TTGAGATPCC
20	7801	TACAGAGCTC	ATGCCTTGGC	GTAATCATGG	TCATAGCTGT	TTCTGTGTG
	7851	AAATTTGTAT	CCGCTCACAA	TTCCACACAA	CATACGAGCC	GGAAGCATAA
	7901	AGTGTAAGC	CTGGGGTGCC	TAATGAGTGA	GCTAACTCAC	ATTAATTGCG
	7951	TTGCGCTCAC	TGCCCCGCTT	CCAGTCGGGA	AACCTGTCGT	GCCAGCTGCA
	8001	TTAATGAATC	GGCCAACGCG	CGGGGAGAGG	CGGTTTGCGT	ATTGGGCGCT
25	8051	CTTCCGCTTC	CTCGCTCACT	GACTCGCTGC	GCTCGGTGCT	TGGGCTGCGG
	8101	CGAGCGGTAT	CAGCTCACTC	AAAGGCGGTA	ATACGGTTAT	CCACAGAATC
	8151	AGGGGATAAC	GCAGGAAAGA	ACATGTGAGC	AAAAGGCCAG	CAAAAGGCCA
	8201	GGAACCGTAA	AAAGGCCGCG	TTGCTGGCGT	TTTTCATAG	GCTCCGCCCC
	8251	CCTGACGAGC	ATCACAAAAA	TCGACGCTCA	AGTCAGAGGT	GGCGAAACCC
30	8301	GACAGGACTA	TAAAGATAACC	AGGCGTTTCC	CCCTGGAAGC	TCCCTCGTGC
	8351	GCCTCTCTGT	TCCGACCCTG	CCGCTTACCG	GATACCTGTC	CGCCTTTCTC
	8401	CCTTCCGGAA	GCGTGGCGCT	TTCTCATAGC	TCACGCTGTA	GGTATCTCAG
	8451	TTCCGTTGTAG	GTCGTTCCGT	CCAAGCTGGG	CTGTGTGCAC	GAACCCCCCG
	8501	TTCCAGCCGA	CCGCTGCGCC	TTATCCGGTA	ACTATCGTCT	TGAGTCCAAC
35	8551	CCGGTAAGAC	ACGACTTATC	GCCACTGGCA	GCAGCCACTG	GTAACAGGAT
	8601	TAGCAGAGCG	AGGTATGTAG	GCGGTGCTAC	AGAGTTCTTG	AAGTGGTGGC
	8651	CTAACTACGG	CTACACTAGA	AGGACAGTAT	TTGGTATCTG	CGCTCTGCTG
	8701	AAGCCAGTTA	CCTTCGGAAA	AAGAGTTGGT	AGCTCTTGAT	CCGGCAAACA
	8751	AACCAACGCT	GGTAGCGGTG	GTTTTTTTGT	TTGCAAGCAG	CAGATTACGC
40	8801	GCAGAAAAAA	AGGATCTCAA	GAAGATCCTT	TGATCTTTTC	TACGGGGTCT
	8851	GACGCTCAGT	GGAACGAAAA	CTCACGTTAA	GGGATTTTGG	TCATGAGATT
	8901	ATCAAAAAGG	ATCTTCACCT	AGATCCTTTT	AAATTAAAAA	TGAAGTTTTA
	8951	AATCAATCTA	AAGTATATAT	GAGTAAACTT	GGTCTGACAG	TTACCAATGC
	9001	TTAATCAGTG	AGGCACCTAT	CTCAGCGATC	TGTCTATTTT	GTTTCATCCAT
45	9051	AGTTGCCTGA	CTCCCCGTCT	TGTAGATAAC	TACGATACGG	GAGGGCTTAC
	9101	CATCTGGCCC	CAGTGCTGCA	ATGATACCGC	GAGACCCACG	CTCACCGGCT
	9151	CCAGATTTAT	CAGCAATAAA	CCAGCCAGCC	GGAAGGGCCG	AGCGCAGAAG
	9201	TGGTCTTGCA	ACTTTATCCG	CCTCCATCCA	GTCTATTAAT	TGTTGCCGGG
	9251	AAGCTAGAGT	AAGTAGTTCC	CCAGTTAATA	GTTTGCAGCA	CGTTGTTGCC
50	9301	ATTGCTACAG	GCATCGTGGT	GTCACGCTCG	TCGTTTGGTA	TGGCTTCATT
	9351	CAGCTCCGGT	TCCCAACGAT	CAAGGCGAGT	TACATGATCC	CCCATGTTGT
	9401	GCAAAAAAGC	GGTTAGCTCC	TTCGGTCCCT	CGATCGTTGT	CAGAAGTAAG
	9451	TTGGCCGCAG	TGTTATCACT	CATGGTTATG	GCAGCACTGC	ATAATTCTCT
	9501	TACTGTCAAT	CCATCCGTAA	GATGCTTTTC	TGTGACTGGT	GAGTACTCAA
55	9551	CCAAGTCATT	CTGAGAATAG	TGTATGCGGC	GACCGAGTTG	CTCTTGCCCC
	9601	GCGTCAATAC	GGGATAATAC	CGCGCCACAT	AGCAGAACTT	TAAAAGTGCT
	9651	CATCAATTGA	AAACGTTCTT	CGGGGCGAAA	ACTCTCAAGG	ATCTTACCGC
	9701	TGTTGAGATC	CAGTTCGATG	TAACCCACTC	GTGCACCCAA	CTGATCTTCA
	9751	GCATCTTTTA	CTTTCACCA	CGTTTCTGGG	TGAGCAAAAA	CAGGAAGGCA
60	9801	AAATGCCGCA	AAAAAGGGAA	TAAGGGCGAC	ACGGAATGT	TGAATACTCA
	9851	TACTCTTCTT	TTTCAATAT	TATTGAAGCA	TTTATCAGGG	TTATTGTCTC
	9901	ATGAGCGGAT	ACATATTTGA	ATGTATTTAG	AAAAATAAAC	AAATAGGGGT
	9951	TCCGCGCACA	TTTCCCGGAA	AAGTGCCACC	TAAATTGTAA	GCGTTAATAT
	10001	TTTGTTAAAA	TTCCGCTTAA	ATTTTGTGTA	AATCAGCTCA	TTTTTTAACC
65	10051	AATAGGCCGA	AATCGGCAAA	ATCCCTTATA	AATCAAAAGA	ATAGACCGAG

10101 ATAGGGTTGA GTGTTGTTCC AGTTTGGAAC AAGAGTCCAC TATTAAAGAA
 10151 CGTGGACTCC AACGTCAAAG GGCGAAAAAC CGTCTATCAG GGCGATGGCC
 10201 CACTACGTGA ACCATCACCC TAATCAAGTT TTTTGGGGTC GAGGTGCCGT
 10251 AAAGCACTAA ATCGGAACCC TAAAGGGAGC CCCCATTGA GAGCTTGACG
 5 10301 GGGAAAGCCA ACCTGCGCTTA TCGAAATTAA TACGACTCAC TATAGGGAGA
 10351 CCGGC

SEQ ID NO:5

10 The nucleotide sequence of pSMART CMV-empty

1 AGATCTTGAA TAATAAAATG TGTGTTTGTC CGAAATACGC GTTTTGAGAT
 51 TTCTGTCGCC GACTAAATTC ATGTCGCGCG ATAGTGGTGT TTATCGCCGA
 101 TAGAGATGGC GATATTGGA AAAATGATAT TTGAAAATAT GGCAATATTGA
 15 151 AAATGTCGCC GATGTGAGTT TCTGTGTAAC TGATATCGCC ATTTTTCCAA
 201 AAGTGATTTT TGGGCATACG CGATATCTGG CGATAGCGCT TATATCGTTT
 251 ACGGGGGATG GCGATAGACG ACTTTGGTGA CTTGGGCGAT TCTGTGTGTC
 301 GCAAATATCG CAGTTTCGAT ATAGGTGACA GACGATATGA GGCTATATCG
 351 CCGATAGAGG CGACATCAAG CTGGCACATG GCCAATGCAT ATCGATCTAT
 401 ACATTGAATC AATATTTGGCC ATTAGCCATA TTATTCATTG GTTATATAGC
 451 ATAAATCAAT ATTGGCTATT GGCCATTGCA TACGTTGTAT CCATATCGTA
 501 ATATGTACAT TTATATTTGGC TCATGTCCAA CATTACCGCC ATGTTGACAT
 551 TGATTATTGA CTAGTTATTA ATAGTAATCA ATTACGGGGT CATTAGTTCA
 601 TAGCCCATAT ATGGAGTTCC GCGTTACATA ACTTACGGTA AATGGCCCCG
 25 651 CTGGCTGACC GCCCAACGAC CCCCAGCCAT TGACGTCAAT AATGACGTAT
 701 GTTCCCATAG TAACGCCAAT AGGGACTTTC CATTGACGTC AATGGGTGGA
 751 GTATTTACGG TAAACTGCCC ACTTGGCAGT ACATCAAGTG TATCATATGC
 801 CAAGTCCGCC CCCTATTGAC GTCATGACG GTAAATGGCC CGCCTGGCAT
 851 TATGCCCAGT ACATGACCTT ACGGGACTTT CCTACTTGGC AGTACATCTA
 30 901 CGTATTAGTC ATCGCTATTA CCATGGTGAT GCGGTTTTGG CAGTACACCA
 951 ATGGGCGTGG ATAGCGGTTT GACTCACGGG GATTTCCAAG TCTCCACCCC
 1001 ATTGACGTCA ATGGGAGTTT GTTTTGGCAC CAAAATCAAC GGGACTTTCC
 1051 AAAATGTCGT AACAAC TGCG ATCGCCGCC CCGTTGACGC AAATGGGCGG
 1101 TAGGCGTGTA CGGTGAGAGG TCTATATAAG CAGAGCTCGT TTAGTGAACC
 35 1151 GGGCACTCAG ATTCTGCGGT CTGAGTCCCT TCTCTGCTGG GCTGAAAAGG
 1201 CCTTTGTAAT AAATATAATT CTCTACTCAG TCCCTGTCTC TAGTTTGTCT
 1251 GTTCGAGATC CTACAGTTGG CGCCGAACA GGGACCTGAG AGGGGCGCAG
 1301 ACCCTACCTG TTGAACCTGG CTGATCGTAG GATCCCCGGG ACAGCAGAGG
 1351 AGAAGTTACA GAAGTCTTCT GGAGGTGTTT CTGGCCAGAA CACAGGAGGA
 40 1401 CAGGTAAGAT TGGGAGACCC TTTGACATTG GAGCAAGGCG CTCAAGAAGT
 1451 TAGAGAAGGT GACGGTACAA GGGTCTCAGA AATTAAC TAC TGGTAACTGT
 1501 AATTGGGCGC TAAGTCTAGT AGACTTATTT CATGATACCA ACTTTGTAAA
 1551 AGAAAAGGCA TGGCAGCTGA GGGATGTCA TCCATTGCTG GAAGATGTAA
 1601 CTCAGACGCT GTCAGGACAA GAAAGAGAGG CCTTTGAAAAG AACATGGTGG
 45 1651 GCAATTTCTG CTGTAAAGAT GGGCTCCAG ATTAATAATG TAGTAGATGG
 1701 AAAGGCATCA TTCCAGCTCC TAAGAGCGAA ATATGAAAAG AAGACTGCTA
 1751 ATAAAAAGCA GTCTGAGCCC TCTGAAGAAT ATCTCTAGAG TCGACGCTCT
 1801 CATTACTTGT AACAAAGGGA GGGAAAGTAT GGGAGGACAG ACACCATGGG
 1851 AAGTATTTAT CACTAATCAA GCACAAGTAA TACATGAGAA ACTTTTACTA
 50 1901 CAGCAAGCAC AATCCTCCAA AAAATTTTGT TTTTACAAA TCCCTGGTGA
 1951 ACATGGTCGA CTCTAGAACT AGTGGATCCC CCGGCTGCA GGAGTGGGGA
 2001 GGCACGATGG CCGCTTTGGT CGAGGCGGAT CCGGCCATTA GCCATATTAT
 2051 TCATTGGTTA TATAGCATAA ATCAATATTG GCTATTGGCC ATTGCATACG
 2101 TTGTATCCAT ATCATAATAT GTACATTTAT ATTGGCTCAT GTCCAACATT
 55 2151 ACCGCCATGT TGACATTGAT TATTGACTAG TTATTAATAG TAATCAATTA
 2201 CCGGGTCATT AGTTCATAGC CCATATATGG AGTTCCGCGT TACATAACTT
 2251 ACGGTAAATG GCCCGCCTGG CTGACCGCCC AACGACCCCC GCCCATTGAC
 2301 GTCATAATG ACGTATGTTT CCATAGTAAC GCCAATAGGG ACTTTCCATT
 2351 GACGTCAATG GGTGGAGTAT TTACGGTAAA CTGCCCCTT GGCAGTACAT
 60 2401 CAAGTGTATC ATATGCCAAG TACGCCCCCT ATTGACGTCA ATGACGGTAA
 2451 ATGGCCCGCC TGGCATTTAT CCCAGTACAT GACCTTATGG GACTTTCCTA
 2501 CTTGGCAGTA CATCTACGTA TTAGTCATCG CTATTACCAT GGTGATGCGG
 2551 TTTTGGCAGT ACATCAATGG GCGTGGATAG CGGTTTGACT CACGGGGATT

	2601	TCCAAGTCTC	CACCCCATTG	ACGTCAATGG	GAGTTTGTTT	TGGCACCAAA
	2651	ATCAACGGGA	CTTTCCAAAA	TGTCGTAACA	ACTCCGCCCC	ATTGACGCAA
	2701	ATGGGCGGTA	GGCATGTACG	GTGGGAGGTC	TATATAAGCA	GAGCTCGTTT
5	2751	AGTGAACCGT	CAGATCGCCT	GGCCGCGACT	CTAGAGTCGA	CCTCGAGGGG
	2801	GGGCCCCGAC	CTACTAGGGT	GCTGTGGAAG	GGTGATGGTG	CAGTAGTAGT
	2851	TAATGATGAA	GGAAAGGGAA	TAATTGCTGT	ACCATTAAAC	AGGACTAAGT
	2901	TACTAATAAA	ACCAAATTGA	GTATTGTTGC	AGGAAGCAAG	ACCCAACCTAC
	2951	CATTGTTCAGC	TGTGTTTCCT	GACCTCAATA	TTTGTATATA	GGTTTGATAT
10	3001	GAATCCGAGG	GGGAATCTCA	ACCCCTATTA	CCCAACAGTC	AGAAAAATCT
	3051	AAGTGTGAGG	AGAACACAAT	GTTTCAACCT	TATTGTTATA	ATAATGACAG
	3101	TAAGAACAGC	ATGGCAGAAT	CGAAGGAAGC	AAGAGACCAA	GAATGAACCT
	3151	GAAAGAAGAA	TCTAAAGAAG	AAAAAAGAAG	AAATGACTGG	TGGAATAATAG
	3201	GATGTTTCT	GTTATGCTTA	GCAGGAACCTA	CTGGAGGAAT	ACTTTGGTGG
	3251	TATGAAGGAC	TCCCACAGCA	ACATTATATA	GGGTTGGTGG	CGATAGGGGG
15	3301	AAGATTAAAC	GGATCTGGCC	AATCAAATGC	TATAGAATGC	TGGGGTTTCCT
	3351	TCCCGGGGTG	TAGACCATT	CAAAATTACT	TCAGTTATGA	GACCAATAGA
	3401	AGCATGCATA	TGGATAATAA	TACTGCTACA	TTATTAGAAG	CTTTAACCAA
	3451	TATAACTGCT	CTATAAATAA	CAAAACAGAA	TTAGAAACAT	GGAGTTAGT
20	3501	AAAGACTTCT	GGCATAACTC	CTTTACCTAT	TTCTTCTGAA	GCTAACACTG
	3551	GACTAATTAG	ACATAAGAGA	GATTTTGGTA	TAAGTGCAAT	AGTGGCAGCT
	3601	ATTGTAGCCG	CTACTGCTAT	TGCTGCTAGC	GCTACTATGT	CTTATGTTGC
	3651	TCTAAGTAG	GTTAAACAAA	TAATGGAAGT	ACAAAAATCAT	ACTTTTGAGG
	3701	TAGAAAATAG	TACTCTAAAT	GGTATGGATT	TAATAGAACG	ACAAATAAAG
	3751	ATATTATATG	CTATGATTCT	TCAAACACAT	GCAGATGTTT	AACTGTTAAA
25	3801	GGAAAGACAA	CAGGTAGAGG	AGACATTTAA	TTTAATTTGGA	TGTATAGAAA
	3851	GAACACATGT	ATTTTGTCTAT	ACTGGTCATC	CCTGGAATAT	GTCATGGGGA
	3901	CATTTAAATG	AGTCAACACA	ATGGGATGAC	TGGGTAAGCA	AAATGGAAGA
	3951	TTTAAATCAA	GAGATACTAA	CTACACTTCA	TGGAGCCAGG	AACAATTTGG
30	4001	CACAATCCAT	GATAACATTC	AATACACCAG	ATAGTATAGC	TCAATTTGGA
	4051	AAAGACCTTT	GGAGTCATAT	TGGAAATTGG	ATTCCCTGGAT	TGGGAGCTTC
	4101	CATTATAAAA	TATATAGTGA	TGTTTTTGCT	TATTTATTTG	TTACTAACCT
	4151	CTTCGCCTAA	GATCCTCAGG	GCCCTCTGGA	AGGTGACCAG	TGGTGCAGGG
	4201	TCCTCCGCGA	GTCGTACCT	GAAGAAAAAA	TTCCATCACA	AACATGCATC
	4251	CGGAGAAGAC	ACCTGGGACC	AGGCCCAACA	CAACATACAC	CTAGCAGGCG
35	4301	TGACCCGGTG	ATCAGGGGAC	AAATACTACA	AGCAGAAGTA	CTCCAGGAAC
	4351	GACTGGAATG	GAGAATCAGA	GGAGTACAAC	AGGCGGCCAA	AGAGCTGGGT
	4401	GAAGTCAATC	GAGGCATTTG	GAGAGAGCTA	TATTTCCGAG	AAGACCAAAG
	4451	GGGAGATTTT	TCAGCCTGGG	GCGGCTATCA	ACGAGCACAA	GAACGGCTCT
	4501	GGGGGGAACA	ATCCTCACCA	AGGGTCCTTA	GACCTGGAGA	TTCGAAGCGA
40	4551	AGGAGGAAAC	ATTTATGACT	GTTCATTTAA	AGCCCAAGAA	GGAACTCTCG
	4601	CTATCCCTTG	CTGTGGATTT	CCCTTATGGC	TATTTTGGGG	ACTAGTAATT
	4651	ATAGTAGGAC	GCATAGCAGG	CTATGGATTA	CGTGGACTCG	CTGTTATAAT
	4701	AAGGATTTGT	ATTAGAGGCT	TAAATTTGAT	ATTTGAAAAA	ATCAGAAAAA
	4751	TGCTTGATTA	TATTGGAAGA	GCTTTAAATC	CTGGCACATC	TCATGTATCA
45	4801	ATGCCTCAGT	ATGTTTAGAA	AAACAAGGGG	GGAACCTGTG	GGTTTATATG
	4851	AGGGGTTTAA	TAAATGATTA	TAAGAGTAAA	AAGAAAGTTG	CTGATGCTCT
	4901	CATAACCTTG	TATAACCCAA	AGGACTAGCT	CATGTTGCTA	GGCAACTAAA
	4951	CCGCAATAAC	CGCATTTGTG	ACGCGAGTTC	CCCATTTGGT	ACGCGTTAAC
50	5001	TTCTCTGTTT	TACAGTATAT	AAGTGCTTGT	ATTCTGACAA	TTGGGCACTC
	5051	AGATTCTGCG	GTCTGAGTCC	CTTCTCTGCT	GGGCTGAAAA	GGCCTTTGTA
	5101	ATAAATATAA	TTCTCTACTC	AGTCCCTGTC	TCTAGTTTGT	CTGTTTCGAGA
	5151	TCCTACAGAG	CTCATGCCTT	GGCGTAATCA	TGGTCATAGC	TGTTTCCTGT
	5201	GTGAAATGTT	TATCCGCTCA	CAATTCCACA	CAACATACGA	GCCGGAAGCA
	5251	TAAAGTGTA	AGCCTGGGGT	GCCTAATGAG	TGAGCTAACT	CACATTAATT
55	5301	GCGTTGCGCT	CACGTCCCGC	TTTCCAGTCG	GGAAACCTGT	CGTGCCAGCT
	5351	GCATTAAATG	ATCGGCCAAC	GCGCGGGGAG	AGGCGGTTTG	CGTATTGGGC
	5401	GCTCTTCCGC	TTCTCTCGCTC	ACTGACTCGC	TGCGCTCGGT	CGTTCGGCTG
	5451	CGGCGAGCGG	TATCAGCTCA	CTCAAAGGCG	GTAATACGGT	TATCCACAGA
	5501	ATCAGGGGAT	AACGCAGGAA	AGAACATGTG	AGCAAAAGGC	CAGCAAAAGG
60	5551	CCAGGAACCG	TAAAAAGGCC	GCGTTGCTGG	CGTTTTTCCA	TAGGCTCCGC
	5601	CCCCCTGACG	AGCATCACAA	AAATCGACGC	TCAAGTCAGA	GGTGGCGAAA
	5651	CCCGACAGGA	CTATAAAGAT	ACCAGGCGTT	TCCCCCTGGA	AGTCCCTCTG
	5701	TGCGCTCTCC	TGTTCCGACC	CTGCCGCTTA	CCGGATACCT	GTCCGCCTTT
	5751	CTCCCTTCGG	GAAGCGTGCG	GCTTTCTCAT	AGCTCACGCT	GTAGGTATCT
65	5801	CAGTTCGGTG	TAGGTCGTTT	GCTCCAAGCT	GGGCTGTGTG	CACGAACCCC

5851 CCGTTCAGCC CGACCGCTGC GCCTTATCCG GTAACATATCG TCTTGAGTCC
 5901 AACCCGGTAA GACACGACTT ATCGCCACTG GCAGCAGCCA CTGGTAACAG
 5951 GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT
 6001 GGCCTAACTA CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG
 5 6051 CTGAAGCCAG TTACCTTCGG AAAAAGAGTT GGTAGCTCTT GATCCGGCAA
 6101 ACAAACCACC GCTGGTAGCG GTGGTTTTTT TGTTTGCAAG CAGCAGATTA
 6151 CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT TTCTACGGGG
 6201 TCTGACGCTC AGTGGAACGA AAACTCACGT TAAGGGATTT TGGTCATGAG
 6251 ATTATCAAAA AGGATCTTCA CCTAGATCCT TTAAATTA AAATGAAGTT
 10 6301 TTAAATCAAT CTAAAGTATA TATGAGTAAA CTGGTCTGA CAGTTACCAA
 6351 TGCTTAATCA GTGAGGCACC TATCTCAGCG ATCTGTCTAT TTCGTTTCATC
 6401 CATAGTTGCC TGAATCCCCG TCGTGTAGAT AACTACGATA CGGGAGGGCT
 6451 TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC ACGCTCACCG
 6501 GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG
 15 6551 AAGTGGTCC TCAACTTTAT CCGCTCCAT CCAGTCTATT AATTGTTGCC
 6601 GGGAAAGCTAG AGTAAGTAGT TCGCCAGTTA ATAGTTTGGC CAACGTTGTT
 6651 GCCATTGCTA CAGGCATCGT GGTGTCACGC TCGTCTGTTG GTATGGCTTC
 6701 ATTCAAGCTCC GGTCCCCAAC GATCAAGGCG AGTTACATGA TCCCCCATGT
 6751 TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT TGTCAGAAGT
 20 6801 AAGTTGGCCG CAGTGTATAT ACTCATGGTT ATGGCAGCAC TGCATAATTC
 6851 TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTACT
 6901 CAACCAAGTC ATTCTGAGAA TAGTGATATG GCGCAGCGAG TTGCTCTTGC
 6951 CCGGCGTCAA TACGGGATAA TACCGCGCCA CATAGCAGAA CTTTAAAAGT
 7001 GCTCATCAT TGGAAAACGTT CTTCGGGGCG AAAACTCTCA AGGATCTTAC
 25 7051 CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC CAACGTGATCT
 7101 TCAGCATCTT TTAATTTTCA CAGCGTTTCT GGGTGAGCAA AAACAGGAAG
 7151 GCAAAATGCC GCAAAAAGG GAATAAGGGC GACACGGAAA TGTGAATAC
 7201 TCATATCTTT CCTTTTTTCAA TATTATGAA GCATTTATCA GGGTTATGTT
 7251 CTATGAGCG GATACATATT TGAATGTATT TAGAAAAATA AACAAATAGG
 30 7301 GGTTCGCGC ACATTTCCTT GAAAAGTGCC ACCTAAATG TAAGCGTTAA
 7351 TATTTTGTTA AAATTCGCGT TAAATTTTGG TTAAATCAGC TCATTTTATA
 7401 ACCAATAGGC CGAAATCGGC AAAATCCCTT ATAAATCAAA AGAATAGACC
 7451 GAGATAGGGT TGAGTGTGTT TCCAGTTTGG AACAAGAGTC CACTATTAAA
 7501 GAACGTGGAC TCCAACGTCA AAGGGCGAAA AACCCTCTAT CAGGGCGATG
 35 7551 GCCCACTACG TGAACCATCA CCCTAATCAA GTTTTTTGGG GTCGAGGTGC
 7601 CGTAAAGCAC TAAATCGGAA CCCTAAAGGG AGCCCCGAT TTAGAGCTTG
 7651 ACGGGGAAAG CCAACCTGGC TTATCGAAAT TAATACGACT CACTATAGGG
 7701 AGACCGGC